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2Abstract
The deacetylase signalling enzyme SIRT1 has been subject of much research
interest, in part due to its ability to promote the survival of cancer cells, and
redundancy in non-cancer cell viability. The deacetylation and downregulation of
p53 and the FOXO family of tumour suppressors has been identified among the
downstream effects of SIRT1 in cancer. Importantly, the regulation of cancer cell
survival upstream of SIRT1 has not been well characterised, creating the possibility
of targeting SIRT1 via its endogenous regulatory mechanisms for anti-cancer
therapeutic gain. This Thesis validates two putative anti-cancer targets that promote
SIRT1 activity and have also been implicated in essential processes that are
commonly aberrant in cancer: cellular metabolism and translational control.
SIRT1 is a sirtuin, which are unique deacetylases due to their requirement for
the redox metabolite NAD+ as a co-enzyme. The potential to promote SIRT1 activity
via provision of NAD+ is analysed here by targeting the metabolic enzyme lactate
dehydrogenase A (LDH-A). LDH-A catalyses NAD+ production and promotes
aberrant cancer metabolism by perpetuating the Anaerobic Glycolysis cycle. A link
is found between cancer metabolism and SIRT1 activity, with LDH-A observed to
suppress cancer cell apoptosis via a mechanism consistent with SIRT1 activation.
SIRT1 is also subject to regulation by direct interaction with the protein
AROS (Active Regulator Of SIRT1). AROS associates with and promotes SIRT1
pro-survival function in cancer cells. Here, AROS is found to specifically promote
cancer cell survival, via a mechanism appearing to involve SIRT1 and downstream
substrates. However, AROS regulation of SIRT1 is not as simple as originally
thought, varying by cell context and substrate. Further to its role in directing SIRT1
activity, AROS also forms a binding interaction with the ribosomal protein RPS19.
The effect of AROS upon RPS19 protein and function is analysed for the first time,
revealing a role for AROS in 40S ribosomal subunit biogenesis. Beyond this, AROS
is discussed as a regulator of translation, and the functional interplay between
RPS19, AROS and SIRT1 is described. This provides a link between cancer
associated anti-apoptotic signalling and ribosome biogenesis centred on regulation of
SIRT1 activity, which could be exploited by anti-cancer therapeutics.
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1 Introduction
1.1 The functions of SIRT1
SIRT1 is a member of the sirtuin family of histone deacetylase enzymes. The
founding member of the family was the Saccharomyces cerevisiae Sir2 protein,
named Silent Information Regulator 2 for its ability to silence repetitive DNA
sequences (Rine and Herskowitz 1987). The discovery that Sir2 could silence
telomeres and rDNA (Gottschling et al. 1990; Bryk et al. 1997; Smith and Boeke
1997) coincided with the emergence of histone post-translational modification as a
means to regulate chromatin, in particular by acetylation (Braunstein et al. 1993;
Thompson et al. 1994; Braunstein et al. 1996). This lead to the discovery that Sir2
acts as a histone deacetylase (Imai et al. 2000), correlating the regulation of
chromatin by Sir2 with the role of reversible acetylation in chromatin biology.
1.1.1 NAD+-dependent enzymatic activity
Sir2 has homologues in bacteria, archaea and eukaryotes, which collectively
are referred to as the sirtuins (Frye 2000). After the identification of Sir2 as a
deacetylase enzyme, Sir2 homologues were analysed and found to be conserved
deacetylases acting via a novel mechanism (Landry et al. 2000; Smith et al. 2000).
Unexpectedly, the analyses of sirtuin enzymatic activity uncovered a strict
requirement for the redox metabolite NAD+ (Imai et al. 2000; Landry et al. 2000;
Smith et al. 2000). NAD+ is required for catalytic removal of acetyl groups from
substrate lysine residues, creating nicotinamide and a novel metabolite O-acetyl-
ADP-ribose (Tanner et al. 2000). The majority of sirtuins are deacetylases, although
some do not appear to have enzymatic activity or catalyse alternative reactions, such
as removal of larger post-translational modifications (Du et al. 2011) or ribosyl-
transferase activity (Bell et al. 2002).
The closest mammalian homologue to Sir2 is the SIRT1 protein (Frye 2000),
which has NAD+-dependent deacetylase activity. As well as regulating chromatin via
deacetylation of histones, SIRT1 was the first sirtuin found to deacetylate a non-
histone protein – namely the p53 tumour suppressor (Luo et al. 2001; Vaziri et al.
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2001). This expanded the repertoire of the sirtuins, which have since been identified
as wide ranging protein deacetylases.
The sirtuins act as sensors of cellular metabolism via their NAD+-
dependence, and can modulate substrate function via reversible deacetylation. For
example, SIRT1 modulates ribosomal RNA transcription via epigenetic silencing of
rDNA loci (Murayama et al. 2008). This enables SIRT1 to react to low nutrient
availability, which manifests as an increase in NAD+ abundance (Canto et al. 2009),
and promote lysine methylation of chromatin by catalysing the initial deacetylation
reaction. Through this mechanism SIRT1 is hypothesised to be integral to a
metabolism responsive ‘throttle’ for cell growth (Grummt and Ladurner 2008). This
serves to demonstrate the strict dependence SIRT1 has upon NAD+, and the precise
modulation of SIRT1 possible via NAD+ abundance.
1.1.2 Longevity
The first ascribed physiological function of the sirtuins was in the
determination of organismal lifespan. Deletion of the Sir2 gene in Saccharomyces
cerevisiae reduced life span, whereas insertion of an extra copy of Sir2 increased
lifespan by up to 30% (Kaeberlein et al. 1999). Interestingly, overexpression of the
closest homologues of Sir2 in both the nematode worm (Caenorhabditis elegans)
and fruit fly (Drosophila melanogaster) also resulted in an increase in lifespan
(Tissenbaum and Guarente 2001; Rogina and Helfand 2004).
SIRT1 was therefore believed to hold the same capacity in mammals,
potentially allowing lifespan extension by activation. However, recent analysis of
mice overexpressing SIRT1 revealed no lifespan extension compared to mice
expressing SIRT1 at normal levels (Herranz et al. 2011). Despite this, intense study
has revealed crucial roles for SIRT1 in the aetiology in a number of human diseases,
as follows.
1.1.3 Type-2 diabetes
SIRT1 has been implicated in type-2 diabetes via two potential mechanisms;
firstly, the regulation of the insulin signalling pathway; and secondly, regulation of
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the metabolic pathways involved in management of carbon bound energy. SIRT1
protects against insulin resistance associated with type-2 diabetes in mice by
ensuring correct function of the insulin signalling cascade in the liver (Wang et al.
2011b). In type-2 diabetes insulin production is normal but the effect insulin has
upon the liver, and other organs, is lost. Thus, by ensuring the insulin signal is
correctly received in the liver SIRT1 may suppress the onset of type-2 diabetes.
SIRT1 also directly deacetylates the metabolic regulator PGC-1α,
modulating glycolysis, anaerobic respiration and gluconeogenesis in metabolic tissue
(Nemoto et al. 2005; Rodgers et al. 2005). Through PGC-1α, SIRT1 appears to
integrate nutrient availability (via NAD+, see above) with the transcriptional control
of enzymes involved in carbon uptake, usage and storage. Thus, SIRT1 may also
ensure the correct processing of carbon, which may be aberrant in type-2 diabetes.
The most compelling evidence that SIRT1 protects against type-2 diabetes comes
with the observation that upregulation of SIRT1 reduces the incidence of type-2
diabetes in mice (Banks et al. 2008; Yoshino et al. 2011). Thus, SIRT1 contributes to
resistance to pathology in type-2 diabetes, likely via modulating the response to
insulin and subsequent management of carbon bound energy.
1.1.4 Neurodegenerative disorders
Similar to the protective role of SIRT1 in the pathology of type-2 diabetes,
SIRT1 function has also been implicated in protecting against neurodegenerative
disorders such as Parkinson’s and Alzheimer’s disease. The accumulation of β-
amyloid and hyper-phosphorylated tau in these diseases is suppressed by the activity
of SIRT1 (Donmez et al. 2010; Min et al. 2010). SIRT1 is able to genetically
upregulate the enzyme ADAM10 and the Notch signalling pathway, which
suppresses β-amyloid production (Donmez et al. 2010) and directly deacetylates the
tau protein, suppressing its aggregation (Min et al. 2010). Crucially, in both of these
studies suppression of SIRT1 correlated with increased disease severity in mouse
models. This indicates the opportunity to activate SIRT1 as a potential method to
treat these common neurodegenerative disorders.
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1.1.5 Ischemia
SIRT1 is expressed in endothelial cells and is important in the response to
localised reduced oxygen availability, termed ischemia (Potente et al. 2007; Hsu et
al. 2010; Nadtochiy et al. 2011). In endothelial cells SIRT1 activity promotes
resistance to ischemia and regenerative neovascularisation following an ischemic
event. SIRT1 activity may therefore be protective against damage from stroke
following brain ischemia, and could protect against cardiac ischemia associated with
myocardial infarction.
As well as type 2 diabetes, neurodegeneration and ischemia, SIRT1 has been
linked to further disease states such as aberrant inflammation and in the regulation of
kidney function (reviewed by Donmez and Guarente 2010; Hao and Haase 2010).
Together this highlights the diverse range of diseases in which SIRT1 has been
implicated. However, chief among these diseases is cancer. This is the context in
which SIRT1 is analysed in this work.
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1.2 SIRT1 and cancer
The role of SIRT1 in cancer has been the source of much debate, with
apparently conflicting reports as to whether SIRT1 promotes or suppresses tumour
growth and formation. Interestingly, the answer appears to be both, with SIRT1
having pleiotropic effects depending on context.
1.2.1 Cancer cell survival
The first indication that SIRT1 has a role in cancer came with the observation
that SIRT1 deacetylates the tumour suppressor protein p53 (Luo et al. 2001; Vaziri et
al. 2001). The importance of p53 in protecting against cancer formation is
demonstrated in its mutation in 50% of cancers, with suppressive misregulation of
the protein hypothesised in the remaining 50% (Vogelstein et al. 2000; Olivier et al.
2010; Goh et al. 2011). Thus, constitutive suppression of p53 appears to be essential
for cancer formation.
Interestingly for the role of SIRT1, the acetylation status of p53 is linked to
its tumour suppressive activity, with acetylation promoting sequence specific DNA
binding (Gu and Roeder 1997). More recently acetylation of p53 has been described
as ‘indispensible’ for p53 activation (Tang et al. 2008). In the ‘Tang Model’ for p53
activation, acetylation of lysine allows activation of p53, while mutant p53 that
cannot be acetylated is unable to transactivate p53 target genes involved in tumour
suppression (Figure 1.1).
According to the Tang Model the reversible acetylation and deacetylation of
p53 will have a determining effect upon p53 activity (Figure 1.1). SIRT1
deacetylates p53, thus promoting its inactivation (Luo et al. 2001; Vaziri et al. 2001).
Given the role of p53 as a tumour suppressor and ‘guardian of the genome’ (Lane
1992), inactivation was hypothesised to promote cancer cell survival. This was found
to be the case, with suppression of SIRT1 correlating with cancer cell arrest and
apoptosis (programmed cell death), with an associated increase in p53 acetylation
(Ford et al. 2005). Furthermore, the increase in p53 acetylation observed following
SIRT1 suppression belies a constitutive cycle of acetylation and deacetylation
(Figure 1.1). Accordingly, perturbation of SIRT1-mediated deacetylation results in
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constitutive acetylation of p53, due to the constitutive activity of the acetyl-
transferase enzymes opposing SIRT1 activity (Ford et al. 2005).
The role of SIRT1 as a regulator of tumour suppression was further enhanced
by the discovery that it can also deacetylate and suppress the FOXO family of
tumour suppressor transcription factors (Brunet et al. 2004; Motta et al. 2004). Thus,
SIRT1 is able to promote cancer cell growth by suppressing the pro-apoptotic and
anti-proliferative signalling of p53 and the FOXO proteins. Importantly, despite
being able to suppress both p53 and the FOXO proteins, SIRT1-mediated cancer cell
survival does not require the expression of p53 or FOXO3 in colorectal
adenocarcinoma cell lines (Ford et al. 2005). However, SIRT1 mediated suppression
of cancer cell apoptosis does require the expression of FOXO4.
Thus, Ford et al identified that SIRT1 suppresses cancer cell apoptosis
independent of p53 and FOXO3, but dependent upon FOXO4 (2005). This
highlights the role of SIRT1 in suppression of FOXO4, or stated differently, FOXO4
is a cancer cell ‘executioner’ with SIRT1 suppressing the activity of this executioner.
It is important to stress that SIRT1 does deacetylate and suppress p53, but that this
was not essential for cancer cell survival in this study. This is an important
mechanistic observation that is drawn upon during the analysis of SIRT1 regulation
in this project.
SIRT1 has been termed a cancer cell survival factor, based on its ability to
suppress cancer cell arrest and apoptosis (Ford et al. 2005). SIRT1 promotion of
cancer cell survival via protein deacetylation appears to be conserved in many types
of cancer, most recently studied in gastric cancer (Bou Kheir et al. 2011),
hepatocellular carcinomas (Chen et al. 2011a) and pancreatic cancer (Zhao et al.
2011). SIRT1 has also been linked with the epigenetic suppression of tumour
suppressor genes in cancer, presumably dependent upon histone deacetylation (Pruitt
et al. 2006). Together this indicates that SIRT1 has a range of mechanisms to
suppress cancer cell death.
Importantly for potential anti-cancer therapeutic inhibition, SIRT1 is not
required for non-cancer cell line survival (Ford et al. 2005). Thus, SIRT1 is not only
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a cancer cell survival factor but a specific cancer cell survival factor. However, the
role of SIRT1 in non-cancer cells has recently been questioned. Evidence suggests
that despite being redundant for survival, SIRT1 may have an important role in
tumour suppression.
1.2.2 Non-cancer cell tumour suppression
The manipulation of the SIRT1 gene in mice has presented a role in tumour
suppression. The first indication that SIRT1 suppresses tumour formation was in
transgenic mice genetically predisposed to cancer where the SIRT1 gene was over-
expressed (Firestein et al. 2008). Mice engineered to over-express SIRT1 specifically
in gastro-intestinal villi were crossed with mice expressing low levels of the APC
gene, which are predisposed to intestinal cancer. In this mouse model, over-
expression of SIRT1 reduced the incidence of colon cancer compared to mice with
normal SIRT1 expression. Thus, the presence of SIRT1 protected against tumour
formation.
The mechanism by which SIRT1 suppresses tumour formation was later
linked to the maintenance of genomic stability in SIRT1+/- haploinsufficient mice
(Wang et al. 2008b). Reduced SIRT1 expression correlated with increased
tumourigenesis, which was reduced by chemical activation of SIRT1 activity. The
inverse experiment in an alternative mouse model of SIRT1 overexpression resulted
in decreased incidence of aging associated cancers (Oberdoerffer et al. 2008).
Together the manipulation of the SIRT1 gene in the mouse provides strong evidence
that SIRT1 acts as a tumour suppressor.
Although a role as a tumour suppressor appears to contradict SIRT1 being a
cancer cell survival factor, the consensus in the field is that SIRT1 acts as both a
tumour suppressor and cancer cell survival factor. A key parameter for SIRT1
function appears to be context. Thus, in normal cells SIRT1 protects against the
formation of tumours, likely via a mechanism involving genomic stability
(Oberdoerffer et al. 2008; Wang et al. 2008b), but following the formation of cancer
SIRT1 acts as a survival factor for cancer cells (Ford et al. 2005).
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This pleiotropy for SIRT1 function has implications for direct inhibition of
the protein as an anti-cancer strategy. Suppressing SIRT1 may induce cancer cell
death but could also subvert normal SIRT1 function in tumour suppression in non-
cancerous tissue. To address this issue novel methods of modulating SIRT1 activity
in cancer are being sought, which may allow specific targeting in cancer, leaving
functions in non-cancer cells unaffected. This draws upon the expanding field of
SIRT1 regulation (see below).
1.2.3 SIRT1 expression in cancer
SIRT1 expression is commonly increased in cancer, consistent with its role as
a cancer cell survival factor (see above). Over-expression of SIRT1 protein has been
reported in human cancer cell lines compared to non-cancer cells (Ford et al. 2008;
Wang et al. 2011a), as well as in two studies of primary prostate cancer samples
compared to samples of non-cancerous origin (Huffman et al. 2007; Zhao et al.
2011). Furthermore, overexpression of SIRT1 protein, but not mRNA, has been
reported in hepatocellular carcinomas (Chen et al. 2011a). This suggests that post-
translational regulation of SIRT1 expression in cancer is important. Post-
translational regulation may also explain the observation that SIRT1 mRNA was
expressed at a lower level in a study of human colorectal tumours compared to
parallel normal specimens (Ozdag et al. 2006). Importantly, this study did not
analyse SIRT1 protein, which may still have been expressed at a higher level and
able to act as a cancer cell survival factor.
Thus, regulation of SIRT1 protein appears to be important in cancer, and will
potentially influence cancer cell survival via the SIRT1-mediated suppression of
cancer cell apoptosis and arrest (Ford et al. 2005). Regulation of SIRT1 protein may
also negate the requirement for increased expression from the SIRT1 gene, which
appears to be varied. Two mechanisms of regulation of SIRT1 protein are analysed
in this project, via a direct SIRT1 binding partner called AROS, and via the
metabolic enzyme LDH-A.
Figure 1.1: SIRT1 and the Tang Model of p53 activation
Deacetylated p53 (left) is inactive, whereas acetylated p53 (right) is active as a
transcription factor. The role of
transferases that catalyse the reversible acetylation of p53 is thus extremely
important. SIRT1 deacetylates p53 at lysine 382 promoting inactivation of p53. This
contributes to a constitutive cycle of acetyl
SIRT1 activates p53 via increased acetylation.
SIRT1, other deacetylase enzymes and the acetyl
ation and deacetylation. Suppression of
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1.3 Regulation of SIRT1 transcription
SIRT1 is subject to regulation at the transcriptional, post-transcriptional and
post-translational level. The final expression of SIRT1 protein may influence its
function, as will SIRT1 subcellular localisation and crucially the availability of the
SIRT1 co-enzyme NAD+. The multiple methods of SIRT1 regulation are outlined
below, with a focus on how this may contribute to increased SIRT1 function in
cancer cells. In many cases the upregulation of SIRT1 can be cited as further
evidence for SIRT1 acting as a cancer cell survival factor due to the cancer
association of many of the regulators described herein.
The SIRT1 gene is located on the ‘q’ arm of chromosome 10. It is subject to
regulation by a number of transcription factors, detailed below. Most of these factors
form autoregulatory feedback loops via SIRT1 protein, which are hypothesised to
limit SIRT1 expression under normal conditions. However, these autoregulatory
loops may be aberrant in cancer to contribute to SIRT1 overexpression. Regulation
of SIRT1 transcription is summarised in Figure 1.2.
1.3.1 Hypoxia inducible factors (HIFs)
The hypoxia inducible factors, HIF1 and HIF2, are transcription factors that
both promote SIRT1 gene expression (Chen et al. 2011b). Both HIF complexes are in
turn subject to regulation by SIRT1-mediated deacetylation, which promotes HIF
target gene transcription (Dioum et al. 2009; Lim et al. 2010). This creates positive
feedback loops for SIRT1 expression, dependent upon HIF activity. These loops may
modulate the metabolic response to hypoxic stress. However, HIF activity is
commonly increased in hypoxic tumours, which may induce increased expression of
SIRT1. This could contribute to the role of SIRT1 as a cancer cell survival factor,
which would be responsive to the physical environment of tumours (Knight and
Milner 2011).
1.3.2 Cyclic-AMP and Carbohydrate Responsive-Element-Binding proteins
(CREB and ChREBP)
SIRT1 mRNA and protein expression can be modulated by nutrient
availability. SIRT1 expression is modulated by two transcription factors in response
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to the availability of nutrients in the liver, adipose and muscle (Noriega et al. 2011).
CREB is activated during low nutrient availability in order to release stored nutrients
to meet organism energy demand. Inversely, ChREBP ensures energy is stored when
available, also via transcriptional regulation. SIRT1 expression is promoted by
CREB and suppressed by ChREBP, providing two additive mechanisms that activate
SIRT1 in low nutrient conditions and suppress SIRT1 in high nutrient conditions
(Noriega et al. 2011).
As well as expression from the SIRT1 gene responding to nutrient
availability, SIRT1 activity can be modulated more rapidly via alterations in the
availability of NAD+. The kinase AMPK responds to ATP abundance and modulates
NAD+ availability via activation of mitochondria (Canto et al. 2009). Fasting or
activation of AMPK increases NAD+ availability and thus SIRT1 activity in
response to nutrient deprivation. This appears to correlate with the genetic
modulation of SIRT1 via CREB and ChREBP in response to nutrients (Noriega et al.
2011), with these together presumably allowing SIRT to be modulated both acutely
(via AMPK) and then maintained for a greater period of time (via CREB/ChREBP).
Importantly, cancerous tissue is often poorly vascularised, leading to poor
nutrient supply to tumours (reviewed by Hanahan and Weinberg 2011). As a result,
many cancer cells experience nutrient stress. In light of the evidence above, nutrient
deprivation may support SIRT1 expression and function in cancer, although these
studies were in non-cancerous cells. Intriguingly, these mechanisms provide a further
example of modulation of SIRT1 expression being linked to the tumour
environment.
1.3.3 Hypermethylated in cancer (HIC1)
The HIC1 gene is commonly down-regulated in cancer by hypermethylation
of its promoter (Wales et al. 1995). Consistent with SIRT1 overexpression in cancer,
the HIC1 protein acts as a transcriptional suppressor at the SIRT1 gene (Chen et al.
2005). As such, reduced HIC1 expression due to cancer associated hypermethylation
may result in increased SIRT1 expression. Interestingly, to suppress the SIRT1 gene,
HIC1 complexes with SIRT1 protein, forming an autoregulatory loop in the process.
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This autoregulation would be lost following HIC1 suppression in cancer, potentially
allowing SIRT1 expression to increase above normal levels.
1.3.4 c-Myc
c-Myc is an endogenous regulator of cell proliferation but is also a proto-
oncogene able to drive the transformation of normal cells into cancerous cells
following aberrant upregulation (reviewed by Soucek and Evan 2010). SIRT1 forms
a negative autoregulatory feedback loop with c-Myc (Yuan et al. 2009). Within this
loop, c-Myc promotes SIRT1 transcription, and is in turn suppressed by SIRT1
deacetylation. Aberrant increased activity of c-Myc contributes to cancerous growth
and it has become a putative therapeutic target (Soucek and Evan 2010). Together,
this evidence suggests that upregulation of SIRT1 may participate in aberrant c-Myc
driven cancers.
1.3.5 E2F transcription factor 1 (E2F1)
The transcription factor E2F1 promotes SIRT1 transcription, in a process
suppressed by interaction between the SIRT1 and E2F1 proteins (Wang et al. 2006).
Thus, SIRT1 protein suppresses transcription of its own gene via E2F1 in a negative
autoregulatory loop. E2F1 is a downstream target of the Rb tumour suppressor and is
commonly deregulated in cancer, leading to increased expression (Wu et al. 2009).
Similar to the mechanism above for c-Myc, increased E2F1 activity in cancer may
lead to increased SIRT1 expression, associated with cancer cell survival.
1.3.6 p53
p53 promotes SIRT1 gene transcription (Nemoto et al. 2004), and is in turn
suppressed via SIRT1 mediated deacetylation (Luo et al. 2001; Vaziri et al. 2001).
This creates a negative feedback loop for SIRT1 expression controlled by a key
tumour suppressor. Wild-type p53 protein expression is lost in 50% of tumours and
the protein is believed to be misregulated in many of the remaining cases (Vogelstein
et al. 2000; Olivier et al. 2010; Goh et al. 2011). This may reduce SIRT1 expression
in cancer, and thus appears to contradict SIRT1 overexpression. However, it is
possible that regulation of SIRT1 by p53 may be secondary to regulation by other
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factors, allowing SIRT1 overexpression. Indeed the upregulation of gene expression
by other factors is likely to counteract loss of upregulation from p53.
1.3.7 Breast cancer type 1 susceptibility protein (BRCA1)
BRCA1, commonly mutated in breast cancer, directly promotes SIRT1
transcription (Wang et al. 2008a). No autoregulatory feedback loop has been
discussed between SIRT1 and BRCA1, although this does not rule out its existence.
Like p53 above, BRCA1 is a tumour suppressor, suggesting that SIRT1 expression
would be reduced following its mutation in cancer. However, as with p53, this may
be counteracted by regulation of SIRT1 by alternative transcription factors known to
modulate SIRT1 expression.
Figure 1.2: Regulation of
Modes of regulation of the
transcription, whereas factors in green promote
that have a feedback loop with SIRT1
CREB respond to nutrient availability (‘Nutrients’) to regulate
SIRT1 gene expression
SIRT1 gene. Transcription factors in red suppress
SIRT1 mRNA production. Factors
are identified by the arrows. ChREBP and
SIRT1
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1.4 Translational regulation of SIRT1
SIRT1 mRNA is subject to regulation by interaction with small regulatory
RNAs and proteins. SIRT1 mRNA is bound by the RNA binding protein HuR
(Abdelmohsen et al. 2007b). HuR stabilises SIRT1 mRNA via this direct interaction,
upregulating protein expression. Interestingly, HuR regulates a number of anti-
apoptotic factors, suggesting that SIRT1 mRNA is stabilised as part of a wider
network to promote cell survival (Abdelmohsen et al. 2007a). This may play a role in
cancer-associated upregulation of SIRT1, but has not been formally assessed.
microRNAs target SIRT1 mRNA for degradation, with this loss of SIRT1
protein having negative effects on cancer cell viability and growth. This provides
further evidence for the survival promoting function of SIRT1 in cancer. The first
microRNA characterised to target SIRT1 mRNA was miR-34a, which promotes
colon cancer cell apoptosis via suppression of SIRT1 (Yamakuchi et al. 2008).
Similarly, microRNAs that target SIRT1 induce breast cancer cell senescence, miR-
22, and reduce gastric cancer cell proliferation, miR-449, via direct suppression of
SIRT1 mRNA (Bou Kheir et al. 2011; Xu et al. 2011). Thus, to correlate with SIRT1
overexpression in cancer it appears that the microRNAs targeting SIRT1 are likely to
be suppressed in cancer. Consistent with this, the SIRT1 targeting microRNA miR-
200a is expressed at low levels in breast cancer cells, which inversely correlates with
SIRT1 expression (Eades et al. 2011).
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1.5 Post-translational modification of SIRT1
SIRT1 protein is subject to regulation via reversible covalent modification,
direct interaction with other proteins and the provision of its essential coenzyme
NAD+. Reversible covalent modification takes the form of phosphorylation and
SUMOylation as outlined below, although there is also evidence for SIRT1
methylation, also discussed. There is likely to be interplay between post-translational
modification and regulation by direct protein binding to fine tune SIRT1 activity.
SIRT1 is subject to phosphorylation by at least 7 cellular kinases, which
modulate SIRT1 activity, stability and localisation. This can promote or suppress
SIRT1 activity and may contribute to increased SIRT1 function in cancer cells.
1.5.1 c-Jun N-terminal Kinases (JNKs)
Phosphorylation of SIRT1 by JNK2 at serine 27 (S27) increases SIRT1
protein stability, in a mechanism linked to increased SIRT1 expression in cancer cell
lines (Ford et al. 2008). The JNK2 homologue, JNK1 is also able to directly
phosphorylate SIRT1 protein at S27, as well as S47 and threonine 530 (T530)
(Nasrin et al. 2009). This enhances SIRT1 activity and increases nuclear localisation
in human and mouse non-cancer cells. The JNK proteins are responsive to stress and
participate in apoptotic signalling (Dhanasekaran and Reddy 2008; Ahmed and
Milner 2009). Interplay between JNK and SIRT1 may represent coordination of
apoptotic signalling pathways.
1.5.2 Dual-specificity tyrosine phosphorylation regulated kinases (DYRKs)
Two pro-survival kinases from the DYRK family (DYRK1a and DYRK3)
directly phosphorylate SIRT1 at T522 (Guo et al. 2010b). In accordance with the
pro-survival role of SIRT1, this increases SIRT1 activity and reduces apoptosis.
Further, SIRT1 phosphorylation is shown to be required for DYRK promotion of cell
survival. Thus, in the form of the JNK and DYRK proteins 4 kinases promote SIRT1
activity and prolong cell survival in the process. However, kinases also suppress
SIRT1 activity.
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1.5.3 Mammalian Target of Rapamycin (mTOR)
mTOR regulates cellular metabolism, longevity and has been implicated in
cancer survival signalling (reviewed by Yecies and Manning 2011). In many ways
mTOR and SIRT1 are extremely similar. Interestingly, the two appear to form a
regulatory loop via reciprocal repression. The mTOR complex has kinase activity
and regulates SIRT1 by phosphorylation of serine 47 (Back et al. 2011).
Phosphorylation decreases SIRT1 activity and sensitises cancer cells to enter
apoptosis in response to DNA damage. In reciprocal, SIRT1 is able to suppress
mTOR via interaction with the TSC2 protein, a component of an inhibitory-complex
upstream of mTOR (Ghosh et al. 2010). Thus, SIRT1 and mTOR repress reciprocal
activity. This may be linked to their similar roles in regulating metabolism and
longevity, requiring each to keep the reciprocal protein in check.
Interestingly, serine 47 phosphorylation was associated with SIRT1
activation by JNK1 in cells of non-cancerous origin (Nasrin et al. 2009), as opposed
to SIRT1 suppression by mTOR in cancer cells under stress (Back et al. 2011). This
implies that phosphorylation may have specific effects according to cell type and
may differ between non-cancer and cancer cells.
1.5.4 Mammalian Sterile 20-like kinase 1 (MST1)
MST1 directly phosphorylates the SIRT1 carboxyl terminal region (Yuan et
al. 2011). This phosphorylation inhibits SIRT1 activity, indicated by loss of SIRT1-
mediated suppression of p53. Suppression of SIRT1 by MST1 is consistent with a
proposed tumour suppressor function for MST1 (Pan 2010).
1.5.5 Casein Kinase II (CK2)
Phosphorylation of SIRT1 by the CK2 protein has also been reported, but
with no functional significance (Zschoernig and Mahlknecht 2009). Importantly for
the study of SIRT1 phosphorylation, no phosphatase has been identified that
counteracts the function of the kinases detailed above. With phosphorylation able to
promote or suppress SIRT1 activity it is clear that phosphatases will also be able to
modulate SIRT1 function.
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1.5.6 SUMOylation
SIRT1 is SUMOylated in the carboxyl terminus of the protein at lysine 734
in a reaction that is opposed by the de-SUMOylation enzyme SENP1 (Yang et al.
2007). SUMOylation increases SIRT1 activity, promoting human cancer cell
survival. The enzyme responsible for SUMOylation of SIRT1 has yet to be identified
but is likely, together with SENP1, to have an important role in regulating SIRT1
activity.
Figure 1.3: Post-translational regulation of SIRT1
SIRT1 protein is subject to both positive (shown in green) a
(shown in red). This can occur via regulation of NAD
blue), direct interaction with other proteins (enclosed in light orange) or post
translational modification (enclosed in light purple). LDH
highlighted in white lettering as the proteins studied within this work. PARP
via suppression of SIRT1 gene expression, but has been included here together with
PARP-1 under the bracket of ‘PARPs.’
nd negative regulation
+ availability (enclosed in light
-A and A
Introduction
36
-
ROS are
-2 acts
Introduction
37
1.6 Regulation of SIRT1 by direct interaction
Modulation by post-translational modification requires direct interaction of
the modifying enzyme with SIRT1. However, SIRT1 is also subject to modulation
by interaction with proteins independent of reversible modification. Protein
association can promote or suppress SIRT1 activity. The first direct modulator of
SIRT1 to be identified was a protein termed AROS, for Active Regulator Of SIRT1
(Kim et al. 2007). AROS is a major focus of the analysis in this project and is thus
discussed in greater detail below (Section 1.8). Here the regulation of SIRT1 by
other direct interactions is outlined.
1.6.1 Deleted in breast cancer 1 (DBC1)
DBC1 directly interacts with SIRT1 and suppresses its deacetylase activity
(Kim et al. 2008; Zhao et al. 2008). The interaction with DBC1 is mediated by the
SIRT1 catalytic domain (Kim et al. 2008), suggesting that DBC1 binding occludes
the association of substrates with SIRT1. At the functional level, suppression of
DBC1 results in increased SIRT1 activity towards p53, and subsequent suppression
of p53-dependent apoptosis (Zhao et al. 2008). As suggested by the nomenclature of
DBC1, it is located in a region of the genome that is commonly lost in breast cancers
(Hamaguchi et al. 2002). Loss of an endogenous suppressor of SIRT1 in cancer
correlates well with the role of SIRT1 in promoting cancer cell survival detailed
above.
1.6.2 Internal peptide sequence
SIRT1 activity is regulated by an intra-molecular interaction between the
catalytic core domain and a 25 amino acid sequence in the carboxyl terminus of
SIRT1 (Kang et al. 2011). This peptide sequence, termed the ESA region – Essential
for SIRT1 Activity region – is highly conserved and may facilitate the interaction of
SIRT1 with substrates. SIRT1 activity is inhibited by deletion or mutation of the
ESA sequence. Interestingly, the ESA region appears to directly compete with DBC1
for autoregulatory binding to the SIRT1 catalytic core, giving mechanistic insight
into how DBC1 suppresses SIRT1 activity. The interaction also presents the
possibility to modulate SIRT1 activity with ESA region mimetics.
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1.6.3 Set domain containing 7/9 (Set7/9)
Set7/9 is a histone methyltransferase important for facilitating transcription
by orchestrating epigenetic modification of histones (Nishioka et al. 2002). Set7/9
has also been implicated in the regulation of p53 localisation and stability, promoting
a longer half life for nuclear p53 protein (Chuikov et al. 2004). As well as directly
regulating p53, Set7/9 has recently been implicated in the regulation of p53 via
modulation of SIRT1 activity (Liu et al. 2011). Set7/9 directly associates with SIRT1
and suppresses the ability of SIRT1 to bind and deacetylate p53. Set7/9 is included
under the bracket of regulation by interaction as, despite the observation that SIRT1
can be methylated, Set7/9 appears to suppress SIRT1 activity independent of
methyltransferase function (Liu et al. 2011).
The effect Set7/9 has on SIRT1 functions other than suppression of p53 has
not been formally assessed. This highlights one of the main areas for expansion in
the field of SIRT1 regulation – analysis of the effect of each modulator on a greater
number of SIRT1 substrates than the classical target p53. This is one area addressed
in relation to the chosen SIRT1 regulators in this project.
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1.7 Regulation of SIRT1 by NAD+ availability
SIRT1 enzymatic activity is entirely dependent upon NAD+ as a co-enzyme
for every deacetylation event (Imai et al. 2000; Landry et al. 2000; Smith et al.
2000). Furthermore, SIRT1 activity is modulated by NAD+ in response to nutrient
availability (Canto et al. 2009). The ability to target SIRT1 via modulation of NAD+
has been postulated ever since the discovery that SIRT1 is dependent upon the redox
metabolite, but has only recently been analysed functionally (reviewed by Cantó and
Auwerx 2011; Imai 2011). The avenues that have currently been explored are via
modulation of NAD+ synthesis or the NAD+ consuming PARP enzymes. It is also
likely that the other sirtuins compete with SIRT1 for NAD+, but this has not been
addressed experimentally.
1.7.1 NAD+ synthesis
NAD+ can be synthesised de novo or recycled after use as a co-enzyme via a
salvage pathway (reviewed by Yang and Sauve 2006; Ying 2008). SIRT1 produces
Nicotinamide (NAM) from NAD+ during deacetylation, which can inhibit SIRT1
activity at high concentrations. NAM is converted back into NAD+ via two reactions
catalysed by two enzymes. Firstly, the Nicotinamide Mononucleotide Adenylyl
Transferase enzyme (NMNAT) converts NAM into Nicotinamide Mononucleotide
(NMN) by the addition of phospho-ribose. NMN is then converted into NAD+ by the
ligation of adenine to the phosphate group creating the dinucelotide structure of
NAD+. The second reaction is catalysed by the enzyme Nicotinamide
Phosphoribosyltransferase (NAMPT). This salvage pathway has the ability to
promote SIRT1 activity by providing further NAD+ and also by reducing potential
inhibition by NAM. NAD+ synthesis is summarised in Figure 1.4.
Interestingly, NMNAT co-localises to gene promoters with SIRT1,
enhancing transcription of genes regulated by SIRT1 (Zhang et al. 2009).
Suppression of NMNAT function reduced SIRT1 activity, suggesting that NMNAT
is required at gene promoters to process NAM to perpetuate SIRT1 activity.
Interestingly, in the same study suppression of NAMPT also affected SIRT1-
mediated gene transcription, but this was not localised at promoters. This identifies
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NMNAT as a potent local regulator of SIRT1 function, likely via the removal of
NAM and perhaps provision of NAD+ via NAMPT.
Upregulation of NAMPT was observed to be sufficient to increase NAD+
availability and SIRT1 deacetylation activity in murine fibroblast cells (Revollo et al.
2004). From this, NAMPT activity was proposed as the rate limiting step in the
NAD+ salvage pathway, giving NAMPT a crucial role in controlling SIRT1 function.
Despite not having the same effect on NAD+ or SIRT1 in the same study, the role of
NMNAT is undoubtedly essential for NAD+ synthesis in this pathway. Perhaps
consistent with the rate limiting role for NAMPT, overexpression of the enzyme has
been reported in prostate cancer cell lines (Wang et al. 2011a). This was linked to
cancer cell survival in the same study, as overexpression of NAMPT permitted the
SIRT1-dependent survival of prostate cancer cells in response to stress.
Thus, NMNAT and NAMPT appear to be important for the provision of
NAD+ to perpetuate SIRT1 activity, in a mechanism that is potentially upregulated in
cancer. Unfortunately, inhibition of NAMPT in an anti-cancer clinical trial resulted
in side effects ranging from vomiting and nausea to alterations in the cellular
constitution of patient blood (von Heideman et al. 2010). These side effects may be
attributable to an essential role of NAMPT in non-cancer cells. Thus, NAMPT does
not appear to be a cancer specific survival factor.
1.7.2 Poly-ADP ribose polymerases (PARPs)
The family of PARP proteins are also NAD+-dependent, catalysing the
ligation of ADP-ribose to a range of substrates to modulate their function (Schreiber
et al. 2006; Krishnakumar and Kraus 2010). The dominant function of the PARP
enzymes appears to be in the orchestration of the DNA damage response following
genotoxic stress. Due to the NAD+ dependence of the PARP proteins they are
believed to compete with SIRT1 for NAD+. The potential to modulate SIRT1
activity via PARP family members was analysed in PARP-1 and PARP-2 knockout
mice (Bai et al. 2011a; Bai et al. 2011b).
Knockout of PARP-1 gave an increase in NAD+ levels, presumably due to
reduced NAD+ expenditure by the PARP-1 enzyme, and a correlative increase in
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SIRT1 activity (Bai et al. 2011b). However, the study also noted an increase in
SIRT1 expression in the absence of PARP-1, indicative of a negative effect on
SIRT1 protein turnover, which may explain the decrease in SIRT1 activity. A
parallel study following knockout of the PARP-2 enzyme also increased SIRT1
activity, but this occurred via upregulation of SIRT1 protein and mRNA levels (Bai
et al. 2011a). This was achieved by PARP-2 suppressing SIRT1 gene transcription
directly at the SIRT1 promoter.
In these studies, modulation of both PARP-1 and PARP-2 was hypothesised
to alter SIRT1 activity and promote mitochondria biogenesis. The clinical
application of this was discussed in relation to type-2 diabetes and obesity. However,
inhibition of the PARP proteins may leave cells susceptible to DNA damage, due to
the role of the PARPs in orchestrating DNA repair. Thus, modulation of SIRT1 via
the PARP proteins may risk genomic instability (Knight and Milner 2011).
Figure 1.4: The process of NAD
NAD+ is synthesised from NAM via the salvage pathway. NAM is converted into
NMN by the action of NMNAT, then converted into NAD
Sauve 2006; Ying 2008
synthesis pathways enter. NAM inhibits the activity of SIRT1 by competing with
NAD+ for its active site.
+ synthesis via the salvage pathway
+ by NAMPT
). The dotted arrows indicate where the NAD
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Introduction
43
1.8 Regulation of SIRT1 in this work
The publication dates on many of the citations above, evinces that the
regulation of SIRT1 is an emerging field. At the undertaking of the project two
potential post-translational positive regulators of SIRT1 activity were identified for
analysis, LDH-A and AROS. These act via distinct mechanisms which potentially
integrate with cancer cell metabolism and ribosome biogenesis respectively.
1.8.1 Lactate Dehydrogenase A (LDH-A)
LDH-A is an enzyme that, along with its isoenzyme LDH-B, catalyses the
interconversion of pyruvate and NADH to lactate and NAD+ (Baumberger et al.
1933). LDH-A favours the production of NAD+, which is known to facilitate SIRT1
activity (Figure 1.3). It is for this reason that LDH-A is studied in this work. LDH-A
has also been implicated in cancer and the alteration in metabolism associated with
transformation (Le et al. 2010). There may be an increased requirement for LDH-A
to process cytoplasmic pyruvate and permit the Aerobic Glycolysis cycle in cancer
cells. The role of LDH-A in cancer metabolism and how this integrates with SIRT1
activity in cancer cell survival is introduced and analysed in Chapter 3.
1.8.2 Active Regulator Of SIRT1 (AROS)
AROS directly binds to SIRT1 in a region towards the amino terminus from
the core catalytic domain (Kim et al. 2007). Via this interaction AROS increases
SIRT1 activity towards p53 in human cancer cells (Figure 1.3). AROS specifically
interacts with SIRT1 over other sirtuins and was linked to cancer cell survival in the
same study by Kim and colleagues (2007). AROS is believed to increase SIRT1
activity by inducing an allosteric alteration in the SIRT1 active site, increasing
SIRT1 catalytic capacity compared to non-AROS bound SIRT1 (Autiero et al.
2009). AROS is analysed in relation to its role in SIRT1 activation in Chapter 4 and
Chapter 5, focusing on the effect upon p53 and FOXO4 as example SIRT1 targets
with relevance to cancer. The regulation of SIRT1 by AROS in non-cancer cells is
also analysed, which has not been previously reported.
Introduction
44
The work undertaken also encompassed analysis of ribosome biogenesis,
where a role for AROS is hypothesised and tested. This is based on the observation
that AROS interacts the ribosomal protein RPS19, which is known to be required for
the synthesis of 40S small ribosomal subunits (Maeda et al. 2006; Choesmel et al.
2007; Flygare et al. 2007; Idol et al. 2007). Analysis of AROS in ribosome
biogenesis and how this integrates with cancer cell survival and the SIRT1 gene
forms the work presented in Chapter 6, Chapter 7 and Chapter 8. For clarity, the
premise of the analysis of ribosome biogenesis is introduced with reference to the
current literature during these Chapters. Proteins, processes and hypotheses are
introduced throughout the progression of the Thesis building from chapter to chapter.
As such, formal introduction to AROS and the other factors studied are confined to
each relevant Results Chapter.
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1.9 Aims of project
The overall aim of this Thesis is to identify and characterise novel anti-cancer
therapeutic targets that specifically promote cancer cell survival via post-
translational modulation of SIRT1. The possibility to target cancer cells via SIRT1 is
based on the role of SIRT1 as a cancer specific survival factor and draws from the
currently expanding field of SIRT1 regulation. As discussed above, direct targeting
of SIRT1 for therapeutic gain may be problematic due to a role of SIRT1 as a tumour
suppressor in non-cancer cells. Thus, the ability to target SIRT1 specifically in
cancer cells, leaving its activity in non-cancer cells unaffected, would be
advantageous. For this reason both cancer and non-cancer cell lines are analysed
throughout the Thesis.
The chosen targets for the experimental work, LDH-A and AROS, have been
implicated in aberrant cancer metabolism and ribosome biogenesis respectively. This
is explained in detail as each protein is introduced in respective Results Chapters. As
such, a second broad aim of the Thesis is to uncover potential links between the
cancer cell survival function of SIRT1, the role of LDH-A in cancer metabolism and
the putative function of AROS in ribosome biogenesis (Figure 1.5).
Figure 1.5: SIRT1, cancer metabolism and ribosome biogenesis
A Venn diagram depicting the putative link between the
of cancer cell survival, cancer metabol
SIRT1 gene and regulation
ism and the biogenesis of ribosomes.
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2 Materials and Methods
2.1 Human cell culture
2.1.1 General cell culture methods
All cell lines were grown at 37°C and 5% CO2 in sterile uncoated plastic-
ware (Corning). Prior to use all media and supplements were warmed to 37°C. All
handling of cell lines was contained within laminar flow tissue culture hoods to
maintain sterility. Aseptic technique was maintained throughout using ethanol and
Barrycidal 36 (Interchem Hygiene). All cells were routinely cultured in the absence
of antibiotics within growth medium.
2.1.2 Subcultivation of cells
Cell lines were maintained in appropriate media, as indicated in Table 2.1
and Table 2.2. Cell passage was by trypsinisation. Growth media was aspirated and
cells washed briefly with 1x phosphate buffered saline (PBS) (Roche). Typically 3-
5mLs trypsin-EDTA (Gibco) per T75 flask was added and cells returned to 37°C and
5% CO2 and monitored to ensure optimum trypsinisation time. Trypsin was
quenched with excess serum proteins in complete media, which was subsequently
aspirated from cells following centrifugation at 150g for 3 minutes. For passage of
MCF10A cells, trypsin was quenched using an equal volume of trypsin inhibitor
(Cascade Biologics), due to lack of serum proteins in the MCF10A growth media.
Cells were resuspended into a single cell suspension and cultivated into fresh growth
media and flasks. The frequency and ratio of each split was cell line specific (See
Table 2.1 and Table 2.2). Flasks were briefly agitated in a diagonal fashion to ensure
even coverage of cells across the growth surface. Cells were not subcultivated for
more than 8 passages or 4 weeks.
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Name
(ATCC)
Origin, cell type and
mutations
Media
formulation
Subcultivation
regime
HCT116†
(CCL-247)
Adult male patient
Epithelial colorectal
carcinoma
Mutated RAS proto-
oncogene
DMEM (Gibco) plus
10% foetal calf
serum (FCS)
(Autogen Bioclear)
and 2mM L-
glutamine (Gibco)
Passage at 1:15
to 1:25 every 3
or 4 days
HCT116
p53-/- †
Isogenic clone of HCT116
Directed knockout of both
p53 alleles
DMEM plus 10%
FCS and 2mM L-
glutamine
Passage at 1:10
to 1:20 every 3
or 4 days
MCF7
(HTB-22)
69 year old Caucasian
female
Epithelial mammary gland
adenocarcinoma
MEM (Gibco) plus
10% FCS, 2mM L-
glutamine, 1mM
sodium pyruvate and
0.1mM Non-
essential amino
acids (all Gibco).
Passage at 1:5
to 1:15 every 3
to 4 days
DLD1
(CCL-221)
Adult male patient
Epithelial colorectal
adenocarcinoma.
Mutant p53 S241F
RMPI 1640 (ATCC)
plus 10% FCS ,
2mM L-Glutamine
and 1mM sodium
pyruvate
Passage at 1:5
to 1:15 every 3
to 4 days
LoVo
(CCL-229)
56 year old male
Epithelial colorectal
adenocarcinoma
DMEM plus 10%
FCS and 2mM L-
glutamine
Passage at 1:2
to 1:4 every 3 to
4 days
Table 2.1: Information on cell lines of cancerous origin
† - A kind gift from Professor Bert Vogelstein, John Hopkins University.
Materials and methods
49
Name
Origin, cell type and
mutations
Media formulation
Subcultivation
regime
ARPE19
(CRL-2302)
19 year old male head
trauma fatality
Retinal pigmented
epithelium
DMEM:F12 (Gibco)
plus 10% FCS
(Autogen Bioclear),
2mM L-Glutamine
(Gibco)
Passage at 1:3
to 1:5 every 3 to
4 days
WI38
(CCL-75)
3 month gestation
Caucasian female foetus
Lung fibroblast
MEM (Gibco) plus 10%
FCS, 2mM L-glutamine,
1mM sodium pyruvate,
0.1mM NEAA (all
Gibco).
Passage at 1:3
to 1:5 every 3 to
4 days
MCF10A
36 year old Caucasian
female with fibrocystic
disease
Mammary gland
epithelium
MEBM plus
recombinant hEGF,
insulin, bovine pituitary
extract, hydrocortisone
(as instructed by
supplier – Lonza) plus
100ng/mL cholera toxin
(Sigma)
Passage at 1:5
to 1:15 every 3
to 4 days
Table 2.2: Information on cell lines of non-cancerous origin
Materials and methods
50
2.1.3 Freezing of cells for storage
Cells were routinely frozen at lower than passage 3 for future revival to
ensure the use of low passage cells throughout the Thesis. Cells were trpysinised as
outlined previously (Section 2.1.2), then resuspended out of trypsin in freeze media
comprising 30% normal growth media (See Table 2.1 and Table 2.2), 60% foetal calf
serum (Autogen Bioclear) and 10% DMSO (Sigma). Cells were frozen at 70%
confluency while still in the log growth phase. 1mL aliquots were frozen at -80°C in
cryovials (Nunc), prior to transfer to liquid nitrogen for long term storage. Cells were
revived out of liquid nitrogen by thawing in a water bath at 37°C and cultivated into
fresh pre-warmed growth media in sterile flasks.
2.1.4 Seeding of cells into six well plates
Cells were trypsinised as outlined previously (Section 2.1.2) and resuspended
to a single cell suspension in an appropriate volume of growth media. From this
volume 10µL was applied to a haematocytometer (Neubauer) for cell counting. Two
independent readings were taken and the total cell number calculated. This was used
to ensure seeding at the desired density for each cell line as outlined in Table 2.3.
Uncoated plastic six well plates (Corning) were briefly agitated in a diagonal fashion
to ensure even coverage of cells across the growth surface.
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Cell line Cells per mL
HCT116 7.0 x 104
HCT116 p53-/- 7.0 x 104
MCF7 5.0 x 104
DLD-1 6.0 x 104
LoVo 6.5 x 104
ARPE19 3.0 x 104
WI38 4.0 x 104
MCF10A 7.0 x 104
Table 2.3: Seeding densities for siRNA transfection by cell line
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2.1.5 Transient transfection of cells with siRNA
Transfection of cells with synthetic siRNA was carried 24 hours after seeding
of cells at the densities shown in Table 2.3. Cells were monitored to ensure
successful even plating across the growth surface. The desired density for
transfection varied between cell lines, but was in the region of 50%. Once this was
assured, siRNA (Dharmacon) was transfected in liposomal vesicles (Oligofectamine
– Invitrogen) at a standard concentration of 200nM per well. For further information
on siRNA design see Section 2.2.1 and Table 2.5.
Low serum media Opti-MEM (Gibco) was used during liposome and siRNA
complex formation as high serum content can disrupt complex formation and lead to
low transfection efficiency. Liposomal vesicles were produced according to the
suppliers guidelines (Invitrogen), diluted with Opti-MEM. siRNA for transfection
was diluted in Opti-MEM to the desired concentration and combined with the
oligofectamine dilution for 30 minutes. Cells in 6 well plates were washed in Opti-
MEM then supplied with 800µL of Opti-MEM media per well. Cells were handled
quickly and direct pipetting onto the cells was avoided to reduce mechanical
dislodging. 200µL of the combined siRNA and Oligofectamine was evenly added
drop-wise followed by mixing of the contents by gentle agitation.
Four hours after transfection, cells were supplemented with 0.5mLs feed
media containing 3x the supplements of the appropriate normal media. MCF10A
cells were fed with an equal volume (1mL) normal growth media due to the
restrictions of the media supplements provided by the supplier.
Cotransfection of siRNA to selectively silence multiple targets followed the
same protocol as above, with the total siRNA used not exceeding the 200nM limit.
For example, to silence two targets individual siRNAs were used at 100nM to give a
total siRNA concentration of 200nM.
2.1.6 Validation of basal RNAi
The Milner laboratory has previously shown that RNAi is achievable without
inducing the cell stress response pathway (Ford et al. 2005; Ahmed and Milner
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2009). For verification here, HCT116 colorectal adenocarcinoma cells were plated
and then transfected following the standard Mock treatment used throughout the
Thesis. This involves transfection with active liposomal vesicles in the absence of
siRNA. As detailed above, Mock transfected cells were fed at 4 hours post-
transfection.
Two further treatments were analysed in parallel: cells treated with a media
change at the point of cell feeding, and entirely untreated cells. Untreated cells were
plated in parallel to the other treatments but not treated any further from this point.
Prior to harvesting, cell phenotypes appeared similar between the conditions (Figure
2.1A). The cells were mostly adherent with a comparable density and appearance to
cells in routine cell culture.
Protein samples from each condition were analysed. Induction of a cell stress
response would manifest as an increase in total p53 levels. This did not occur, as p53
expression was comparable between all three conditions (Figure 2.1B). The levels of
SIRT1, AROS and RPS19 were also not greatly altered by the manipulation of the
cells. The Mock treatment shown here is the same as that used in RNAi transfection
throughout the Thesis. The treatment does not alter cell phenotype or expression of
the proteins of interest compared to untreated cells, making Mock treatment a valid
comparison for functional RNAi.
Figure 2.1: Validation of RNAi controls under basal conditions
(A) Phase contrast micrographs of HCT116 cells treated as indicated. U
were undisturbed between plating for transfection and harvesting. Mock cells were
treated with Opti-MEM and Oligofectamine as for all Mock transfections herein.
Media change cells were treated with new media on transfection day, in parallel
Mock treatment. Cells were harvested 48 hours after Mock treatment.
samples from cells shown in (A) were analysed by SDS
for the abundance of proteins indicated. Equivalent protein was loaded by mass.
-PAGE and Western blotting
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ntreated cells
to
(B) Protein
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2.1.7 Transient transfection of cells with DNA plasmids
Transfection of cells with cDNA encoding proteins for exogenous expression
under control of a constitutive human promoter followed a similar protocol to siRNA
transfection. Cells were seeded 24 hours before transfection in six well plates at
twice the density of siRNA transfection detailed above. This allowed transfection at
a higher density (~70%) 24 hours later and the harvesting of cells a further 24 hours
later for subsequent analysis.
Transfection was in liposomal vesicles (Lipofectamine – Invitrogen) diluted
in low serum Opti-MEM according to the suppliers guidelines. Low serum Opti-
MEM was used to ensure unhindered liposomal complex formation. Liposomes
formed after 30 minute incubation. cDNA was diluted in Opti-MEM then combined
with the liposomal formulation and incubated for a further 30 minutes. The
administered concentration of DNA did not exceed 1µg per well to avoid potential
cytotoxicity. For cotransfection of multiple plasmids, DNA was pooled and mixed,
ensuring the total concentration did not exceed 1µg per well. Details of the cDNAs
used are shown in Table 2.4.
Cells were transfected as for siRNA transfection in Section 2.1.5; in 800µL
low serum Opti-MEM, plus 200µL cDNA/liposome, pipetted drop-wise evenly
across each well and the plates agitated gently to ensure even distribution of
liposomes. Over-expression of protein occurred under control of the constitutive
cytomegalovirus promoter for all cDNAs detailed in Table 2.4. Over-expression was
seen within 24 hours of transfection in human cells.
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Open reading
frame
Plasmid
vector
Bacterial
selection
Typical use
in HCT116
Source or
reference
Flag-AROS pcDNA3
Ampicillin at
100µg/mL
400ng per well
(Kim et al.
2007)
Myc-Flag-
RPS19
pCMV6
Kanamycin at
25µg/mL
400ng per well
Origene
TrueORF
Myc-His-
SIRT1-FL
pcDNA3.1
Ampicillin at
100µg/mL
500ng per well
(Lynch et al.
2010)
Myc-His-
SIRT1-Δ8
pcDNA3.1
Ampicillin at
100µg/mL
500ng per well
(Lynch et al.
2010)
Table 2.4: Details of cDNAs used during the project
The Flag-AROS pcDNA3 vector was a kind gift from Eun-Joo Kim and Soo-Jong
Um, Sejong University, South Korea. The Myc-Flag-RPS19 pCMV6 construct was
purchased from Origene TrueORF. The Myc-His-SIRT1-FL and Myc-His-SIRT1-Δ8
pcDNA3.1 vectors were produced in the YCR p53 Research Unit by Dr Zahid Shah.
Expression of all ORFs is under the control of the constitutive cytomegalovirus
(CMV) promoter. Kanamycin and Ampicillin were purchased from Sigma.
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2.1.8 Application of ultraviolet irradiation
Prior to treatment media was aspirated from cells to ensure radiation was not
absorbed. Cells were washed in PBS to remove remaining media. Cells were
positioned perpendicular to the ultraviolet source within growth plates and exposed
to radiation as indicated at a fluency of 2J/m2/s. Growth plate lids were removed
during irradiation. Cells were then grown in normal growth media prior to harvesting
at the stated time post UV exposure.
2.1.9 Application of soluble drug treatments
Media was aspirated from cells. Cells were then washed in pre-warmed PBS.
Soluble drugs were applied to cells at the indicated concentrations premixed within
normal growth media. Cells were returned to 37°C for the stated duration prior to
harvesting.
2.1.10 Harvesting of cells
Directly prior to harvesting cell phenotypes were recorded by phase contrast
light microscopy using an Olympus CKX41 compact inverted microscope at 200x
zoom. A representative area was chosen for each condition and recorded using an
Olympus C-7070 digital camera. Micrographs were adjusted for optimum contrast in
greyscale and cropped using Corel PhotoPaint X3.
Cells were harvested by trypsinisation. Harvesting of cells from flasks
followed the same protocol as for subcultivation (2.1.2). Prior to trypsinisation cells
were washed in PBS to remove all growth media (unless stated in specific
protocols).Growth media and PBS from pre-trypsin washes was retained in harvested
material. Harvesting from six well plates used 0.5 – 1.0mLs trypsin per well,
incubated at 37°C and 5% CO2 until cells became detached, followed by quenching
and pooling of cells from multiple wells where appropriate. Media was removed by
centrifugation and cells were washed twice with ice cold PBS, allowing final
resuspension in desired medium.
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2.2 Preparation of material for transfection
2.2.1 Custom siRNA design and preparation
The design of custom siRNAs allowed specificity to produce target specific
mRNA knock down. In all cases knockdown was verified at both the mRNA and
protein level (See Sections 2.6.4and 2.5.5). However, in some cases issues with
antibody availability did not permit protein level analysis. The target sequence for all
siRNAs was 19 nucleotides long with two deoxythymidine (dT) bases at the 3’ end,
making 21 nucleotides overall. The 19 nucleotide sequence is complementary to the
mRNA sequence to be silenced. The ‘dTdT’ addition is important for siRNA
stability in mammalian cells.
Sequences of mRNA targets were attained from public databases, such as
FASTA and GENBANK. Sequences were viewed using the bioinformatics software
Vector NTI (Invitrogen). 19 nucleotide sequences were analysed within this mRNA
sequence to meet three criteria: 1) a ‘GC%’ value of between 40% and 60%; 2) no
repeats of the same nucleotide for more than 3 bases; 3) minimal formation of
dimeric or hairpin structures. Failure to meet these criteria is predicted to result in
siRNAs that remain annealed or form non-duplexed structures. As such, these
criteria were should ensure efficacy of the custom siRNA.
Sequences meeting these criteria were then analysed for homology to other
human mRNA sequences. This was a crucial step to ensure specific knock down of
the desired mRNA. For this the online ‘Basic Local Alignment Search Tool’
(BLAST) was used (available at the National Centre for Biotechnology Information
website). A nucleotide BLAST homology search of human mRNA sequences was
carried out and any significant (>60%) homology to other mRNAs was generally
considered unacceptable.
Targeting of specific splice variants of genes is possible, but leaves few
options for target sequence. Specific variants lacking a single exon were targeted at
the relevant exon-exon boundary to ensure specificity. For example, for SIRT1-Δ8,
which lacks exon 8, the 7 to 9 exon boundary was targeted by siRNA. During the
project siRNA sequences were also used that had been previously published. In these
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cases the siRNA sequence was checked using the same criteria as above to ensure
that it met the standard required. A list of all the siRNA sequences used is shown in
Table 2.5.
Custom siRNAs were ordered from Dharmacon as a desalted and duplexed
precipitated solid. These were stored at -80°C as solid until required. siRNA was
dissolved in siRNA buffer (Dharmacon – containing 300mM KCl, 30mM HEPES,
1.0mM magnesium chloride at pH 7.5). Solutions were briefly mixed by pipette then
placed on an orbital shaker for 30 minutes. To break up aggregates from the drying
process, siRNA was heated to 95°C for 2 minutes then slowly cooled to 37°C for 1
hour. Repeated freeze-thaw cycles of siRNAs were avoided. This procedure was
implemented to decrease the possibility of non-duplexed siRNA, important to attain
knockdown of target mRNA.
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Target mRNA siRNA sense sequence
AROS (1) 5’-CCGUGUUC ACCGAGGAAGA-(dTdT)-3’
AROS (2) 5’-GACCACCUCAGAGUAAACC-(dTdT)-3’
FOXO3 † 5’-GCACAGAGUUGGAUGAAGU-(dTdT)-3’
FOXO4 † 5’-AGAAGCCGAUAUGUGGACC-(dTdT)-3’
LDH-A 5’-CCAGCCGUGAUAAUGACCA-(dTdT)-3’
LDH-B 5’-ACUUAAUCCAAUAGCCCAG-(dTdT)-3’
RPS19 † 5’-AGAGCUUGCUCCCUACGAU(dTdT)-3’
SIRT1-FL † 5’-ACUUUGCUGUAACCCUGUA-(dTdT)-3’
SIRT1-Δ8 † 5’-UAAUUCCAAGUAAUCAGUA-(dTdT)-3’
TP53 † 5’-CAGCAUCUUAUCCGAGUGG-(dTdT)-3’
Table 2.5: List of validated siRNA sequences used
(†) denotes previously published as indicated: RPS19 (1) - (Choesmel et al. 2007),
SIRT1-FL, FOXO4, FOXO3 - (Ford et al. 2005), SIRT1-Δ8, TP53 - (Lynch et al.
2010)
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2.2.2 Amplification of expression plasmids in bacterial cells
All work with bacteria was carried out on an ethanol sterilised lab bench under
a blue Bunsen flame. XL10 Gold ultra-competent Escherichia Coli cells (Stratagene)
were cultured in liquid broth and on agar plates. Liquid broth was made by the litre,
consisting of 10g sodium chloride, 10g tryptone and 5g yeast extract at pH 7.0,
sterilised by autoclave. Agar plates (Sterilin) were cast with 1.6% weight-by-volume
agar dissolved in liquid broth. To ensure antibiotic activity, antibiotics were added
below 55°C at a concentration of 25µg/mL (Kanamycin) and 100µg/mL
(Ampicillin).
cDNA plasmids were amplified by transformation into XL10 Gold bacterial
cells. Once transformed cDNA plasmids were subject to replication from SV40
origins of replication. Transformation was by heat shock of E. Coli incubated with
cDNA for 30 seconds at 42°C. Bacteria were then cultured at 37°C on an orbital
shaker at 200rpm. This was in the absence of selection antibiotics to allow initial
expression of the resistance gene. After 1 hour, 200µL of the cultured cells were
spread onto agar plates containing selection antibiotic. Plates were incubated at 37°C
overnight. Antibiotics used for each expression plasmid are shown in Table 2.4.
Individual colonies were picked using a pipette tip and transferred to liquid
broth containing selection antibiotic. Cells were grown at 37°C on an orbital shaker
at 200rpm for 8 hours, or until broth had become cloudy. Cells were then transferred
into a larger volume of liquid broth (25mL) containing antibiotic for overnight
(minimum 16 hours) incubation.
Following incubation, bacterial cells were pelleted from liquid broth by
centrifugation at 14,000g for 15 minutes at 4°C. Purification of plasmid DNA
followed the QIAGEN plasmid purification protocol according to the manufacturer’s
protocol. Final cDNA resuspension was in QIAGEN elution buffer (10mM TrisCl at
pH 8.5). Plasmid cDNA was quantified by OD260nm reading (See Section 2.6.2)
and purity by analysis of the protein content at OD280nm. cDNA was diluted in
RNase / DNase free water (Gibco) to appropriate dilutions for transfection.
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2.3 Analysis of whole cells
2.3.1 Determination of apoptosis by Annexin-V and propidium iodide staining
This technique worked with live cells, and was thus carried out at room
temperature. All media, trypsin and PBS were used at room temperature throughout,
as were all centrifugation techniques. Great care was taken throughout to produce a
single cell suspension, to ensure cells enter the fluorescence activated cell sorter
(FACS) machine individually. Other than these modifications cells were harvested
following the protocol in Section 2.1.8.
Final resuspension of cells was in ‘Incubation buffer’ provided in Annexin-
V-FLUOS Staining Kit (Roche), supplemented with a 1:50 dilution of Annexin-V-
Fluorescein and propidium iodide (PI) (as provided in kit). Cells were incubated at
room temperature for 10 minutes with periodic agitation to maintain suspension of
cells. Cells were then transferred to FACS falcon tubes (Beckton Dickinson) and
diluted in ‘Incubation buffer’ as appropriate. After a further 5 minute incubation
cells were analysed by FACS on a FACSCalibur machine with CellQuest interface
(Beckton Dickinson).
Both Annexin-V-Fluorescein and PI were excited at 488nm. Annexin-V-
Fluorescein emission was read in the ‘FL-1 channel’ at 518nm and PI in the ‘FL-2
channel’ at 617nm, according to suppliers guidelines (Roche). Forward-scatter and
side-scatter attributes were routinely analysed to confirm efficacy of single cell
suspension techniques. 10,000 events were read for each condition and conditions
read as independent duplicates.
For analysis of apoptosis a scatter plot of FL-1 (Annexin-V-Fluorescein)
against FL-2 (propidium iodide) was drawn. Early apoptotic cells stain positive for
Annexin-V-Fluorescein due to the presence of phosphatidylserine on the outer leaflet
of the cell membrane; phosphatidylserine is usually maintained on the inner leaflet
only. PI is a DNA intercalator unable to freely cross phospholipid membranes. The
membrane integrity maintained by apoptotic cells ensures that they stain negative for
PI, allowing differentiation from cells undergoing necrosis which stain positive for
both Annexin-V-Fluorescein and PI.
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The open access software WinMDI (The Scripps Research Institute) was
used for quantification of apoptosis from raw scatter plots. Figure 2.2A shows a
representation of the data and the quadrant based gating used. The number of early
apoptotic cells was expressed as a percentage of the total cell number. Mock treated
cells were then set to a value of 1, and other conditions compared against this –
giving a fold change in apoptosis. This data is presented in graph format in the
Results chapters (SigmaPlot). The error bars shown on these graphs are the standard
deviation between replicates, standardised to the fold change. Statistical analysis was
carried out using Student’s t-test. A value of less than 0.05 was considered to be
statistically significant, as indicated. Raw scatter plots are presented in the
Appendices.
2.3.2 Cell cycle distribution analysis by propidium iodide staining
Cells were harvested following the protocol in Section 2.1.8 and fixed in
solution in ice cold ethanol. The final resuspension after trypsinisation was in 1mL
of ice cold PBS. To this 4mL of ice cold 90% ethanol (Fisher) was pipetted drop-
wise whilst vortexing. The final ethanol percentage for fixation was 72%. Fixed cells
were kept on wet ice for 1.5 hours then maintained at 4°C until staining with
propidium iodide. Fixed cells were not left for longer than one week before analysis.
For staining, cells were spun out of 72% ethanol at 4°C at 150g for 5 minutes
then washed twice in 10mL ice cold PBS. The centrifugations out of PBS were at
600g. Cells were resuspended in 500µL PBS containing 50 U/mL RNase A
(QIAGEN) and incubated at 37°C for 15 minutes. An equal volume of 60µg/mL
propidium iodide solution was added and thoroughly mixed by pipette. Staining
occurred for 30 minutes at room temperature.
The fluorescent properties of the DNA intercalator propidium iodide (excited
at 488nm and read at 617nm) were exploited to allow cell cycle phase to be analysed
using a FACSCalibur machine with CellQuest interface (Beckton Dickinson). This
allowed the separation and quantification of cells according to stage in the cell cycle.
Propidium iodide (PI) fluorescence (in the FL-2 channel) was plotted against the
number of events to produce a histogram. Strict gating of cells was essential during
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FACS due to the tendency for cells to aggregate during the fixation process. Cells
were gated from the total population to an experimental population of cells according
to forward-scatter and side-scatter. This was to reduce the number of aggregated
cells entering the analysis. Aggregated cells were visualised in the FL-2 channel due
to the appearance of large numbers of ‘cells’ containing 8n or more copies of DNA.
These were deemed to represent aggregations in the most part, not polyploid cells.
Gating was deemed sufficient when the aggregated population was low, after which
experimental readings were taken for 10,000 cells in duplicate.
PI intercalates with cellular DNA in a proportional manner, allowing the
elucidation of G1, S and G2/M population. A representation of the raw data gained
from this analysis is shown in Figure 2.2B. The open access software Cylchred
(Cardiff University) was used to analyse the data from CellQuest. G1, S and G2/M
phase populations were designated within the overall histogram, defining the S phase
population between the G1 and G2/M peaks. The software produced values for the
percentage of cells in each population, allowing these values to be plotted as stacked
histograms (SigmaPlot).
Figure 2.2: Representative data for whole cell analysis techniques
(A) Apoptotic cells were determined as cells staining positive for Annexin
Fluorescein but negative for propidium iodide, as depict
lower right quadrant was defined as apoptotic and data gathered in duplicate using
WinMDI. (B) Cells in G1 stain with the lowest intensity for propidium iodide due to
the lower copy number of DNA. After replication of DNA cells in
twice the DNA content of G1 cells and thus stain more intensely for propidium
iodide. Cells passing through S phase have a DNA content between that of G1 and
G2/M cells, giving a continuum of intensities between the two. The Cylchred
software is able to define and distinguish between S phase and the peaks either side,
presenting the data as shown here. Values for the percentage of cells in each phase
were gathered by this method.
ed in a scatter plot. The
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-V-
G2/M phase have
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2.4 Fractionation of cells for subcellular analysis
2.4.1 Sucrose gradient ultra-centrifugation for analysis of ribosomes
Sucrose density ultra-centrifugation was based on recently published
protocols (Choesmel et al. 2007; Guo et al. 2010a). The protocol is summarised
diagrammatically in Figure 2.3. Sucrose was dissolved in gradient buffer containing
20mM TrisHCl, 80mM sodium chloride, 5mM magnesium chloride, 2mM DTT and
20U/mL RNase inhibitor (SUPERase – Ambion) at pH 7.4. 50% and 10% sucrose
weight-by-volume solutions were made and maintained at 4°C. 24 hours prior to use
an equal volume of 10% sucrose solution was layered above 50% sucrose solution in
UltraClear 12.5mL open top centrifuge tubes (Beckman). The tube tops were sealed
using parafilm and carefully tilted to horizontal and kept at 4°C for 6.5 hours. Tubes
were then returned to the vertical and maintained at 4°C overnight until use.
Cells were treated with 100µg/mL cycloheximide for 10 minutes then
harvested by trypsinisation. Lysis at 4°C used lysis buffer containing 10mM TRIS-
HCl, 5mM magnesium chloride, 10mM potassium chloride, 2mM DTT, 500U/mL
RNase inhibitor, 2% Triton X-100 supplemented with protease inhibitor cocktail
(Roche) at pH 7.4. Cell membranes were disrupted by gentle pipetting and nuclei
pelleted by centrifugation at 8,000g for 5 minutes at 4°C. The cytoplasmic fraction
was removed and protein content estimated (Section 2.5.1) to standardise the protein
concentration between experimental conditions. Samples were subjected to 160,000g
for 2 hours at 4°C under a vacuum using an Ultra Beckman 100XP centrifuge in a
SW41Ti swing out rotor (Beckman).
After ultra-centrifugation, samples were kept on ice within centrifuge
buckets. Fractions (~400µL each) were removed from the gradient by pipette,
starting from the top, and stored at -20°C. Optical density at 260nm (OD260nm) was
used to quantify RNA (Section 2.6.2). Readings were taken in duplicate and data
aligned using SigmaPlot into spline-curve joined graphs. Samples were also analysed
by SDS-PAGE as detailed in Section 2.5.4.
Figure 2.3: Summary of sucrose density ultra
Sucrose gradients were layered 24 hours prior to use. Equal volumes of 50% and
10% sucrose in gradient buffer were
horizontal incubation at 4°C, then incubation in the vertical position overnight at
4°C. Isolated cytoplasm was loaded onto the gradient and ultra
160,000g for 2 hours. Fractions were then remove
ribosomal subunits.
-centrifugation protocol
layered and allowed to form a gradient during
-centrifuged at
d and analysed for their separated
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2.4.2 Subcellular fractionation for protein analysis
The protocol follows that of the supplier (NE-PER kit – Pierce) for the
fractionation of cells into cytoplasmic protein, nuclear soluble protein and nuclear
insoluble protein. In brief, cells were harvested and resuspension in ice cold CER I
and CER II buffers supplemented with protease inhibitor cocktail (Roche). After
incubation to lyse the cell membrane nuclei were pelleted by centrifugation at
14,000g for 5 minutes at 4°C. The supernatant was removed as the cytoplasmic
fraction, and the nuclei were lysed in NER I buffer supplemented with protease
inhibitor cocktail (Roche). Following a further incubation nuclear insoluble protein
was pelleted by centrifugation at 14,000g for 10 minutes at 4°C. The supernatant was
removed as the nuclear soluble fraction and the remaining protein treated with lysis
buffer containing 140mM sodium chloride, 10mM TrisBase, 2mM calcium chloride,
0.5% v/v NP-40 at pH 8.0, supplemented with protease inhibitor cocktail (Roche)
and 5 U/mL micrococcal nuclease (Sigma). After incubation for 5 minutes at room
temperature all samples were frozen at -80°C prior to analysis by SDS-PAGE
(Section 2.5.4).
This method was modified and extended to allow immunoprecipitation of
exogenous Flag-tagged nuclear proteins. The cytoplasmic fraction was removed as
detailed here, and then the nuclear pellet was used in place of the total cell lysate for
immunoprecipitation as detailed in Section 2.5.2.
2.4.3 Subcellular fractionation for RNA analysis
This protocol was similar to that above for protein analysis, allowing the
separation of cells and isolation of cytoplasmic and nuclear RNA. Again, buffers
were used as provided by the supplier (Pierce) supplemented with protease inhibitor
cocktail and RNase inhibitor (Ambion) to prevent degradation of proteins and
RNAs. Cytoplasm was removed as previously then nuclei were lysed in buffer
containing 140mM sodium chloride, 10mM TrisBase, 0.5% v/v NP-40 at pH 8.0,
supplemented protease inhibitor cocktail, 1,000 U/mL RNase inhibitor and 65 U/mL
DNase I with RDD buffer (QIAGEN). All fractions were immediately used for RNA
purification, as detailed in Section 2.6.1.
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2.5 Molecular biological analyses of proteins
2.5.1 Determination of protein concentration
The protocol is based on the bicinchoninic acid (BCA) method as supplied by
Pierce. The technique quantifies protein concentration in samples against a standard
curve of the spectrophotometric change at 562nm from bovine serum albumin
standard solutions of known concentrations. Standards were read in quadruplicate
from 96 well plates (Nunc) using a FluoSTAR Omega plate reader (BMG Labtech)
and a standard curve was drawn using the attached software. Samples were also read
in quadruplicate. Any outlying readings were omitted and the average protein
concentration (in mg/mL) was attained for each protein sample. This value allowed
the accurate dilution of protein for various techniques.
2.5.2 Immunoprecipitation of exogenous Flag-tagged proteins
Cells were harvested following the protocol in Section 2.1.8. Final
resuspension of cells was in ‘Lysis buffer’ supplied by Sigma (150mM sodium
chloride, 1% v/v Triton X-100, 50mM TrisHCl, 1mM EDTA) supplemented with
protease inhibitor cocktail (Roche). Cells were sonicated at 2.5 microns for 10
seconds three times in total, kept on wet ice for 30 seconds between pulses (Soniprep
150 – MSE). Cell debris was pelleted at 10,000g for 5 minutes at 4°C then discarded.
The protein content of the lysate was assayed following protocol 2.5.1.
Protein quantity (500 - 1500μg) was matched between conditions and a negative
control was included with ‘Lysis buffer’ only, termed the ‘No lysate’ control.
Remaining Input protein was stored at -80°C. Lysate was incubated on SigmaPrep
spin columns with 60µL Anti-Flag M2-Agarose affinity beads (Sigma) for 2 hours at
4°C on an inversion wheel. Anti-Flag M2-Agarose affinity beads were pre-washed 4
times with ‘Wash buffer’ supplied by Sigma (50mM TrisHCl, 150mM sodium
chloride at pH 7.4). During incubation, the Anti-Flag M2-Agarose affinity beads
bound the exogenously expressed Flag-tagged protein of interest.
After incubation, the ‘Immunodepletion’ was removed by centrifugation at
5,000g for 1 minute through the spin column. Bound proteins were then washed four
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times in ice cold ‘Wash buffer’ supplemented with protease inhibitor cocktail
(Roche). Samples were washed on an inversion wheel for 2 minutes at 4°C after each
wash and separated by centrifugation at 5,000g for 1 minute. These washing steps
reduced the amount of non-specific binding of protein to the agarose beads.
After the final wash, bound protein was eluted by addition of excess Flag-
peptide (Sigma) to compete for the Anti-Flag M2-Agarose affinity beads. 15µg Flag-
peptide was added to the beads in a low volume of ‘Wash buffer’ and mixed on an
orbital shaker for 1 hour. ‘Elution’ was collected by centrifugation at 5,000g for 2
minutes and termed the ‘Flag-IP’. Samples were stored at -80°C. Figure 2.4A
summarises the Flag immunoprecipitation protocol in a flow diagram.
Samples were analysed by SDS-PAGE and Western blotting to detect
proteins of interest using specific antibodies. ‘Input’ protein was loaded as a fraction
of the original ‘Input’ loaded into each immunoprecipitation. This fraction
represented 1/Y amount of immunoprecipitation ‘Input’. Thus, upon analysis the
‘Flag-IP’ samples are equivalent to a Y-fold excess of protein compared to respective
‘Input’ samples. This allows the quantification of the proportion of total protein that
is immunoprecipitated in the analysis. The scheme for loading of SDS-PAGEs for
analysis of immunoprecipitation samples is shown in Figure 2.4B.
Figure 2.4: Schematic of Flag-immunoprecipitation protocol
(A) An equivalent, defined quantity of ‘Input’ lysate (
SigmaPrep columns for each experimental condition, retaining a portion of each
‘Input’ for analysis by SDS-PAGE. Lysate was incubated with Anti
Agarose beads for 2 hours at 4°C, mixed by inversion. Immunodepletion was
separated by centrifugation and beads washed on-column 4 times. Excess Flag
peptide was added and mixed by orbital shaking for 1 hour. The ‘Fla
elution was collected after separation by centrifugation.
immunoprecipitation samples. ‘Flag-IP’ sample was loaded and the quantity of
original ‘Input’ adjusted to represent a fraction (1/Y) of the ‘Input’ lysate that
entered each immunoprecipitation. Thus, the ‘Flag-IPs’ represents a
excess of protein compared to the ‘Inputs’.
X µg) was loaded onto
-Flag M2-
-
g-IP’
(B) SDS-PAGE of
Y-fold
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2.5.3 Lysis of cells for total protein
Cells were harvested following the protocol in Section 2.1.8, then
resuspended in ice cold lysis buffer containing 140mM sodium chloride, 10mM
TrisBase, 2mM calcium chloride, 0.5% v/v NP-40 at pH 8.0, supplemented with
protease inhibitor cocktail (Roche) and 5 U/mL micrococcal nuclease (Sigma). This
was incubated at room temperature for 5 minutes for nuclease digest. After digestion
samples were used for protein estimation (Section 2.5.1) and SDS-PAGE (Section
2.5.4).
2.5.4 SDS-PAGE
Samples were prepared for SDS-PAGE by addition of SDS-loading buffer.
This was made at a six fold concentration consisting of 12% w/v sodium dodecyl
sulphate, 300mM TrisBase, 35% v/v glycerol, a few crystals of bromophenol blue,
6% v/v β-mercaptoethanol, then added to sample to a final 1x concentration.
Samples were then placed at 95°C for 3 minutes and allowed to cool to room
temperature before use. Protein lysates were also stored at -80°C under these
conditions.
Poly-acrylamide gels were used for electrophoretic separation of proteins by
molecular mass under denaturing conditions provided by sodium dodecyl sulphate.
The poly-acrylamide resolving gels were poured at either 10 or 15% v/v acrylamide
and allowed to set at room temperature for 30 minutes under a layer of distilled
water. Once set, the distilled water was removed and the appropriate stacking gel
(4% acrylamide for 10% resolver, 5% acrylamide for 15% resolver) was poured with
wells created using a comb. Gels were cast using the Mini Protean II gel assembly
apparatus (BioRad). Gel electrophoresis was applied at 90 volts for 2.5 hours in
running buffer containing 250mM glycine, 25mM TrisBase and 0.1% w/v SDS. A
PageRuler pre-stained protein ladder was used to visualise the separation of proteins
on the gel (Fermentas). Following SDS-PAGE gels were taken into the protocol for
Westerns blotting below.
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2.5.5 Western blotting
Proteins separated by SDS-PAGE were transferred to nitrocellulose
membranes (Whatman) by overnight transfer at 35 mAmps. The Mini Trans-Blot
Electrophoretic Transfer Cell (BioRad) was used as instructed by the supplier, with
transfer buffer containing 200mM glycine, 25mM TrisBase, 0.1% w/v SDS and 20%
v/v methanol.
For immunoblotting the standard buffer used was TBST consisting of
200mM TrisBase, 250mM sodium chloride and 0.1% Tween-20 at pH 7.5. An
alternative buffer was used for antibodies provided by Cell Signalling Technology,
termed CST-TBST. This was made following the supplier’s recommendations,
consisting of 20mM TrisBase, 135mM sodium chloride and 0.1% Tween-20 at pH
7.6. Buffers were 0.22µm filter sterilised prior to use (Millipore).
Following overnight transfer, membranes were washed for 5 minutes in
TBST or CST-TBST then blocked for 1 hour at room temperature in 5% w/v low fat
dried milk (Marvell). All washes and incubations were carried out with rotational
agitation of membranes. Membranes were then placed into appropriate dilution of
primary antibody in blocking buffer and incubated overnight at 4°C. Cell Signalling
Technology antibodies were diluted in 5% w/v bovine serum albumin (Sigma) in
CST-TBST and incubated overnight at 4°C. CST membranes were washed three
times for 5 minutes between milk block and application of antibody in CST-TBST.
A list of primary antibodies used is shown in Table 2.6.
Membranes were washed after primary antibody incubation with three 5
minute washes in appropriate TBST. The appropriate species-matched horse radish
peroxidise conjugated secondary antibody was applied in 5% low fat dried milk
blocking buffer for all antibodies and incubated at room temperature for a minimum
of 1 hour. A list of secondary antibodies used is shown in Table 2.7. Membranes
were washed three times for 5 minutes to remove excess secondary antibody.
Immuno-detection of bound antibodies was achieved using the
electrochemiluminescence method. Membranes were incubated in POD reagent
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(Roche) for 1 minute then exposed to Hyperfilm (GE Healthcare) within light safe
cassettes. Films were developed using a Xograph X2.
Hyperfilms were scanned to picture files for presentation of results. Images
were altered and cropped to show optimal results using Corel PhotoPaint X3.
Densitometry from these files was calculated using Quantity One software (BioRad)
and presented as histograms created with SigmaPlot.
Materials and methods
75
Protein target
Species and
isoform
Clone and
supplier
Typical dilution
range
Actin
Mouse
IgG1κ
C4 monoclonal
Millipore
1:5,000 to
1:10,000
AROS
Rabbit
Not specified
AT135 polyclonal
Alexis
1:500 to 1:2,000
c-Myc
Mouse
IgG1
9E10 monoclonal
Santa Cruz
1:500 to 1:2,000
HDM2
Mouse
IgG
4B2 monoclonal
Produced in house
1:3 to 1:5
Lamin AC
Mouse
IgG2b
636 monoclonal
Santa Cruz
1:1000 to 1:4000
LDH
Rabbit
IgG
1563Y monoclonal
Epitomics
1:2,000 to 1:5,000
p53
Mouse
IgG2a
DO-1 monoclonal
Santa Cruz
1:1,000 to 1:4,000
p53 K382Ac (1)
Rabbit
IgG
2525 polyclonal
Cell Signalling
1:500 to 1:2,000
p53 K382Ac (2)
Rabbit
IgG
356(2) monoclonal
Epitomics
1:500 to 1:2,000
RPL3
Rabbit
IgG
C-14 polyclonal
Santa Cruz
1:1,000 to 1:4,000
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Protein target
Species and
isoform
Clone and
supplier
Typical dilution
range
RPS19
Mouse
IgG2b
3C6 monoclonal
AbCam
1:2,000 to 1:5,000
RPS6
Rabbit
IgG
5G10 monoclonal
Cell Signalling
1:2,000 to 1:5,000
SIRT1
Rabbit
IgG
H-300 polyclonal
Santa Cruz
1:1,000 to 1:4,000
Table 2.6: List of primary antibodies
Protein target
Species and
isoform
Clone and
supplier
Typical dilution
range
HRP-conjugated
anti-mouse
Rabbit
Mainly IgG
P-0260 polyclonal
DakoCytomation
1:1,000 to
1:10,000
HRP-conjugated
anti-rabbit
Goat
Mainly IgG
P-0449 polyclonal
DakoCytomation
1:1,000 to
1:10,000
Table 2.7: List of secondary antibodies
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2.6 Molecular biological analyses of RNAs
2.6.1 Isolation of RNA
This protocol followed the RNeasy method (QIAGEN). Cell or nuclear
pellets (from Section 2.4.3) were lysed in the recommended volume of RLT buffer
containing 1% v/v β-mercaptoethanol (Sigma). Lysates were applied to a
QIAShredder homogeniser at 10,000 g for 2 minutes. The lysate was then
supplemented with an equal volume of 70% ethanol, applied to an RNeasy column
and centrifuged at 10,000 g for 15 seconds.
The column contents were washed with buffer RW1 and an on-column
DNase I digest was carried out. 25 units of DNase I was diluted in buffer RDD (both
QIAGEN) and incubated on column for 15 minutes. This removed genomic DNA
from subsequent analyses of RNA. Samples were then washed with buffer RW1.
Samples were finally washed twice in buffer RPE (made from concentrate by
addition of ethanol) and RNA was eluted using RNase free distilled water. Samples
were stored at -80°C and freeze-thaw cycles were avoided.
2.6.2 Quantification of RNA
This technique allowed the determination of RNA concentration by
exploitation of the spectrophotometric properties of nucleotides at 260nm. From the
values attained, accurate dilution of RNA was carried out to ensure equal loading of
template in polymerase chain reactions (Sections 2.6.3 and 2.6.4), or to provide an
accurate reading of the quantity of ribosomal RNA separated by sucrose density
ultra-centrifugation (Section 2.4.1). RNA was quantified using a GeneSpec V
spectrophotometer (Hitachi) and associated computer software. A volume of 2µL
was used in a quartz micro-cuvette (Hitachi) with a pathlength of 1mm. The
apparatus was blanked using RNase / DNase free water (Gibco) and the cuvette
cleaned between samples using 100% ethanol and RNase / DNase free water.
This technique was also applied for the quantification of DNA, with the
apparatus able to detect DNA using an alternate set of parameters defined in the
computer software. The protocol carried out was otherwise identical.
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2.6.3 Reverse transcription PCR
This technique synthesised cDNA from isolated RNA by reverse
transcription. Subsequent polymerase chain reaction amplification of cDNA on a
Dyad DNA Engine (MJ Research) was followed by analysis of products by agarose
gel electrophoresis (Section 2.6.5). The protocol followed the OneStep RT-PCR Kit
(QIAGEN) and made use of the primers detailed in Section 2.6.6.
A master mix containing reverse transcription and Taq polymerase enzymes,
appropriate buffers and forward and reverse primers was made and aliquoted across
purified RNA to be analysed. The primers for amplification were used at 750nM
(detailed in Table 2.9). 50ng of total RNA was routinely used for amplification of
mRNA targets and 5ng of total RNA for rRNA targets. In all cases a reaction lacking
template was analysed, termed the blank. Amplification in the blank sample was
monitored to ensure no contamination of reagents. Typical thermal cycling followed
the steps shown in Table 2.8.
2.6.4 Quantitative Real Time RT-PCR
This protocol is essentially identical to that outlined for RT-PCR above but
employs the QuantiTect SYBR Green kit (QIAGEN). This allows the quantification
of cDNA as it is synthesised, by detecting the fluorescence from SYBR Green bound
to DNA on an Opticon Monitor 2 machine (BioRad). The thermal cycling used was
the same as that used for RT-PCRs, with the addition of a ‘read’ step at a designated
temperature during which the fluorescence was recorded (See Table 2.8). The
primers were used at 400nM and are shown in Table 2.9.
A standard curve of RNA dilutions was created to facilitate the plotting of a
graph depicting RNA quantity against cycle number of amplification. This standard
curve was created by serial dilution and designed to cover the range of data to be
produced from the PCR. The relative quantities of RNA were intercepted from the
standard curve and an average of at least three independent polymerase chain
reactions taken (i.e. n≥3). These were standardised against one sample allotted the
mRNA content of ‘100%.’
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Data were plotted as histograms with standard deviation error bars using
SigmaPlot. Housekeeping gene mRNAs were used as indicated to standardise the
mRNA quantities between samples. For statistical analysis the Student t-test was
used with a P value less than 0.05 considered significant. This method of data
analysis is in accordance with the Larionov-Krause-Miller Method (Larionov et al.
2005).
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Step Temperature Time Purpose
1 50°C 30 m Reverse transcription
2 94°C 15 m Taq polymerase activation
3 94°C 30 s Denaturing of DNA
4 50-65°C * 30 s Annealing of primers
5 72°C 30-60 s Extension of DNA
6 Repeat 3 to5 25 to 40 times † Amplification
7 72°C 10 m Final extension of DNA
Table 2.8: Thermal cycling used in RT-PCR
* - Annealing temperature depended on the melting temperature of the primers used
for amplification. Typically the annealing temperature was 5°C below the lowest
melting temperature of the primers.
† - The number of repeated cycles depended on the abundance of the RNA target.
Low abundance targets required more cycles, whereas higher abundance targets
required fewer.
N.B. Thermal cycling for qRT-PCR analysis was identical, except for the addition of
a step between 5 and 6 where the Opticon Monitor 2 carried out a plate read of
SYBR Green fluorescence at a designated temperature.
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2.6.5 Agarose gel electrophoresis
This technique allowed the separation of cDNA according to size. This was
used to verify the expected size of PCR products as shown in Table 2.9 and the
Appendices. 1-1.5% weight-by-volume of agarose was dissolved in TAE
supplemented with 170µg/mL ethidium bromide (Amresco) and cast into gels.
6x DNA loading dye (Fermentas) was added to PCR primer products to a
final concentration of 1x. TAE was used as the electrophoresis running buffer for
electrophoresis at 90V for a minimum of 30 minutes (Flowgen Bioscience).
Intercalated ethidium bromide was visualised by ultra-violet transillumination. Data
was recorded using Canon PowerShot G10 digital camera mounted to a CSL-
MICRODOC System (Wolf Laboratories). Images were processed using Corel
PhotoPaint X3 to optimise contrast.
2.6.6 Design and production of DNA primers
Primers were designed to ensure specific amplification of cDNA in
polymerase chain reactions. The sequences of some primer pairs were designed and
verified by other laboratory members, where indicated. RNA sequences were
retrieved from public access databases such as FASTA and GENBANK and
analysed using Vector NTI (Invitrogen).
Primer sequences were selected which fulfil the following three criteria in the
‘Thermodynamic properties’ in Vector NTI; 1) 50-60% GC content, with no
repeated bases more than 3 bases long, 2) a melting temperature above 50°C and
within 5°C of the relevant primer partner, 3) no predicted stem loop or dimeric
structures. These parameters were chosen to reduce the possibility of primer dimer or
secondary structure formation. Sequences were between 19 and 24 base pairs long
and were selected to have less than 60% BLAST homology to other human RNAs.
Where appropriate, primers were designed to amplify only the splice variant of
interest. Primers were ordered from Sigma and diluted in RNase / DNase free water
(Gibco). All primers designed not previously verified were analysed by agarose gel
electrophoresis to ensure correct cDNA product size (see Appendices).
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mRNA Primers sequences Product size
18S rRNA
Fd: 5’-GGACACGGACAGGATTGACAG-3’
Rvs: 5’-GCTTATGACCCGCACTTACTCG-3’
395bps
28S rRNA†
Fd: 5’-CGTGGAATGCGAGTGCCTAG-3’
Rvs: 5’-TTGATTCGGCAGGTGAGTTG-3’
199bps
Actin
(ACTG1)†
Fd: 5’-GCCAACAGAGAGAAGATGAC-3’
Rvs: 5’-CGCAAGATTCCATACCCAGG-3’
477bps
AROS
Fd: 5’-GGAAGACGAAGGCAATTCAGGC-3’
Rvs: 5’-TCCTCGGTGAACACGGTGCC-3’
261bps
BIM L†
Fd: 5’-ACCAGGCGGACAATGTAACGTAA-3’
Rvs: 5’-CCACAAACAGGAGCCCAGCA-3’
281bps
FOXO4†
Fd: 5’-GCAGGATGGAAGAACTCGAT-3’
Rvs: 5’-ACTGCTGACTGAAGCTGGTA-3’
432bps
GAPDH†
Fd: 5’-CGGAGTCAACGGATTTGGTCGTAT-3’
Rvs: 5’-AGCCTTCTCCATGGTGGTGAAGAC-
3’
307bps
Lamin AC†
Fd: 5’-AAGCAGCGTGAGTTTGAGAGC-3’
Rvs: 5’-AGGGTGAACTTTGGTGGGAAC-3’
770bps
LDH-A
Fd: 5’-TTGGTCCAGCGTAACGTGAAC-3’
Rvs: 5’-CCAGGATGTGTAGCCTTTGAG-3’
426bps
LDH-B
Fd: 5’-CTGGGAAAGTCTCTGGCTGATG-3’
Rvs: 5’-CACTCCACACAGCCACACTTGA-3’
489bps
RPS19
Fd: 5’-ACCAGCAGGAGTTCGTCAGAGC-3’
Rvs: 5’-CCACCTGTCCGGCGATTCTG-3’
386bps
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mRNA Primers sequences Product size
SIRT1-FL†
Fd: 5’-TCAGTGTCATGGTTCCTTTGC-3’
Rvs: 5’-AATCTGCTCCTTTGCCACTCT-3’
820bps
SIRT1-Δ8†
Fd: 5’-GGGATGGTATTTATGCTCGC-3’
Rvs: 5’-AACAGATACTGATTACTTGGA-3’
547bps
Table 2.9: List of primers used for amplification of RNA
(†) - Designed and verified by other members of the YCR p53 Research Unit.
Dr Jack Ford – FOXO4, GAPDH, Lamin AC, SIRT1-FL.
Dr Cian Lynch – SIRT1-Δ8.
Dr Shafiq Ahmed – 28S rRNA, Actin, BIM-L.
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3 Regulation of SIRT1 activity by LDH-A
3.1 Overview
In this Chapter the role of lactate dehydrogenase A (LDH-A) in facilitating
SIRT1 activity is assessed. Selective RNAi was employed to silence LDH-A, as well
as its isoenzyme LDH-B, providing a case study for the specificity of RNAi. Cell
phenotypes and fate for cancer and non-cancer cells were analysed, giving
encouraging data for potential future cancer therapy. Molecular biological analyses
further explored the consequences of LDH-A knockdown in cancer and non-cancer
cells.
The premise of this analysis draws on two factors: first the requirement SIRT1
has upon the metabolite NAD+, the levels of which are managed by LDH-A, and
second the common metabolic switch in cancer cells from Oxidative
Phosphorylation to using the Aerobic Glycolysis Cycle, which relies upon an
increase in LDH-A activity. The broader aim of the Thesis is maintained with the
characterisation of a target that positively regulates SIRT1 activity.
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3.2 Introduction
3.2.1 Nicotinamide adenine dinucleotide
Nicotinamide adenine dinucleotide is a dinucleotide consisting of one
adenine and one nicotinamide base. The nicotinamide base can exist in two stable
forms according to oxidation status (Warburg and Christian 1936). The oxidised
form, NAD+, is able to accept two electrons and a hydrogen ion to become the
reduced form, NADH. NADH can then be oxidised back into NAD+ when required.
This interconversion is coupled to substrate oxidation and reduction during carbon
catabolism, allowing the energy of electrons to be harnessed and linked to the
generation of ATP (see below). NAD+ is also an essential co-enzyme for SIRT1
(Imai et al. 2000; Landry et al. 2000; Smith et al. 2000).
3.2.2 Carbon catabolism and energy production
The controlled release of energy bound in glucose into the manageable unit
of cellular energy, ATP, was principally investigated in the early 20th century. The
forerunner in the field was Otto Meyerhof, for which he was recognised by the
Nobel Prize in Physiology and Medicine in 1922. Along with collaborators,
Meyerhof described the multistep process and intermediates of the biologically
ubiquitous pathway of glycolysis – which for a time was called the Embden-
Meyerhof pathway. Another seminal discovery of Meyerhof’s was the investigation
of the increase in glucose consumption under oxygen limiting conditions. This was
termed the Pasteur-Meyerhof Effect and is now known as the Anaerobic Glycolysis
Cycle. The work of Meyerhof is well summarised in a review of his career published
in 2005, containing reference to his original research papers and that of his
colleagues (Kresge et al. 2005).
Further release of energy from carbon occurs via mitochondrial Oxidative
Phosphorylation. Mitochondrial carbon metabolism utilises the Citric Acid Cycle,
detailed by Albert Szent-Györgyi and Hans Krebs in the early 20th century. The
chemiosmotic mechanism of ATP production parallel to this pathway was first
proposed by Peter Mitchell in 1961 (Mitchell 1961). A very brief summary of these
pathways is presented to set the scene for the analysis undertaken.
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Glucose is oxidised to pyruvate during glycolysis. The oxidative potential for
glycolysis is provided by NAD+, which is reduced to NADH. Glycolysis yields two
molecules of ATP per molecule of glucose oxidised (Figure 3.1A – left panel). This
occurs by substrate level phosphorylation of ADP.
Pyruvate is further oxidised by mitochondrial Oxidative Phosphorylation,
again using the oxidative potential of NAD+. The final products of Oxidative
Phosphorylation are CO2 and NADH (Figure 3.1A – left panel). The electrons stored
in this NADH, and NADH from glycolysis, are then used in the electron transport
chain. This is coupled to the production of ATP by ATP-synthase (Mitchell 1961),
yielding a further thirty-four molecules of ATP for each glucose molecule that
entered glycolysis. Importantly, donation of electrons from NADH oxidises it to
NAD+, allowing further glycolysis and Oxidative Phosphorylation to occur.
Glycolysis and subsequent Oxidative Phosphorylation are the dominant
metabolic pathways used by non-cancer cells (Figure 3.1A). However, under
anaerobic conditions Oxidative Phosphorylation cannot occur. ATP production is
maintained by glycolysis. Without Oxidative Phosphorylation to consume pyruvate
and NADH these products accumulate. Anaerobic cells also become deficient for the
oxidative potential of NAD+, which is no longer regenerated by Oxidative
Phosphorylation. To overcome this, an alternative metabolic pathway is engaged,
which requires lactate dehydrogenase (LDH).
3.2.3 LDH – decision maker in carbon catabolism
LDH catalyses the interconversion of pyruvate and NADH to lactate and
NAD+ (Baumberger et al. 1933). The ability to regenerate NAD+ from NADH
enables cells to continue glycolysis, with the NAD+ used for further glucose
oxidation. This is termed the Anaerobic Glycolysis Cycle (Figure 3.1A – right
panel). Lactate from this reaction is excreted from the cell. Importantly, LDH
catalyses the reaction in both directions, allowing either NADH and pyruvate or
NAD+ and lactate to be favoured (Baumberger et al. 1933) (Figure 3.1B). This gives
LDH power as a decision maker at the end of glycolysis – with either Oxidative
Phosphorylation or the Anaerobic Glycolysis Cycle the prospective pathways.
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LDH is a tetrameric enzyme encoded by different genes; LDH-A, LDH-B and
LDH-C (Markert et al. 1975). LDH-C expression is confined to the testis (Hintz and
Goldberg 1977; Goldberg et al. 2010). LDH-C can be aberrantly expressed in cancer,
but there is no evidence for this in the cell lines used here (Koslowski et al. 2002).
Therefore, this analysis has focussed on the more common LDH-A and LDH-B. The
relative expression of each isoenzyme is believed to determine function (Read et al.
2001). LDH-A favours the conversion of NADH and pyruvate into NAD+ and
lactate, whereas LDH-B favours the opposite reaction, NAD+ and lactate conversion
into NADH and pyruvate (Figure 3.1B). This is due to amino acid charge differences
in non-catalytic surface residues between the two isoenzymes. As such, the LDH
isoenzymes play an important role in deciding the direction of carbon catabolism.
Dominant LDH-A would favour the Anaerobic Glycolysis Cycle, whereas dominant
LDH-B would promote Oxidative Phosphorylation.
3.2.4 Metabolic alterations in cancer cells
The production of ATP from carbon catabolism is essential for the survival of
all cells. However, cancer cells have a high rate of proliferation, giving a higher
metabolic requirement for ATP. In contrast the majority of non-cancer cells do not
have high metabolic activity due to a slower rate of proliferation. This difference
presents an opportunity to specifically target energy production as a means to
selectively eliminate cancer cells. One of the earliest characterisations of cancer cell
biology was increased release of lactate, even under aerobic conditions (Warburg
1956). This was the first indication that not only the metabolic requirements of
cancer cells are altered, but also the means employed to meet these requirements.
Consistent with increased release of lactate, cancer cells commonly undergo a
metabolic shift towards the Anaerobic Glycolysis Cycle, even in the presence of
adequate oxygen (Figure 3.1A – right panel) – leading to the definition of this form
of cancer metabolism as ‘Aerobic Glycolysis’ (Warburg 1956). Later, in recognition
of the work of Otto Warburg in the field, this was termed The Warburg Effect.
Despite its early observation The Warburg Effect has only recently been studied with
great intensity, leading to ‘altered metabolism’ being designated status as an
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emerging hallmark of cancer (Hanahan and Weinberg 2011). Increasing knowledge
of the mechanisms and enzymes behind The Warburg Effect has earned this status.
Of note among these enzymes is LDH-A. As discussed, LDH-A promotes
carbon catabolism through the Anaerobic Glycolysis Cycle, in opposition to its
isoenzyme LDH-B (Read et al. 2001). With this metabolic phenotype favoured in
cancer cells, LDH-A has been analysed as the potential culprit for the altered
metabolism of cancer cells. Evidence in support of this comes from expression
studies for LDH-A and targeting of LDH-A in vivo.
3.2.5 LDH-A expression in cancer
LDH-A is expressed at higher levels in human tumour tissues compared to
paired non-cancerous tissue (Goldman et al. 1964). This early observation has been
supplemented by molecular biological analyses into the mechanisms behind this
overexpression, which have revealed that LDH-A is upregulated by two important
tumour-related transcription factors: c-Myc and HIF1 (hypoxia inducible factor 1).
c-Myc orchestrates cell proliferation by transactivating a wide range of genes
(Vita and Henriksson 2006). In malignancy c-Myc acts as an oncogene, able to
aberrantly promote the proliferation of cancer cells. c-Myc transactivates the LDH-A
promoter, with overexpression of c-Myc resulting in a 6-fold increase in LDH-A
mRNA (Lewis et al. 1997). Adding further to a role for LDH-A in cancer, LDH-A is
required for c-Myc regulated transformation (Shim et al. 1997). These data illustrate
the potential overexpression of LDH-A in cancer and implicate the enzyme in the c-
Myc driven progression of cells to a cancerous state.
LDH-A mRNA expression increases 2-fold under hypoxia, due to the tumour-
related HIF1 hetero-dimer binding to elements in the LDH-A promoter (Firth et al.
1995). Hypoxia commonly occurs in tumours, resulting in the derepression of HIF1α
(Majmundar et al. 2010). HIF1α then hetero-dimerises with the HIFβ subunit to
function as a selective transcription factor. HIF1 transactivates genes to promote
hypoxic cell survival, a facet cancer cells are able to exploit (Majmundar et al.
2010). The transactivation of the LDH-A gene by HIF1 is indicative of a role in
hypoxic tumour maintenance. HIF1 targeting for anti-cancer therapeutic gain is a
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popular concept (Semenza 2003). Targeting the genes activated by HIF1 may also
represent a means to reduce hypoxic cancer growth, with LDH-A a putative target
among these.
Interestingly the activation of LDH-A by c-Myc and HIF1 is not evident for
the LDH-B isoenzyme. Indeed the LDH-B isoenzyme is a target for promoter
hypermethylation and epigenetic silencing in prostate cancer (Leiblich et al. 2006).
Together these data indicate that LDH-A expression may be dominant over LDH-B
expression in cancer. This correlates with The Warburg Effect where LDH-A is
predicted to be required to favour the Aerobic Glycolysis Cyclic (Figure 3.1A). This
putative dependence upon overexpression of LDH-A identifies it as a potential anti-
cancer therapeutic target.
3.2.6 Targeting LDH-A in tumours
LDH-A is required for tumour maintenance in a mouse tumour model (Fantin
et al. 2006). Targeting LDH-A in tumours results in a switch to Oxidative
Phosphorylation for energy production, consistent with the hypothesis that LDH
determines the direction of carbon catabolism, and that LDH-A favours the Aerobic
Glycolysis Cycle. Interestingly, targeting LDH-A also reduces tumour growth
capacity under hypoxia, indicating that LDH-A promotes tumour cell viability.
In an independent in vivo analysis, LDH-A targeting reduced tumour
initiation and expansion (Le et al. 2010). Targeting of LDH-A in this study reduced
cellular NAD+ levels, and simultaneous targeting of LDH-A and NAD+ synthesis
enhanced cancer cell death. This strongly implicates the maintenance of NAD+ levels
by LDH-A as the mechanism promoting cancer cell survival. The requirement for
NAD+ is presumably to enable the Aerobic Glycolysis Cycle outlined above (Figure
3.1A – right panel). However, there is the possibility that reduced NAD+ availability
could impact on other essential enzymes that require NAD+.
3.2.7 NAD+ as a facilitator of SIRT1 activity
SIRT1 has a strict requirement for NAD+ as a coenzyme for all deacetylase
activity (Imai et al. 2000; Landry et al. 2000; Smith et al. 2000). SIRT1 removes the
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acetyl group from target lysine residues, transferring it to NAD+, which is cleaved
during the process to nicotinamide and a novel substrate, O-acetyl-ADP-ribose
(Tanner et al. 2000). Without NAD+, SIRT1 cannot function.
SIRT1 is overexpressed in many cancers and has a strong role in maintaining
cancer cell viability (see Chapter 1). LDH-A is important for the production of
NAD+ in cancer cells, which appears to be essential for their viability, although the
exact mechanism is unclear (Le et al. 2010). One possibility is that NAD+ generated
by LDH-A drives the cancer-related pro-survival functions of SIRT1 (Ford et al.
2005). This could expand the emerging pro-survival role of LDH-A in cancer,
beyond altered metabolism, to also include anti-apoptotic signalling. Indeed, there is
the potential for LDH-A linking the altered metabolic phenotype to the activation of
SIRT1 in cancer. The analysis of these hypotheses forms this Chapter.
3.2.8 Hypotheses
1. LDH-A, but not LDH-B, is essential for the survival of human cancer
cells.
2. LDH-A sustains the deacetylase and cancer related anti-apoptotic
activities of SIRT1.
Figure 3.1: Metabolism of non
(A) Schematic of the energy
cells (left) and cancer cells (right). OXPHOS = Oxidative Phosphorylation. Dashed
lines indicate suppressed pathways and filled lines active pathways. Oxidative
Phosphorylation is favoured in non
their metabolism towards the (An)aerobic Glycolysis Cycle (See Text).
Representation of the control that the LDH isoenzyme tetramer has over carbon
catabolism. LDH-A is shown in green and favours the (An)aerobic Glycolysis Cycle
LDH-B, in red, favours Oxidative Phosphorylation.
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3.3 Specific silencing of LDH isoenzymes by RNAi
3.3.1 A note on specific siRNA and primer design
LDH-A and LDH-B have amino acid sequence identity of 75% (Read et al.
2001). This is also the case for the mRNA sequences (68% identity), necessitating
careful design of specific siRNAs and DNA primers for each isoenzyme. The
sequences are shown in Figure 3.2, with annotation of siRNA and primer positions.
Specificity was paramount to the analysis, requiring low sequence identity to the
alternate mRNA for each target mRNA. The identity of the LDH-A siRNA to LDH-
B mRNA was 57.9%, and the identity of the LDH-B siRNA to LDH-A mRNA was
78.9%. Specificity of knockdown was determined by qRT-PCR using the primers
shown as detailed herein.
3.3.2 Knockdown of LDH-A
Initial investigation focussed on LDH-A, with LDH-B analysed in later
experiments. RNAi against LDH-A was carried out in parallel to Lamin AC
silencing, which acted a positive control for RNAi. Silencing of LDH-A mRNA was
achieved in a panel of four cell lines: three cancer cell lines, HCT116 (wild-type
p53), DLD1 (mutant p53) and HCT116 p53-/- (null for p53); and a non-cancer cell
line, ARPE19 (Figure 3.3A-D). LDH-A mRNA was significantly reduced compared
to Mock transfected cells in all four lines.
A rabbit monoclonal antibody detected LDH-A and LDH-B proteins by
western blot. LDH-A has a molecular weight of ~35kDa, running below LDH-B at
~36kDa (Read et al. 2001) . RNAi against LDH-A reduced in the lower band
(representing LDH-A) in all four cell lines analysed compared to Mock or Lamin AC
siRNA treatments (Figure 3.3A-D). This is consistent with the silencing seen at the
mRNA level. The effect of LDH-A silencing on the upper band, representing LDH-
B, was negligible in all four cell lines, exemplary of the selectivity of RNAi.
Control Lamin AC siRNA transfection significantly reduced Lamin AC mRNA
in all four cell lines (Figure 3.3A-D). Lamin AC protein levels were also efficiently
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reduced by RNAi in all four cell lines compared to Mock treated cells (Figure 3.4A-
D).
3.3.3 Knockdown of LDH-B
To further validate the specificity of the siRNAs against LDH-A and LDH-B
before progressing to analyse cell phenotypes, parallel transfection of each siRNA
was undertaken in the HCT116 cancer and ARPE19 non-cancer cell lines. LDH-A
and LDH-B cosilencing was also performed in the analysis.
LDH-B mRNA was significantly reduced compared to Mock transfection in
both cell lines following LDH-B siRNA transfection (Figure 3.5A). LDH-A silencing
was again efficient, consistent with the initial observations in Figure 3.4. Cosilencing
of both isoenzymes resulted in a reduction of both target mRNAs compared to
Mock. The extent of silencing was similar to or lower than that of the individual
silencing carried out in parallel. This supports isoenzyme selectivity in the RNAi, as
the use of both siRNAs did not give an additive silencing compared to single siRNA
usage.
The selective silencing of LDH-A and LDH-B is shown at the protein level
(Figure 3.5B). This is the case for both cell lines but is perhaps best seen for the
HCT116 cells due to a more favourable ratio of LDH-A to LDH-B. LDH-A protein
is reduced compared to Mock treatment in lanes 2, 4, 6 and 8, where LDH-A siRNA
was used. LDH-B protein is reduced in lanes 3, 4, 7 and 8 where LDH-B siRNA was
used. The specificity of this was high. There is potentially a reduction in LDH-A
protein following LDH-B silencing in the HCT116 cell line (lane 3), but this is not
evident at the RNA level (Figure 3.5A).
These initial experiments in Section 3.3 indicate that targeting of LDH-A or
LDH-B by RNAi gives a robust reduction in target mRNA and that this translates to
the protein level. The specificity of RNAi silencing for both isoenzymes allows
further analysis of the cellular and molecular effects of silencing of LDH-A or LDH-
B, which can be done with confidence of isoenzyme selectivity.
Figure 3.2: Comparison
Aligned coding mRNA sequences for the human LDH isoenzymes A and B. Total
sequence identity of the isoenzymes is 68.1%. Highlighted regions indicate siRNAs
and DNA primers used
Regulation of SIRT1 activity by LDH
of LDH isoenzyme mRNA sequences
– LDH-A is shown in green and LDH-B in red.
-A
94
100
120
100
120
0
20
40
60
80
100
120
140
160
*** ***
0
20
40
60
80
100
120
*** ***
HCT116
M
oc
k
La
m
in
A
C
LD
H
-A
M
oc
k
La
m
in
A
C
LD
H
-A
M
oc
k
La
m
in
A
C
LD
H
-A
M
oc
k
La
m
in
A
C
LD
H
-A
LDH-A Lamin ACmRNA
siRNA
Cell line
m
R
N
A
ab
un
da
nc
e
(%
)
ARPE19
LDH-A Lamin AC
HCT116 p53-/-
LDH-A Lamin ACmRNA
Cell line DLD1
LDH-A Lamin AC
m
R
N
A
ab
un
da
nc
e
(%
)
A B
C D
0
20
40
60
80
***
***
0
20
40
60
80
***
***
M
oc
k
La
m
in
A
C
LD
H
-A
M
oc
k
La
m
in
A
C
LD
H
-A
M
oc
k
La
m
in
A
C
LD
H
-A
M
oc
k
La
m
in
A
C
LD
H
-A
siRNA
m
R
N
A
ab
un
da
nc
e
(%
)
Figure 3.3: Targeting LDH-A mRNA by RNAi
(A) Quantification of LDH-A and Lamin AC mRNAs following specific
RNAi against each target in the HCT116 cancer cell line. Cells were
transfected with siRNA as indicated, harvested 48 hours post-transfection.
RNA was isolated by RNeasy method and qRT-PCR carried out as indicated
(See Methods). (B) Data as for (A) for the ARPE19 non-cancer cell line.
Harvesting of cells was at 72 hours post-transfection. (C) Data as for (A) for
the HCT116 p53-/- cancer cell line. Harvesting of cells was at 72 hours post-
transfection. (D) Data as for (A) for the DLD1 cancer cell line. Harvesting of
cells was at 72 hours post-transfection. *** P<0.001.
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Figure 3.4: Targeting LDH-A protein by RNAi
(A) Analysis of LDH isoenzyme and Lamin AC expression following
targeting by RNAi in HCT116 cells. Actin is used as a loading control. Cells
were transfected with siRNA as indicated, harvested 48 hours post-
transfection and lysed in protein lysis buffer (see Methods). Equivalent
protein was loaded by calculated mass. (B) Data as for (A) for the ARPE19
cell line. Harvesting of cells was at 72 hours post-transfection. (C) Data as for
(A) for the HCT116 p53-/- cell line. Harvesting of cells was at 72 hours post-
transfection. (D) Data as for (A) for the DLD1 cell line. Harvesting of cells
was at 72 hours post-transfection.
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Figure 3.5: Targeting LDH-B by RNAi
(A) Parallel independent silencing and cosilencing of LDH-A and LDH-B as
indicated. RNA was purified by RNeasy method and quantified by qRT-PCR
(see Methods) using specific primers detailed in Figure 3.2. Cells were
harvested at 48 hours (HCT116) or 72 hours (ARPE19). (B) Analysis of LDH
isoenzyme expression following the same independent silencing and
cosilencing in (A). Actin is used as a loading control. *** P<0.001.
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3.4 Characterisation of cell phenotype following LDH isoenzyme
silencing
3.4.1 Cancer cell lines
Phase contrast microscopy of the cancer cell lines HCT116 (Figure 3.6Ai)
HCT116 p53-/- (Figure 3.6Aii) and MCF7 (Figure 3.6Aiii) revealed little difference
in phenotype between Mock treatment and LDH-B silenced cells. The majority of
cells remained adhered to the surface and appeared at a similar density to Mock
treatment. Following RNAi against LDH-A in each line there was an increase in cell
detachment and more cells were refringent under microscopy. There appeared to be
concomitant reduction in the adhered population. Following cosilencing of both
LDH-A and LDH-B in the HCT116 and HCT116 p53-/- cell lines, the phenotype was
similar to that of the LDH-A silenced cells – an increase in detached, refringent cells
and a reduction in adhered cell density.
The use of the LDH-A siRNA, with or without LDH-B cosilencing, produced
a phenotype consistent with an induction of apoptosis. This was confirmed by
quantification of apoptosis by flow cytometry (see Methods). In the HCT116,
HCT116 p53-/- and MCF7 cell lines, LDH-A silencing induced a significant
induction in apoptosis (Figure 3.7A-C). Apoptotic induction is greater in the p53
wild-type cell lines (HCT116 and MCF7) than the null cell line (HCT116 p53-/-).
This suggests that p53 is important in LDH-A suppressed apoptosis. However, this
phenomenon may be attributable to apoptosis occurring over a longer period in the
HCT116 p53-/- cell line than the HCT116.
The apoptotic detection method used quantifies cells in early apoptosis (see
Methods). HCT117 p53-/- cells appeared to enter apoptosis over a longer period of
time (from 48 to 72 hours and beyond), in contrast to HCT116 cells which appeared
to peak in their early apoptotic quantity at 48 hours then have reduced apoptotic
numbers thereafter. As such, p53 is not required for apoptosis (as evidenced by
HCT116 p53-/- cell death) but may play a facilitating role in allowing faster induction
of apoptosis (as illustrated by greater induction at a specific early time point in p53
wild-type over null cells).
Regulation of SIRT1 activity by LDH-A
99
LDH-B silencing did not greatly alter the scored number of apoptotic cells in
the three lines, compared to Mock (Figure 3.7A-C). Further, cosilencing of LDH-A
and LDH-B in the HCT116 and HCT116 p53-/- cell lines resulted in a significant
induction of apoptosis (Figure 3.7A and B). This is consistent with the micrographs
in Figure 3.6A, and a correlation between LDH-A silencing and induction of
apoptosis.
The post-silencing phenotypes of the LoVo cell line were broadly consistent
with those above (Figure 3.6Aiv); LDH-B siRNA treatment caused little alteration
compared to Mock, whereas LDH-A siRNA treatment caused a reduction in adhered
cell density. There was also an increase in the number of refringent cells following
LDH-A siRNA treatment, although few cells appeared to have detached. This is
again consistent with an induction of apoptosis following RNAi against LDH-A in
this cancer cell line.
LDH-A was also targeted in the DLD1 cancer cell line, but not in parallel
with LDH-B silencing (Figure 3.6B). Lamin AC was targeted as a positive control
for RNAi with no effect on cell phenotype, and did not induce apoptosis (Figure
3.7D). LDH-A silencing resulted in an increase in detached cells compared to Mock
treatment. This phenotype is consistent with the induction of apoptosis, which was
again confirmed by flow cytometry (Figure 3.7D).
3.4.2 Non-cancer cell line
The data in Section 3.4.1 indicate that LDH-A has a role in promoting the
survival of five cancer cell lines. The effect of silencing LDH-A in non-cancer cell
lines will therefore allow an analysis of the cancer specificity of this effect. For this
the ARPE19 epithelial cell line was used as a representative line of non-cancerous
origin.
Silencing of each LDH isoenzyme individually did not greatly alter the
phenotype or density of the cell line compared to Mock treatment (Figure 3.8A).
LDH-B depleted cells appeared more rounded than Mock transfected cells.
Following LDH-A siRNA transfection there was a potential increase in refringent
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cells, but these remained attached to the plate. The phenotypes were not consistent
with an induction of apoptosis.
In agreement with this, silencing of LDH-A or LDH-B did not greatly alter the
number of apoptotic cells compared to Mock treatment, as is the case for cosilencing
of the two isoenzymes (Figure 3.8B). All four conditions analysed returned an
apoptotic cell count of ~1% of the total population, with no significant deviation
from Mock with any of the specific siRNA treatments. This indicates that neither
LDH-A or LDH-B are required for ARPE19 cell survival, which may be
representative of non-cancer cells in general.
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Figure 3.6: The effect of LDH isoenzyme silencing on cancer cell
phenotype
(A) Phase contrast microscopy at 200x magnification of four cancer cell lines
(HCT116, HCT116 p53-/-, MCF7 and LoVo) following silencing of LDH-A or
LDH-B and, for the HCT116 and HCT116 p53-/-, cosilencing of the isoenzymes
together. Micrographs were recorded 48 hours (HCT116, MCF7, LoVo) or 72
hours (HCT116 p53-/-) post siRNA transfection in all cases. (B) Images as in (A)
for the DLD1 cell line following LDH-A silencing and Lamin AC silencing as a
control. Harvesting of cells was at 72 hours.
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Figure 3.7: The effect of LDH isoenzyme silencing on cancer cell
apoptosis
(A) Fold apoptosis induction compared to Mock siRNA treated cells following
individual LDH isoenzyme silencing and cosilencing of both isoenzymes, in the
HCT116 cell line. Cells were treated with siRNA for 48 hours post-transfection
and analysed by Annexin V staining and flow cytometry (See Methods). (B)
Data as in (A) for the HCT116 p53-/- cell line at 72 hours post-transfection. (C)
Data as in (A) for the MCF7 cell line following individual silencing of LDH-A
and LDH-B. (D) Data as in (A) following Lamin AC and LDH-A silencing in
the DLD1 cell line at 72 hours post-transfection. *** P<0.001, ** P<0.01.
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Figure 3.8: The effect of LDH isoenzyme silencing on non-cancer
cell apoptosis
(A) Phase contrast microscopy at 200x magnification of the ARPE19 non-
cancer cell line following independent silencing of LDH-A and LDH-B and
cosilencing of the isoenzymes together. Micrographs were recorded 72 hours
post siRNA transfection in all cases. (B) Fold apoptosis induction compared
to Mock siRNA treated cells following individual LDH isoenzyme silencing
and cosilencing of both isoenzymes in the ARPE19 cell line. Cells were
treated with siRNA for 72 hours post-transfection and analysed by Annexin V
staining and flow cytometry (See Methods).
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3.5 Influence of LDH-A silencing on SIRT1 activity
The data so far agree with hypothesis 1, that ‘LDH-A, but not LDH-B, is
essential for the survival of human cancer cells’. To understand the cellular events
contributing to the apoptotic phenotype in cancer cells depleted of LDH-A, the effect
on SIRT1 activity was analysed, the second hypothesis being that ‘LDH-A promotes
the deacetylase and cancer related anti-apoptotic activities of SIRT1’.
3.5.1 LDH-A and acetylation of p53
SIRT1 deacetylates the tumour suppressor p53 at lysine 382, resulting in
attenuation of p53 activity (Luo et al. 2001; Vaziri et al. 2001). This contributes to a
constitutive cycle of acetylation and deacetylation (see Chapter 1 and Ford et al.
2005). Silencing of SIRT1 by RNAi increases p53 acetylation as the cycle is broken
and constitutive acetylation dominates. If LDH-A sustains SIRT1 activity, LDH-A
silencing will manifest as an increase in p53 acetylation at lysine 382, without
alteration in SIRT1 protein levels.
Silencing of LDH-A in the HCT116 and DLD1 cell lines resulted in an
increase in p53 acetylation at lysine 382 compared to control and Lamin AC siRNA
treated cells (Figure 3.9A and D). Total p53 levels were unchanged by LDH-A
knockdown, making this a post-translation modification specific effect. Importantly,
there was no effect on the expression of SIRT1 protein following LDH-A silencing.
These data are consistent with LDH-A sustaining the constitutive activity of SIRT1
towards p53 protein acetylated at lysine 382.
In the non-cancer ARPE19 cell line, the silencing of LDH-A may have altered
the acetylation of p53 at lysine 382 (Figure 3.9B). In comparison to the cancer cell
lines, basal acetylation of p53 is low in the ARPE19 cells. A band is visible for the
LDH-A lane but may or may not be present in the Mock lane given the proximity of
non-specific bands above and below the band of interest. Thus, commenting on the
acetylation status of p53 in the ARPE19 cell line is difficult. The effect of LDH-A
silencing on p53 expression is negligible.
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Lamin AC silencing reduced total and acetyl-p53 expression in the HCT116
and ARPE19 cell lines (Figure 3.9A and B). This was unexpected but is not
inconsistent with the use of Lamin AC siRNA as a positive control, and lack of p53
induction under these conditions. Western blots for total p53 and acetylated p53 in
the HCT116 p53-/- cell line returned negative as expected for this p53 null cell line.
3.5.2 Regulation of p53 target genes
p53 acts as a transcription factor, modulating gene expression. p53 promotes
the expression of its own ubiquitin ligase HDM2 (Momand et al. 1992; Barak et al.
1993). The acetylation of p53 is essential for transcriptional activation of p53 tumour
suppressive target genes (Tang et al. 2008). Given that p53 acetylation increases
following LDH-A silencing in the HCT116, DLD1 and potentially ARPE19 cell
lines, the expression of HDM2 protein was analysed.
HDM2 protein was elevated compared to Mock treatment following LDH-A
silencing in both the HCT116 and ARPE19 cell lines (Figure 3.9A and B). This is
consistent with an increase in p53 transcriptional activity. Importantly the induction
of HDM2 was not seen in either p53 null (HCT116 p53-/- – Figure 3.9C) or mutant
(DLD1 – Figure 3.9D) cell lines. This is a strong indication that the elevation of
HDM2 expression following LDH-A silencing requires wild-type, functional p53.
The p53 expressed in the DLD1 cell line carries a mutation in the DNA-
binding domain (S241F) predicted to disrupt p53 tertiary structure and reduce
transactivation of target genes (Rippin et al. 2002). The results here support this. p53
in the DLD1 cell line is hyper-acetylated following LDH-A silencing (Figure 3.9C)
but HDM2 protein levels are unchanged.
Together the data from Figure 3.9 indicate that 1) LDH-A suppresses p53
acetylation, but not SIRT1 protein expression, and 2) p53 acetylation correlates with
HDM2 protein expression, but only in a p53 wild-type background.
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3.5.3 Regulation of FOXO4 pro-apoptotic function
SIRT1 is required for survival of cancer cells with wild-type, mutant and null
p53 status (Ford et al. 2005). As such, p53 is not an essential apoptotic mediator
following reduction of SIRT1 activity by RNAi. The data for LDH-A presented in
Section 3.4 correlates well with this published role of SIRT1; LDH-A silencing
induces apoptosis in cancer cell lines of wild-type, mutant and null p53 status and is
consistent with a role for LDH-A in sustaining SIRT1 activity in these cancer cell
lines.
Despite an independence from p53 for the induction of apoptosis, SIRT1
silencing requires the expression of the pro-apoptotic factor FOXO4 to initiate
apoptosis. Cosilencing of FOXO4 rescues apoptosis induced by SIRT1 silencing
alone (Ford et al. 2005). From this, constitutive suppression of FOXO4 by SIRT1
has been inferred. To further test the hypothesis that ‘LDH-A sustains the
deacetylase and cancer related anti-apoptotic activities of SIRT1’, cell fate
following cosilencing of LDH-A and FOXO4 was analysed. LDH-A silencing
should correlate with SIRT1 silencing in its requirement for FOXO4 expression to
induce apoptosis.
Silencing of LDH-A, as previously carried out in Section 3.4, resulted in an
increase in detached and refringent HCT116 cancer cells compared to Mock treated
cells (Figure 3.10A). There was also a slight reduction in the number of adhered
cells. The number of apoptotic cells scored by flow cytometry after LDH-A silencing
increased compared to Mock treatment (Figure 3.10B), consistent with previous data
in this Chapter (Figure 3.7A).
Following cosilencing of LDH-A and FOXO4 the number of detached and
refringent cells appeared to fall slightly (Figure 3.10A). Cosilencing reduced the fold
induction of apoptosis compared to Mock treatment (Figure 3.10B). This constituted
a significant 1.8-fold reduction in apoptosis for cosilencing with FOXO4 compared
to LDH-A silencing alone. These data support the hypothesis that ‘LDH-A sustains
the deacetylase and cancer related anti-apoptotic activities of SIRT1’.
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Figure 3.9: The effect of LDH-A silencing on SIRT1 and p53
protein
(A) Analysis of protein abundance by western blot following silencing of
LDH-A, using Lamin AC as a positive control siRNA in the HCT116 cell
lines. RNAi was carried out 48 hours prior to harvesting of cells and lysis for
total protein. Protein was loaded for SDS-PAGE with equivalent mass of
protein (See Methods). Actin expression was used as a loading control. (B)
Data as for (A) for the ARPE19 cell line, harvested at 72 hours post-
transfection. (C) Data as for (A) for the HCT116 p53-/- cell line, harvested at
72 hours post-transfection. (D) Data as for (A) for the DLD1 cell line,
harvested at 72 hours post-transfection.
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Figure 3.10: LDH-A silencing induced apoptosis is suppressed
by FOXO4 silencing
(A) Phase contrast micrographs at 200x magnification of HCT116 cancer
cells following silencing of LDH-A and cosilencing of LDH-A with FOXO4.
Cells treated with siRNA were harvested 48 hours later and analysed by
Annexin V staining and flow cytometry (See Methods). (B) Fold induction of
apoptosis compared to Mock treated cells following the same silencing
conditions in (A). *** P<0.001, ** P<0.01.
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3.6 Discussion
3.6.1 Relative expression of the LDH isoenzymes
The literature suggests that LDH-A is the dominant isoenzyme in cancer cells
(Goldman et al. 1964; Leiblich et al. 2006). The LDH antibody used here detects
both isoenzymes, inviting comparison of expression levels. However, this may not
be possible as the avidity of the antibody for each target may differ such that one
form is favoured. This would bias the binding of one isoenzyme over the other,
increasing its apparent expression. As a result, this analysis has not been carried out.
In Figure 3.5B samples from the HCT116 cancer and ARPE19 non-cancer cell
lines were analysed side-by-side by western blot. This allows comparison of the
relative levels of each isoenzyme between the two cell lines. Expression of LDH-A
is higher in the ARPE19 cell line, and expression of LDH-B is higher in the HCT116
cell line – the inverse of the predicted expression levels for cancer and non-cancer
cells. However, these are only two cell lines; a wider analysis of further cancer and
non-cancer cell lines may correlate better with the literature.
In the HCT116 cell line, silencing of LDH-B reduces the protein level of
LDH-A (Figure 3.5B). The effect occurs at the protein level, but not the mRNA level
(Figure 3.7A). LDH forms tetramers containing both A and B isoenzymes (Markert
et al. 1975). The impact of reducing one isoenzyme on the other is not known. The
data presented here suggest a potential impact on isoenzyme stability with silencing
of the alternate isoenzyme. Following this line of investigation fell outside the scope
of the work so was not pursued.
3.6.2 LDH isoenzymes and cancer therapy
LDH-A may be a cancer specific survival factor; silencing LDH-A in five
cancer cell lines induced apoptotic phenotypes, confirmed by flow cytometry in four
of these lines (Figure 3.6 and Figure 3.8). In contrast, in the ARPE19 non-cancer cell
line apoptosis was not recorded (Figure 3.8). Cancer cell apoptosis is specific for the
LDH-A isoenzyme as silencing of the LDH-B form does not induce apoptosis in the
four cell lines analysed, including both cancer and non-cancer cells. This is
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consistent with the hypothesis that ‘LDH-A, but not LDH-B, is essential for the
survival of cancer cells’. The role of LDH-A in promoting tumour growth and
progression is well known (Shim et al. 1997; Fantin et al. 2006; Le et al. 2010), but
this is the first comparison to the role of LDH-B.
The tumour suppressor p53 is lost or mutated in 50% of all tumours, and
believed to be misregulated in the remaining tumours (Vogelstein et al. 2000; Olivier
et al. 2010; Goh et al. 2011). Thus the independence from p53 expression for the
induction of cell death is desirable for an anti-cancer therapeutic. This is the first
assessment of the requirement for p53 as a pro-apoptotic mediator following LDH-A
repression. The data here indicate that LDH-A targeting induced apoptosis in cancer
cell lines with wild-type, mutant and null TP53 genotypes. This adds significantly to
the field and supports the anti-cancer targeting of LDH-A.
Despite this, it is difficult to definitively conclude as to cancer specificity for
LDH-A survival function from the data presented here. Expansion of the non-cancer
cohort of the analysis to a similar level acquired for AROS silencing in Chapter 4
would be required for more confidence in a conclusion of cancer specificity.
Nevertheless these observations are consistent with published data demonstrating
that LDH-A targeting reduced tumour initiation and growth in the mouse (Fantin et
al. 2006; Le et al. 2010). Importantly these reports indicated no side effects from
LDH-A repression.
Furthermore, deficiency in LDH-A has been documented in the human
population (Kanno et al. 1988). The genotype manifests as an exertional myopathy;
patients suffer during exercise due to a build up of pyruvate, consistent with reduced
LDH-A activity in promoting the Anaerobic Glycolysis Cycle. Other than this,
patients lead unhindered lifestyles. The existence of LDH-A deficiency in the human
population suggests that targeting the function of the protein would not cause
negative side effects.
3.6.3 LDH-A and SIRT1 activity
The novel data here add to the expanding analysis of LDH-A as a therapeutic
target for cancer, where it may be specific and p53 independent. The mechanism of
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LDH-A tumour promotion has been linked to its role in carbon catabolism (Fantin et
al. 2006), and also in the provision of NAD+ (Le et al. 2010). Adequate NAD+ would
potentiate the Aerobic Glycolysis Cycle, but may also sustain the activity of the
NAD+-dependent enzyme SIRT1. The data here represents the first observation of a
potential reduction in SIRT1 activity following LDH-A silencing.
LDH-A silencing resulted in an increase in p53 acetylation in two of the three
p53-expressing cell lines analysed, with the third difficult to interpret (Figure 3.9). In
each of these cell lines the levels of SIRT1 protein were unaltered. This supports the
mechanism outlined in the hypothesis, where LDH-A sustains SIRT1 cancer related
function. This is summarised diagrammatically in Figure 3.11. Further to this,
targeting of LDH-A appears to effect p53 function. The Tang Model details
increased p53 target gene transactivation potential as a result of increased acetylation
(Tang et al. 2008). Increased acetylation of p53 following LDH-A silencing
correlated with increased expression of the known p53 target HDM2 (Momand et al.
1992; Barak et al. 1993) (Figure 3.9). Importantly this did not occur in p53 null
cells, or in p53 mutant cells, where LDH-A silencing did not correlate with increase
HDM2 expression (Figure 3.11).
However The Tang Model explicitly does not apply to HDM2 transactivation,
making the data appear contradictory (Tang et al. 2008). However, the model
describes p53-mediated HDM2 transcription as being independent of acetylation (i.e.
able to occur in the absence of acetylation) but does not rule out an increase upon
acetylation. Indeed with p53 transactivation potential increased by acetylation it is
likely that all p53 target gene transcription would be elevated upon acetylation –
supporting the increase in HDM2 protein seen here.
As further evidence for a role in sustaining SIRT1 activity, LDH-A suppresses
the pro-apoptotic signalling of FOXO4 in cancer cells (Figure 3.10), summarised in
Figure 3.11. This is a well documented cancer related function of SIRT1 (Ford et al.
2005). This correlation in function between SIRT1 and LDH-A, and the observation
that LDH-A suppresses p53 acetylation, supports the hypothesis that ‘LDH-A
sustains the deacetylase and cancer related anti-apoptotic activities of SIRT1’.
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3.6.4 Mechanisms of LDH-A promotion of cancer cell survival
LDH-A is required for cancer cell survival, with evidence here suggests
suggesting that this may occur via facilitation of SIRT1 activity. However, the data
do not exclude LDH-A promoting cancer cell survival via alternative mechanisms.
The metabolism of cancer cells is commonly altered, such that LDH-A is crucial for
the regeneration of NAD+ to potentiate Aerobic Glycolysis (Figure 3.1A – right
panel). Knockdown of LDH-A may therefore render cancer cells unable to generate
sufficient ATP, which would undoubtedly be detrimental to their viability. LDH-A
inhibition may provide a means to target the metabolic phenotype of cancer as well
as the aberrant signalling pathways promoted by SIRT1.
It is possible that LDH-A sustains other non-glycolytic NAD+-dependent
enzymes to promote cancer cell survival. Of the known non-glycolytic NAD+-
dependent enzymes few have known biological roles in humans. The sirtuins and the
poly(ADP)-ribose polymerase enzymes represent the two well characterised groups
of NAD+-dependent enzymes. Of the sirtuins, SIRT1 in cancer is well documented
(See Chapter 1). However, the other sirtuins, SIRT2-7, are all NAD+-dependent
(Landry et al. 2000), and will probably be modulated by NAD+ availability. The
broad role of the sirtuins in cancer and longevity has been previously discussed
(Saunders and Verdin 2007). Sirtuins 2, 4, 5 and 7 have documented roles in a range
of biological activities, but with little implication in cancer beyond reports of
chromosomal abnormalities at their loci in certain malignancies (Alhazzazi et al.
2011). However, SIRT3 and SIRT6 have been implicated, particularly in the context
of cancer metabolism.
3.6.4.1 SIRT3:
SIRT3 has been implicated as both a tumour suppressor and promoter,
according to cancer type and context (Alhazzazi et al. 2011). Functionally, SIRT3 is
the dominant deacetylase in mitochondria (Lombard et al. 2007), regulating
mitochondrial carbon metabolism and energy production. Despite evidence that
SIRT3 suppresses mitochondrial p53 function (Li et al. 2010), strong evidence
indicates that SIRT3 promotes apoptotic signalling pathways (Allison and Milner
2007). Further to this, SIRT3 suppresses metabolic reprogramming in cancer via
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negative regulation of HIF1α (Finley et al. 2011). LDH-A is a target of HIF1 (Firth et
al. 1995), meaning SIRT3 may suppress LDH-A transcription. These data suggest
that, although not formally analysed, it is unlikely that SIRT3 is sustained by LDH-A
to promote cancer cell survival.
3.6.4.2 SIRT6:
SIRT6 has also been implicated in the choice between Oxidative
Phosphorylation and the Glycolysis Cycle (Zhong and Mostoslavsky 2010). Of note
in this putative model, SIRT6 influences HIF1 in the transactivation of the LDH-A
gene. This is based on upregulation of LDH-A expression in SIRT6 knockout
embryonic stem cells (Zhong et al. 2010). However, this is non-specific as the LDH-
B gene is also upregulated in the same analysis, by an unknown mechanism. Thus
the role of SIRT6 in regulating carbon metabolism remains unclear, as does a role in
the altered metabolism of cancer.
SIRT6 regulates histone 3 by deacetylation of lysine 9 (Michishita et al.
2008). This activity maintains chromosomal integrity at telomeres, and suppresses
ageing-related NF-κB signalling (Michishita et al. 2008; Kawahara et al. 2009),
potentially contributing to genomic instability and premature aging in SIRT6
knockout mice (Mostoslavsky et al. 2006). However, SIRT6 has not been implicated
in pro- or anti-apoptotic signalling. As for SIRT3, this makes it unlikely that LDH-A
sustaining SIRT6 function promotes cancer cell survival. This brings greater
significance to the data here relating to the role of LDH-A in sustaining SIRT1
activity.
3.6.4.3 Poly(ADP)-ribose polymerases:
The poly(ADP)-ribose polymerase (PARP) enzymes, of which 18 have been
discovered by sequence homology analysis (Schreiber et al. 2006), are also NAD+-
dependent enzymes. PARP-1 and PARP-2 participate in the DNA damage response,
promoting DNA repair and the induction of apoptosis when appropriate
(Krishnakumar and Kraus 2010). A role for PARP-3 in DNA repair has also
emerged, suggesting that the PARP enzymes may specialise in DNA repair (Boehler
et al. 2011). The effect of the postulated reduction in NAD+ availability following
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LDH-A silencing would be a reduction in the pro-apoptotic activity of the PARP
proteins. This is contradictory to the data here where LDH-A has an anti-apoptotic
role. As such, it seems unlikely that LDH-A suppression of apoptosis occurs via the
PARP enzymes.
The published data for these NAD+-dependent enzymes adds to the
hypothesis that ‘LDH-A sustains the deacetylase and cancer related anti-apoptotic
activities of SIRT1’, and not other NAD+-dependent enzymes. The roles of SIRT3
and SIRT6 in carbon metabolism have parallels with emerging roles for SIRT1.
Figure 3.11: Schematic of the role of LDH
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3.7 Conclusions
1. LDH-A is required for the survival of a panel of cancer cell lines but not for a
non-cancer cell line.
2. LDH-A suppresses apoptosis in cancer cell lines independent of p53 status –
wild-type, mutant or null.
3. LDH-B is not required for survival of any of the cell lines analysed,
cancerous or non-cancerous.
4. LDH-A appears to sustain SIRT1 activity in cancer cells:
a. p53 acetylation increases following LDH-A silencing, consistent with
decreased constitutive deacetylation by SIRT1.
b. Increased p53 acetylation correlates with an increase in the p53 target
gene product HDM2, in the presence of wild-type p53.
c. LDH-A suppresses FOXO4 pro-apoptotic signalling, correlative with
SIRT1 suppression of FOXO4.
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4 Regulation of SIRT1 activity by AROS
4.1 Overview
This Chapter describes the initial investigations of the protein AROS. The
expression and conservation of AROS is detailed and targeting of AROS by
selective RNAi is achieved. Differences in the role of AROS are revealed between
basal and stress conditions, suggesting that the AROS-SIRT1 interaction is more
complicated than obligate activation. Multiple cell lines are used throughout the
Thesis, which are each analysed within this Chapter. This allowed the comparison of
data between the lines, revealing further differences in the role of AROS in SIRT1
activation.
The Chapter also introduces the work undertaken and the methodologies used.
Conclusions are drawn regarding the role of AROS in SIRT1 activation, specifically
in the suppression of p53. This links to Chapter 5, which extends the data presented
here to analyse cell phenotype following AROS silencing, and considers FOXO4 as
a further target of SIRT1.
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4.2 Introduction
4.2.1 Active Regulator Of SIRT1
AROS was first identified in a yeast two hybrid screen as a protein that
interacts with the ribosomal protein RPS19 (Maeda et al. 2006). This was observed
in murine cells and the interaction was mapped to residues 81 to 142 of murine
AROS (Figure 4.1). In this context AROS was termed RPS19 binding protein 1, or
RPS19BP1. For clarity it shall be referred to as AROS throughout this work. AROS
was expressed in all tissues analysed and localised to the nucleus of Cos-7 cells
(Maeda et al. 2006). AROS has also been observed in the nuclei of human cells (Kim
et al. 2007). Further, in some cells AROS localised to foci within the nuclei, which
were speculated to be nucleoli by the authors (Maeda et al. 2006; Kim et al. 2007).
No function has been attributed to the interaction between AROS and RPS19.
However, a later analysis of RPS19 phosphorylation revealed modulation of the
AROS-RPS19 interaction by CaM kinase Iα (Maeda et al. 2009). Phosphorylation of
RPS19 at serines 59 and 90 promoted the interaction with AROS in rat and human
cells (Figure 4.1). Human AROS is a relatively small protein at 136 amino acids in
length and only 15.4kDa. It was first characterised in relation to the function of
SIRT1.
4.2.2 AROS and SIRT1
AROS was termed Active Regulator Of SIRT1 due to its functional
interaction with the NAD+-deacetylase SIRT1 (Kim et al. 2007). This interaction is
specific for SIRT1 protein, with no interaction observed between AROS and the
other 6 human sirtuins. The AROS binding site was mapped to a region distal to the
SIRT1 active site (Figure 4.1). A subsequent in silico structural analysis predicted
this location for the AROS interaction, and suggested that AROS causes a
conformational change in SIRT1 protein upon binding (Figure 3.1 and Autiero et al.
2009).
The AROS-SIRT1 interaction and associated allosteric alteration in SIRT1
suggest that AROS influences SIRT1 activity. Among other targets, SIRT1
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deacetylates lysine residue 382 of the tumour suppressor p53 (Luo et al. 2001; Vaziri
et al. 2001). This occurs as part of a constitutive cycle of acetylation and
deacetylation, such that loss of SIRT1 results in hyper-acetylation of p53 (Ford et al.
2005). By assaying the activity of SIRT1 as inversely proportional to the acetylation
of p53 at lysine 382, AROS was identified as an activator of SIRT1 activity (Kim et
al. 2007). This observation was used to identify AROS as the first protein-level
regulator of SIRT1 activity; however the full extent of regulation of SIRT1 by
AROS required further investigation. This is the purpose of Chapters 4 and 5 here
where a more detailed investigation of the AROS-SIRT1 relationship was
undertaken.
AROS was identified as a positive regulator of SIRT1 via analysis of the
acetylation status of SIRT1 targets, namely p53 (Kim et al. 2007). The acetylation
status of p53 was assumed to be inversely correlative with SIRT1 activity. Thus,
overexpression of AROS reduced p53 acetylation, but only in the presence of SIRT1.
However, it is important to note that the conclusion that AROS activates SIRT1 was
based on experimental data where human cells were subjected to applied stress in the
form of etoposide and trichostatin A drug treatment (Kim et al. 2007) . These
chemical agents induce DNA-damage and increase p53 acetylation respectively
(Chen et al. 1984; Yoshida et al. 1990). As such, the conditions where AROS was
identified as an activator of SIRT1 activity cannot be considered physiological.
Furthermore, these conditions are likely to have induced acetylation of p53, which
may be regulated differently by AROS than under normal physiological conditions.
Thus, an initial aim of the analyses was to clarify the role of AROS in SIRT1
activation under physiological/basal conditions. For this, transient RNAi against
AROS was used, which is possible under basal conditions (See Methods and Ford et
al. 2005; Ahmed and Milner 2009).
A further line of investigation was identified as the regulation of SIRT1
targets other than p53. SIRT1 regulates a diverse range of proteins via deacetylation
at specific lysine residues (for a recent review see Knight and Milner 2011). AROS
has been characterised in its suppression of p53 acetylation via SIRT1 (Kim et al.
2007), however whether AROS regulates further SIRT1 targets is not know. This
raises the possibility that AROS is not an obligate activator of SIRT1, perhaps acting
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to specifically promote SIRT1 function towards specific targets such as p53. To this
end, AROS regulation of FOXO4 is analysed as a second target of SIRT1 in Chapter
5.
To gain a wider appreciation of the role of AROS in suppression of p53 a
range of cell lines of both cancer and non-cancer origin (see Methods for full details)
were analysed following silencing of AROS. This was carried out under basal
conditions, as well as following the application of both drug and irradiation induced
stress.
4.2.3 Hypotheses
1. The AROS gene is widely expressed in humans and has orthologues in other
species.
2. The regulation of SIRT1 by AROS is complex. This will be analysed in
terms of:
a. cell line dependent effects,
b. cell context dependent effects.
Figure 4.1: Schematics of SIRT1,
To scale annotated schematic representations of the SIRT1, AROS and RPS19
protein primary sequences. SIRT1 shows the mapped AROS binding site (114
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4.3 Initial analyses of AROS
4.3.1 Conservation of AROS in animalia
The AROS protein is conserved across animalia, with high levels of
conservation between closely related species (Figure 4.2). Most striking is the 100%
sequence identity between the human and chimpanzee forms of the protein. Human
AROS retains almost 75% identity to all mammalian forms of the protein analysed,
with lower sequence identity seen to AROS orthologues from other animal
kingdoms. Also of note is the 87.4% identity between the mouse and rat orthologues
of AROS.
Database searches found AROS in all vertebrate branches of the animal
kingdom; birds, reptiles, fish, amphibians and marsupials (Figure 4.2). An AROS
orthologue was found in the species Brachiostoma floridiae, one of the simplest
vertebrates known and a model organism for chordate development (Yu et al. 2007).
This organism is believed to represent the earliest divergence of vertebrates from
invertebrates, and shares sequence identity with many invertebrate genes. AROS also
has orthologues in invertebrate species, such as the pea aphid (Acyrthosiphon pisum),
suggesting that AROS is conserved in invertebrates as well as vertebrates (Figure
4.2).
Interestingly, no orthologue of AROS could be found outside the animal
kingdom. Fellow eukaryotes, the fungi and plants do not have an AROS orthologue,
neither do any species of bacteria or archaea analysed. This indicates that AROS is a
conserved protein only among animalia.
Sirtuin orthologues are found in eukaryotes, most archaea and bacteria
species (Greiss and Gartner 2009). However, specific SIRT1 orthologues are only
found in animalia and some fungi – no SIRT1 orthologues were reported in plants,
archaea or bacteria. SIRT1 conservation in animalia is thus similar to the status of
AROS, however the SIRT1 gene may appear in the absence of AROS in some species
of fungi. Animal species outnumber fungal species by around 10:1 (Blackwell 2011).
This implies that the majority of species with a SIRT1 orthologue also bear an AROS
gene and indicates the potential for co-evolution of the two genes in animalia.
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4.3.2 Human homologues of AROS
AROS is not a member of a gene family. Sequence identity searches for the
AROS mRNA returns only three human genes above 50% identity (Figure 4.3). This
identity is modular based on regions of the alternative gene that have identity to the
full AROS sequence. These 3 genes have no unifying function, although two (REV3
and Spinophilin) are both subunits of larger enzymatic machines. This has partial
parallels to the role of AROS as a regulator of SIRT1 activity; although it seems
likely that this similarity is coincidental.
4.3.3 Expression of AROS mRNA and protein
AROS was ubiquitously expressed across a representative panel of human
tissues (Figure 4.4A). Expression was comparable between tissues with no large
variation between samples. Consistent with wide expression, searching the online
gene expression database ‘RefExA’ revealed expression in all cell lines and tissues
analysed (http://www.lsbm.org). RPS19 was also expressed in all of the tissues
analysed, both here (Figure 4.4A) and in the ‘RefExA’ database. This is consistent
with its role as an essential ribosomal protein gene. SIRT1-FLexpression has been
reported in the same panel (Lynch et al. 2010), similar to the expression of AROS.
With wide RNA expression of AROS the relative levels of the protein were
analysed in a panel of human cell lines from the colorectal epithelium (HCT116,
DLD1, LoVo), mammary gland epithelium (MCF10A, MCF7), retinal pigmented
epithelium (ARPE19) and lung fibroblast (WI38). AROS was expressed in all eight
cell lines analysed, but with high variability (Figure 4.4B). Expression was lowest in
the WI38 line, being undetectable in these images. However AROS was detected in
WI38 cells in later experiments (Figure 4.9). AROS expression was also low in the
MCF10A and MCF7 cell lines. AROS protein expression was greatest in the
HCT116 and ARPE19 cell lines. These two cell lines form the basis of experiments
in the Thesis, with the other six cell lines analysed where appropriate.
Despite the varied expression of AROS this could not be correlated with the
expression of its two known binding partners. SIRT1 was expressed in each of the
cell lines (Figure 4.4B), with expression highest in the five cancer cell lines (Lanes
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4-8) and lower in the three non-cancer cell lines (Lanes 1 to 3). This correlates well
with the role of SIRT1 as a cancer cell survival factor (see Chapter 1 and Ford et al.
2005), but does not correlate with the expression of AROS across the panel of cell
lines. Similarly, RPS19 protein was expressed across all cell lines analysed (Figure
4.4B). RPS19 expression was similar in each cell line and did not correlate with the
expression of AROS.
Expression of p53 was extremely variable between cell lines (Figure 4.4B).
As expected no p53 protein was observed in the HCT116 p53-/- cell line where the
p53 gene is disrupted (Bunz et al. 1998). The p53 protein expressed in the DLD1 cell
line carries a mutation leading to substitution of serine 241 to a phenylalanine
(Rippin et al. 2002). Despite this p53 is expressed at a similar level to cell lines from
colorectal adenocarcinomas. Indeed p53 expression was high in the three colorectal
adenocarcinoma cell lines – HCT116, DLD1 and LoVo – (Lanes 4, 7 and 8) with
lower expression seen in the cell lines from other origins. The variable expression of
p53 did not correlate with the variability in AROS expression.
Figure 4.2: Conservation of AROS protein
The sequence of human AROS (NP_919307) was used in a BLAST search against
all published sequences. Sequences annotated as orthologous to AROS were used for
alignment in Vector NTI to generate percent
table. Mammalian species were:
(Chimpanzee), Macaca mulatta
rat) and Mus musculus
anatinus (Platypus). Bird species:
species: Danio rerio (Zebrafish), Reptile species:
lizard). Amphibian species:
species: Acyrthosiphon pisum
discussed.
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Gallus gallus (Domesticated chicken). Fish
Anolis carolinensis
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Figure 4.3: Homologues of AROS mRNA
(B) The sequence of human
against all human mRNAs. The table lists the 3 genes which returned sequence
identity higher than 50% and a brief description of gene function.
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Figure 4.4: Expression of human AROS mRNA and protein
(A) Expression of AROS and RPS19 mRNAs across a representative panel of
human cell lines (AMS Biotechnology). Data represents agarose gel separated
cDNA from RT-PCR using specific primers against each mRNA (see
Methods). Visualisation was by transillumination of ethidium bromide
intercalated into the cDNA. ‘Blank’ represents RT-PCR in the absence of
template RNA. (B) Expression of proteins across a panel of human cell lines.
All samples were Mock treated in siRNA transfection and harvested at either
48 or 72 hours post-transfection. The ARPE19, WI38 and MCF10A represent
non-cancer cell lines, whereas the HCT116, HCT116 p53-/-, MCF7, DLD1
and LoVo cell lines are all of cancerous origin. Equivalent protein was loaded
by mass, as calculated by the Pierce BCA method. ‘Blank’ represents RT-PCR
in the absence of template RNA.
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4.4 Targeting of AROS by RNAi
Silencing of AROS mRNA was achieved in the HCT116 and ARPE19 cell
lines using two independent siRNAs (Figure 4.5). Both siRNAs reduced AROS
mRNA expression to below 15% of Mock expression. In both cell lines AROS
siRNA 1 was more effective. Parallel RNAi against SIRT1 specifically reduced
SIRT1 mRNA levels, as did transfection of the positive control siRNA against Lamin
AC, reducing Lamin AC mRNA. Importantly the silencing in all cases was specific,
with the expression of each mRNA only reduced by transfection of the
complementary siRNA.
Silencing of SIRT1 and Lamin AC translated to the protein level in the
HCT116 cells (Figure 4.6A). However, total AROS protein levels were not reduced
by RNAi with either independent siRNA. Total AROS protein expression may have
been partially reduced but not to the extent seen for Lamin AC or SIRT1, or the
extent expected given the efficient mRNA silencing seen in Figure 4.5A. This
Subcellular fractionation of the HCT116 cells was used to analyse the effect of
AROS siRNA 1 within different fractions of the cells. AROS siRNA 1 treatment
reduced the expression of nuclear AROS but had little effect on AROS present in the
cytoplasmic fraction (Figure 4.6B). It appears likely that the cytoplasmic fraction
contributed to the persistence of total AROS protein. Cytoplasmic localisation of
AROS has not been previously reported, making this a novel population of the
protein to the field.
Similar to the HCT116 cell line, targeting of Lamin AC, SIRT1 and AROS
(with siRNA 1) in the ARPE19 non-cancer cell line specifically reduced target
protein expression (Figure 4.6C). AROS siRNA 2 did not reduce AROS protein
expression, again despite efficient mRNA knockdown (Figure 4.5B). Subcellular
fractionation following AROS siRNA 1 transfection confirms that all fractions of
AROS are reduced by RNAi, giving the total protein level loss observed (Figure
4.6D). This fractionation also indicates that the novel cytoplasmic population of
AROS is present in high quantity in the ARPE19 cell line.
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The reason for greater efficacy of AROS siRNA 1 compared to siRNA 2 is
not known. The two siRNAs target regions just 128bps apart within AROS mRNA.
The siRNAs target neighbouring exons, exon 3 (siRNA 2) and exon 4 (siRNA 1). It
is possible that the differential in efficiency is attributable to protection of AROS
mRNA either by nucleotide base pairing or mRNA-protein interactions.
Nevertheless, with AROS siRNA 1 appearing the most effective at silencing AROS,
at least at the mRNA level, this was used throughout the analyses in the Thesis.
Targeting of AROS did not alter the protein abundance of SIRT1 in the
HCT116 cancer, or ARPE19 non-cancer cell lines, and vice versa (A and C). This is
consistent with the reported role of AROS in regulation of SIRT1 (Kim et al. 2007),
and indicates that any effect AROS has upon SIRT1 activity is not due to alterations
in SIRT1 endogenous protein level. With this noted the effect of AROS upon SIRT1
activity was analysed, using p53 acetylation status as an assay.
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Figure 4.5: RNAi against AROS mRNA
(A) Quantification of mRNA following RNAi against Lamin AC, SIRT1 or
AROS (2 independent siRNAs). HCT116 cancer cells were transfected with
siRNA as indicated, harvested 48 hours post-transfection. RNA was isolated
by RNeasy method and qRT-PCR carried out as indicated (See Methods). (B)
Quantification of mRNA as in (A). ARPE19 non-cancer cells were harvested
72 hours post-transfection. *** P<0.001
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Figure 4.6: AROS protein knockdown following RNAi
(A) Analysis of target protein abundance following RNAi in HCT116 cancer
cells. Cells were transfected with siRNA as indicated, harvested 48 hours
post-transfection and lysed in protein lysis buffer (see Methods). Equivalent
protein by mass was analysed and Actin expression used as a loading control.
(B) Subcellular localisation of AROS protein following fractionation of
HCT116 cancer cells according to Pierce protocol (see Methods). Cells were
treated with siRNA for 48 hours prior to harvesting. LDH is used as a
cytoplasmic marker protein, and Lamin AC as a nuclear marker protein. (C)
Analysis of protein abundance from RNAi analysis as in (A) for the ARPE19
non-cancer cell line, harvested at 72 hours post-transfection. (D) Subcellular
localisation of AROS and the effect of AROS siRNA as in (B) for the
ARPE19 cell line, harvested 72 hours post-transfection.
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4.5 The effect of AROS on SIRT1 activity
4.5.1 AROS suppression of p53
Under basal conditions in the HCT116 cancer cell line SIRT1 is known to
constitutively suppress p53 acetylation (Ford et al. 2005). This result was repeated
here, with silencing of SIRT1 resulting in an increase in p53 acetylation and total
p53 levels (Figure 4.7A). In contrast, parallel use of AROS siRNA in the HCT116
cells did not stabilise either total or acetylated p53 compared to Mock treatment
(Figure 4.7A). This appears to disagree with the previously published role of AROS
as an activator of SIRT1 activity (Kim et al. 2007) and is the first indication that ‘the
regulation of SIRT1 by AROS is complex’. As outlined in the Introduction, the reason
for this disparity may be different cellular contexts used. Here under basal conditions
AROS does not appear to be required for SIRT1 activity, whereas in the original
analysis AROS was required following the application of stress.
AROS silencing in the ARPE19 non-cancer cell line gave inconclusive
results regarding the modulation of p53 acetylation (Figure 4.7B). Acetylation of p53
in this non-cancer cell line is constitutively low, especially under these basal
conditions. Thus, although bands could be detected upon long exposure these are
difficult to interpret with confidence. Taking the lower band as acetylated p53 the
trend appears to be an increase in acetylation following silencing of either SIRT1 or
AROS compared to Mock treatment (Figure 4.7B). Partly consistent with this, total
p53 protein levels appeared to increase following AROS silencing but not SIRT1
silencing. This may indicate that in the ARPE19 cell line under basal conditions that
AROS suppresses p53, presumably via activation of SIRT1. This is in agreement
with the work of Kim and colleagues (2007).
The potential for complexity in the regulation of p53 by AROS lead to the
combinatorial silencing of SIRT1 and AROS in the HCT116 cell line (Figure 4.7C).
SIRT1 protein was depleted by both individual (lane 2) and combinatorial (lane 4)
siRNA application. AROS protein exhibited partial resistance to siRNA treatment
where used (lanes 3 and 4) as reported above. Individual silencing of SIRT1 again
increased the total and acetylated levels of p53 compared to Mock, whereas
individual targeting of AROS had little effect on p53 (Figure 4.7C). This agrees with
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the data in Figure 4.7A. Interestingly, combinatorial silencing of SIRT1 and AROS
appeared to have a reduced effect on p53 acetylation compared to SIRT1 silencing
alone, despite similarly efficient reduction in SIRT1 protein expression (Figure
4.7C). This is consistent with the regulation of AROS by SIRT1 being more complex
than originally reported.
Densitometry standardised against actin expression from two independent
biological replicates allowed statistical analysis of the difference in p53 acetylation
shown in Figure 4.7C. Densitometry quantified the increase in p53 acetylation
following SIRT1 knock down as greater than 2.5-fold (Figure 4.7D). In contrast
targeting of AROS had no significant effect upon acetylation of p53. Interestingly,
densitometry indicated that the cosilencing of AROS with SIRT1 did not result in the
stabilisation of p53 acetylation (Figure 4.7D). This is in contrast to the effect of
single SIRT1 silencing and the reported role for AROS as an activator of SIRT1
(Kim et al. 2007). Furthermore, this result suggests that AROS does not suppress
p53 acetylation, but conversely that it may actively promote acetylation, potentially
in opposition to SIRT1 (see Discussion).
The acetylation of p53 may have been suppressed by AROS in the ARPE19
cell line but was not in the HCT116 cell line. This suggests that the AROS-SIRT1
relationship is more complex than obligate activation. Apparent cell line specific
effects prompted analysis of five further cell lines for the effect of silencing AROS
on p53. The validation of silencing was also carried out in each cell line, important
for the analysis of resulting phenotypes in Chapter 5.
4.5.2 Silencing of AROS in further cell lines
4.5.2.1 MCF7
Silencing of AROS was apparent at the total protein level in the MCF7
mammary gland epithelial cancer cell line (Figure 4.8A – lane 1 compared to lane 2).
SIRT1 was silenced at both the mRNA and protein level but this did not modulate
p53 levels (lane 1 compared to lane 3); total p53 levels did not appear to be affected
and acetylated p53 remained undetectable. In contrast AROS silencing appeared to
increase total p53 levels compared to Mock, but again acetylated p53 was
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undetectable. This increase in total p53 following AROS silencing implies that
AROS suppresses p53 in the MCF7 cell line. Furthermore, this may be independent
of SIRT1, which did not affect p53 upon knock down. This is a further indication
‘the regulation of SIRT1 by AROS is complex’.
Interestingly, AROS protein was also reduced by SIRT1 silencing (lane 1
compared to lane 3). This is likely via a post-transcriptional mechanism as the
abundance of AROS mRNA was not reduced beyond control Actin mRNA levels by
SIRT1 silencing (Figure 4.8B). This represents a subset of conditions where SIRT1
was seen to effect AROS abundance (discussed herein).
4.5.2.2 DLD1
Targeting of AROS in the DLD1 colorectal adenocarcinoma cell line did not
greatly diminish AROS protein expression (Figure 4.8C – lane 1 compared to lane
3). However, AROS mRNA expression was significantly reduced compared to Mock
treatment (Figure 4.8D). This is similar to the data for the HCT116 colorectal cancer
cell line (Figure 4.6A), and as such AROS may be selectively silenced in the nuclear
fractions of DLD1 cells. SIRT1 was efficiently silenced at both the mRNA and
protein level (Figure 4.8C and D).
DLD1 cells express mutant p53 protein, with an amino acid alteration from
serine 241 to phenylalanine (Rippin et al. 2002). Nevertheless this p53 protein
appears to be subject to regulation by post-translational modification as acetylation
of p53 was detected by Western blot (Figure 4.8C). This appeared to increase
following silencing of SIRT1 compared to Mock (lane 2 compared to lane 1) and
silencing of AROS (lane 3 compared to lane 1). The increase was greater following
SIRT1 silencing. Following silencing of either SIRT1 or AROS the total level of p53
protein also appeared to increase compared to Mock. This implies that both SIRT1
and AROS have the same effect on the mutant p53 in DLD1 cells, suppressing
acetylation and total protein levels. This is consistent with AROS promoting SIRT1
activity.
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4.5.2.3 LoVo
Similar to the silencing of AROS in the HCT116 and DLD1 cell lines,
targeting of AROS in the LoVo colorectal adenocarcinoma cell line did not result in
a reduction in AROS protein (Figure 4.8E – lane 4 compared to lane 1). This was
despite a significant reduction in AROS mRNA (Figure 4.8F). Silencing of Lamin
AC and SIRT1 was efficient at both the mRNA and protein levels. Lamin AC siRNA
treatment did not appear to effect p53 expression, consistent with its use as a positive
control for RNAi under basal conditions.
Targeting of AROS by siRNA appeared to stabilise total p53 levels and
increase the acetylation of p53 (Figure 4.8E – lane 4 compared to lane 1).
Interestingly, this was in contrast to silencing of SIRT1, which did not appear to
affect either total or acetylated p53 levels (Figure 4.8E – lane 3 compared to lane 1).
This implies that, AROS may be able to suppress p53 under conditions where SIRT1
does not. This difference adds further support to the hypothesis that ‘the regulation
of SIRT1 by AROS is complex’.
4.5.2.4 WI38
AROS was targeted in cell lines of non-cancerous origin, firstly the WI38
lung fibroblast line. Expression of AROS was low in the WI38 cell line compared to
the other cell lines analysed (Figure 4.4B). This is seen in Figure 4.9A where AROS
expression was close to the threshold of detection. Knockdown of AROS may have
occurred at the protein level in this cell line but the data is open for interpretation.
AROS was selectively silenced at the mRNA level by siRNA treatment (Figure
4.9B). Silencing of both Lamin AC and SIRT1 was efficient at the protein level in
this cell line (Figure 4.9A).
Silencing of both AROS and SIRT1 in the WI38 line induced a large increase
in total p53 protein (Figure 4.9A). There also appeared to be an increase in the
acetylation of p53 under both silencing conditions. This suggests that AROS and
SIRT1 have the same effect on p53 in this cell line. This presumably involves AROS
promoting SIRT1 activity towards acetylated p53 as identified in the original
characterisation of AROS (Kim et al. 2007).
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Interestingly, SIRT1 knockdown appeared to result in an increase in AROS
protein, suggesting that SIRT1 suppresses AROS expression in the WI38 cell line
(Figure 4.9C). AROS mRNA was not affected by SIRT1 silencing, suggestive of
post-transcriptional modulation of AROS by SIRT1. This represents an example of
SIRT1 effecting AROS levels, which forms part of the Discussion.
4.5.2.5 MCF10A
AROS was also targeted in the MCF10A mammary gland epithelium line,
which is of non-cancerous origin. AROS was selectively silenced in the MCF10A
cell line at both the mRNA and protein level (Figure 4.9C and D). Knockdown of
both Lamin AC and SIRT1 was also efficient at both the mRNA and protein level.
Total p53 levels were slightly increase by silencing of AROS or SIRT1 in the
MCF10A non-cancer cell line (Figure 4.9C). Unfortunately, acetylated p53 was not
analysed in this line due to lack of sample. However the trend shown by total p53
levels suggests that AROS and SIRT1 both suppress p53 stabilisation.
Interestingly, the knockdown of SIRT1 appeared to effect AROS protein
expression in this non-cancer cell line (Figure 4.9A). This is despite no effect on
AROS mRNA with SIRT1 siRNA (Figure 4.9B). SIRT1 appears to promote AROS
protein in the MCF10A cell line (Figure 4.9C), similar to the effect seen previously
in the MCF7 cell line (Figure 4.8A). These two lines are both from the mammary
gland epithelium, indicating that this may be a conserved effect in this tissue.
4.5.2.6 HCT116 p53-/-
AROS was successfully targeted by RNAi in the HCT116 p53-/- cell line.
This was carried out in parallel to silencing of Lamin AC and SIRT1. Depletion of
target mRNA was significant and specific (Figure 4.10A), and this translated to the
protein level for each of the 3 targets (Figure 4.10B). p53 is not expressed in this null
cell line, making analysis of p53 protein levels void. However, the cell line is a
useful tool for analysis of p53-depenendency. This confirmation of knockdown will
allow analysis of the resulting phenotype in Chapter 5. Also of note, is that SIRT1
silencing did not appear to effect AROS protein expression in this cell line.
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Figure 4.7: AROS has a variable effect on p53 acetylation
(A) Analysis of the effect of SIRT1 and AROS RNAi on total and acetylated
p53 levels by Western blot. HCT116 cells here were those analysed in Figure
5.5A. Actin is used as a loading control. (B) Analysis of ARPE19 cells as in
Figure 5.5C for total and acetylated p53 levels. (C) The effect of SIRT1 and
AROS individual and combined silencing on total and acetylated p53 levels.
HCT116 cells were transfected with siRNA and harvested 48 hours later in
protein lysis buffer (see Methods). Protein was loaded by equivalent mass and
separated by SDS-PAGE followed by Western blotting with antibodies as
indicated. (D) Quantification of data from (C). Quantity One software was
used to quantify total and acetylated p53 levels. These values were
standardised to Actin and expressed as a ratio. Values here represent two
independent experiments with error bars as standard deviation. *** P<0.001
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Figure 4.8: RNAi against AROS by cell line (I) – cancer cells
(A) Protein abundance following RNAi against AROS and SIRT1 in the MCF7
mammary gland epithelial cancer cell line. Cells were transfected with siRNA and
harvested 48 hours later by lysis in protein lysis buffer (see Methods). Protein was
analysed by SDS-PAGE and Western blotting with protein loaded according to
equivalent mass. Empty arrow indicates expected position of relevant protein. (B)
Quantification of mRNAs following RNAi against AROS and SIRT1 from same
experiment as in (A). RNA was isolated by the RNeasy method and analysed by
qRT-PCR. (C) Protein abundance by Western blot of target proteins and p53
following silencing of SIRT1 and AROS in the DLD1 colorectal adenocarcinoma
cell line. Cells were treated and harvested as in (A). (D) Quantification of mRNAs as
carried out in (B) for the DLD1 cell line, harvested in parallel to protein samples
shown in (C). (E) p53 and target protein abundance following RNAi in the LoVo
colorectal carcinoma cell line harvested 48 hours post-transfection. For all Western
blotting Actin was used as a loading control. (F) Quantification of mRNAs as carried
out in (B) for the LoVo cell line, harvested in parallel to protein samples shown in
(E). *** P<0.001.
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Figure 4.9: RNAi against AROS by cell line (II) – non-cancer cells
(A) Abundance of target proteins and p53 following RNAi against AROS, SIRT1 and
Lamin AC mRNAs. WI38 lung fibroblast cells were harvested 72 hours post siRNA
transfection and lysed for total protein content. Equivalent mass of protein was
analysed by Western blotting following separation by SDS-PAGE. (B)
Quantification of mRNA abundances harvested in parallel to protein analysis in (A).
RNA isolated by RNeasy method and analysed by qRT-PCR. (C) Analysis of
relative protein abundance in the MCF10A mammary gland epithelial cell line
following RNAi as indicated. Cells treated as in (A). (D) mRNA quantification by
qRT-PCR from parallel RNA isolation in parallel to protein data in (C). ** P<0.01,
*** P<0.001.
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Figure 4.10: RNAi against AROS by cell line (III) – HCT116 p53-/-
(A) Quantification of mRNA in the HCT116 p53-/- cell line following RNAi.
Total RNA was harvested 72 hours post-transfection by the RNeasy method
and used in qRT-PCR (see Methods). GAPDH mRNA is used as a loading
control. *** P<0.001. (B) Protein abundance from protein samples harvested
in parallel to total RNA samples analysed in (A).
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4.6 The role of AROS following stress
4.6.1 Etoposide and Trichostatin A
Etoposide is an inhibitor of the topoisomerase II enzyme, with administration
resulting in DNA damage during DNA replication (Chen et al. 1984). Trichostatin A
(TSA) is an inhibitor of all histone deacetylases, except the sirtuins (Yoshida et al.
1990; Barlow et al. 2001). These cytotoxic drugs were used in combination during
the original characterisation of AROS (Kim et al. 2007). Under these conditions
silencing of AROS by shRNA induced an increase in p53 acetylation. The effect of
AROS upon p53 acetylation is variable under basal conditions (see above). The
potential for differences between basal and stress conditions was analysed, initially
using the same cytotoxic drug regime employed by Kim and colleagues (2007).
Administration of etoposide and TSA markedly increased p53 protein levels,
both total and acetylated (Figure 4.11). This was seen in both the HCT116 and
ARPE19 cell lines. Given the effect of the drugs this was not unexpected. DNA
damage resulting from etoposide treatment activates the p53 stress response
pathway; and inhibition of non-sirtuin deacetylation by TSA increases p53
acetylation.
The effect of silencing SIRT1 and AROS was assessed under these stress
conditions. Application of etoposide and TSA did not significantly alter the
expression of the mRNAs analysed, and silencing of AROS and SIRT1 was efficient
and specific at the mRNA level in the HCT116 cells (Figure 4.12). SIRT1 protein
was depleted by SIRT1 siRNA, but AROS protein was not greatly reduced in the
HCT116 cell line (Figure 4.11). This is similar to the results following AROS
silencing under basal conditions (Figure 4.6).
Silencing of SIRT1 stabilised p53 acetylation, compared to Mock siRNA in
drug treated HCT116 cells (Figure 4.11). In contrast, AROS siRNA treatment did
not alter the acetylation of p53 under these stress conditions. This is consistent with
the data from the earlier basal experiments where SIRT1, but not AROS, was seen to
suppress p53 acetylation. The data appear to contradict the role of AROS reported
under these stress conditions (Kim et al. 2007). However, this may be attributable to
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cell line specific effects. Thus analysis of the role of AROS in the ARPE19 cells was
undertaken.
Silencing of SIRT1 and AROS was efficient at both the mRNA and protein
levels in the ARPE19 cell line under these stress conditions (Figure 4.11 and Figure
4.12). p53 acetylation was increased by SIRT1 silencing compared to Mock
silencing. However, AROS silencing did not stabilise p53 acetylation. Interestingly,
this may be contrary to basal conditions where both SIRT1 and AROS may have
suppressed p53 acetylation (Figure 4.7B). This suggests that not only is the role of
AROS in p53 suppression different by cell line but also perhaps different according
to cell context – basal versus stress. This supports the hypothesis that ‘the regulation
of SIRT1 by AROS is complex’.
Interestingly AROS silencing in both the HCT116 and ARPE19 cell lines
appeared to result in a loss of SIRT1 protein (Figure 4.11). This was not seen under
any other condition analysed. This loss of SIRT1 might be expected to impact on
SIRT1 activity. However, as outlined above, AROS silencing did not alter p53
acetylation under these conditions. Furthermore, this suggests a role of AROS in
promoting the expression of SIRT1, not merely its activity. Again this is supportive
of a more complex AROS-SIRT1 relationship than originally outlined by Kim and
colleagues (2007).
4.6.2 Ultraviolet irradiation
Irradiation by ultraviolet light (UV) damages DNA, evoking the DNA
damage response which stabilises p53 protein expression. To this end, exposure to
UV was used as a second method of inducing cellular stress. This was carried out in
the HCT116 cell line to assess the effect on p53 acetylation. Protein level
knockdown of AROS and SIRT1 was also validated in the HCT116 p53-/-, important
for phenotype analyses in Chapter 5.
Application of UV stress appeared to increase the level of total and acetylated
p53 protein, consistent with the induction of a stress response (Figure 4.13Ai).
Silencing of both AROS and SIRT1 protein was seen in both the p53 wild-type and
null cell lines (Figure 4.13A). Interestingly, an apparent reduction in AROS
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expression was seen following SIRT1 silencing in both cell lines under these
conditions, which was not due to a significant loss of AROS mRNA in the HCT116
cell line this (Figure 4.13B). This represents another condition where SIRT1
appeared to modulate AROS expression.
Consistent with the known role of SIRT1, silencing of the deacetylase
stabilised total and acetylated p53 under these stress conditions (Figure 4.13Ai). In
contrast to the previous data following AROS silencing in the HCT116 line, in UV
treated cells total and acetylated p53 levels were stabilised following AROS RNAi.
This has parallels to the potential disparity between basal and etoposide / TSA
treated ARPE19 cells. Together these data indicate that the role of AROS in
suppression of p53 is context dependent. This provides more evidence supporting the
hypothesis that ‘the regulation of SIRT1 by AROS is complex’.
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Figure 4.11: The role of AROS under stress (I) – cytotoxic drugs
Protein abundance following combined RNAi and cytotoxic drug treatment.
RNAi was carried out as previously and etoposide (ETO) and trichostatin A
(TSA) administered for 6 hours directly prior to harvesting as indicated. Non-
drug treated controls are included for comparison. HCT116 cells were treated
with siRNA for 48 hours and ARPE19 cells for 72 hours.
Regulation of SIRT1 activity by LDH-A
144
20
40
60
80
100
120
140
0
20
40
60
80
100
120
140
m
R
N
A
ab
un
da
nc
e
(%
)
HCT116Cell line
***
***
***
ARPE19Cell line
m
R
N
A
ab
un
da
nc
e
(%
)
0
Mock AROS 1SIRT1siRNA Mock
+ 20µM ETO
+ 0.5µM TSA
for 6 hours
***
mRNA
AROS
SIRT1
Lamin AC
Figure 4.12: The role of AROS under stress (I) – cytotoxic drugs
mRNA quantification following total RNA isolation from cells transfected
and drug treated in parallel to those in Figure 4.11. Data standardised against
Mock transfected, drug treated cells. *** P<0.001.
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Figure 4.13: The role of AROS under stress (II) – UV radiation
(A) Target protein and p53 abundance following combined RNAi and
ultraviolet (UV) radiation treatment. UV radiation was administered at the
indicated dosage 24 hours prior to harvesting (see Methods). Total protein
samples was isolated by lysis of cells in protein lysis buffer and analysed by
equivalent protein mass. HCT116 cells were harvested 48 hours after siRNA
transfection (Ai) and HCT116 p53-/- cells 72 hours post-transfection (Aii). (B)
mRNA quantification by qRT-PCR following RNAi. HCT116 cells were
harvested for total RNA in parallel to protein samples shown in (Ai). Data
standardised against Mock transfected, UV irradiated cells. *** P<0.001.
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4.7 Discussion
4.7.1 Subcellular localisation of AROS
AROS has been reported as a nuclear protein, with expression in the
cytoplasm unspecified (Maeda et al. 2006; Kim et al. 2007). Here, subcellular
fractionation reveals a large proportion of AROS in the cytoplasm of the HCT116
cancer and ARPE19 non-cancer epithelial cells (Figure 4.6B and D). A smaller
fraction of AROS appears to be expressed in the nucleus of both cell lines. Online
tools allow the prediction of nuclear localisation sequences (NLSs) and nuclear
export signals (NESs) within the primary sequences of proteins (la Cour et al. 2004;
Brameier et al. 2007). Analysis of AROS protein reveals conserved NLS and NES
regions, which suggests that AROS can be imported and exported from the nucleus.
This appears to be consistent with expression of AROS in both the nucleus and the
cytoplasm.
The Western blotting data indicates that the dominant population of AROS is
the cytoplasmic fraction and provokes the question, why was it not observed
previously? AROS was previously visualised in the nucleus by immunofluorescence
(Maeda et al. 2006; Kim et al. 2007). This technique relies on a cumulative signal to
identify protein localisation within individual cells. This can be focused within
nuclei but dispersed across the cytoplasm. Here, subcellular fractionation does not
rely on local protein concentrations for visualisation, accumulating the total
expression of protein from multiple cells into the analysis. As such disperse
cytoplasmic protein may explain the cytoplasmic AROS reported here escaping
previous characterisation.
Another possibility is the difference in antibodies used to detect human
AROS between the studies. In this Chapter, a polyclonal antibody raised against the
full length of AROS was used for immuno-detection, whereas Kim and colleagues
used a monoclonal antibody raised against residues 25-33 of AROS (Kim et al.
2007). This presents the possibility that the epitope detected by the Kim et al
antibody is occluded in the cytoplasm, and thus AROS was not detected in this
fraction of human cells. Whereas in the nucleus the epitope is not occluded, allowing
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detection. In contrast, the polyclonal antibody used in this characterisation is able to
detect AROS regardless of localisation or occlusion of individual epitopes.
This observation also asks what significance does the cytoplasmic
localisation of AROS carry? SIRT1 is known to shuttle between the nucleus and the
cytoplasm, with expression of the protein reported in each compartment (Tanno et al.
2007). Localisation of AROS in both compartments suggests that AROS may be able
to modulate SIRT1 throughout the cell. AROS also interacts with the protein RPS19,
which is a structural component of the small ribosomal subunit (Maeda et al. 2006;
Ben-Shem et al. 2010; Rabl et al. 2011). Ribosomes are cytoplasmic
ribonucleoprotein complexes required for the synthesis of proteins. They are present
at high abundance in the cytoplasm and synthesised in the subnuclear structure the
nucleolus. Interestingly, AROS may localise to nucleoli, suggesting a role in
ribosome synthesis (Maeda et al. 2006; Kim et al. 2007). AROS is analysed in the
context of the ribosome in Chapter 8. This is partly based on the observation here
that populations of AROS appear to reside in the cytoplasm and the nucleolus.
4.7.2 AROS and p53 – a variable suppression
p53 acetylation is essential for its transactivation of pro-apoptotic genes
(Tang et al. 2008). SIRT1 constitutively deacetylates and suppresses p53 activity
(Luo et al. 2001; Vaziri et al. 2001; Ford et al. 2005). The original characterisation of
AROS described a role in activation of SIRT1, seen as suppression of p53
acetylation and function (Kim et al. 2007). AROS activated SIRT1 deacetylation of
p53 thus suppressing p53 acetylation in the HCT116 human cancer cell line.
However, these analyses applied stress in the form of the cytotoxic drugs etoposide
and TSA.
The cumulative data in this Chapter suggests that AROS does not always
suppress p53. This was apparent under physiological conditions in the HCT116 cells,
the cell line used in the original analysis by Kim et al (Figure 4.7A). Interestingly,
applying the same drug regime as Kim and colleagues in this system did not appear
to alter the role of AROS – AROS still did not suppress p53 (Figure 4.11). However
under an alternative stress treatment, UV irradiation, AROS was found to suppress
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p53 in HCT116 cells (Figure 4.13A). This suggests that within the same cell line
AROS has different effects on p53 according to context.
It must be noted that the silencing of AROS protein was most successful in
the UV irradiated cells, compared to the basal and etoposide / TSA treated cells.
However, an extent of knockdown was seen under all conditions, which would be
predicted to effect SIRT1 deacetylation of p53. Similar context variability in p53
suppression may occur for the ARPE19 cell line where knockdown of AROS was
comparable between contexts (Figure 4.7B and Figure 4.11). These data are
summarised in Table 4.1 and together suggest differentials in the role of AROS in
response to external stress stimulation of the cell. The observation is consistent with
the hypothesis that ‘the regulation of SIRT1 by AROS is complex’.
The effect of AROS and SIRT1 upon p53 acetylation was determined under
seven different conditions, either by cell line or context. In three of these conditions
the effect of AROS silencing correlated with that of SIRT1 silencing (Table 4.1).
However, in the other four conditions AROS appeared to have a different effect on
p53 acetylation than SIRT1 (Table 4.1). This took both possible forms; SIRT1
having an effect on p53 and AROS not (HCT116 – basal and etoposide / TSA,
ARPE19 – etoposide / TSA), or the inverse; AROS having an effect on p53 and
SIRT1 not (LoVo). The implication of this is that SIRT1 does not always require
AROS for deacetylation of p53. In the case of the LoVo cells, AROS may be able to
suppress p53 independent of SIRT1. This again agrees with the hypothesis of a more
complex relationship between AROS and SIRT1 than originally characterised.
The mechanism behind these discrete differences is unknown. It is likely that
between stress and basal conditions and between cell lines there are differences in
regulators of both AROS and SIRT1. For example, following stress many
endogenous kinases become activated, which may modify the functional interaction
between AROS and SIRT1. Similarly the expression of such regulators is likely to
differ between cell lines. It is important to consider the multitude of pathways likely
intersecting upon AROS and SIRT1, which will differ greatly between systems. This
suggests a dynamic AROS-SIRT1 relationship responding to both internal and
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external stimuli. This is far from the original characterisation of AROS as an obligate
activator of SIRT1.
Perhaps the most interesting evidence presented here as to the complexity of
the AROS-SIRT1 relationship is the effect of combinatorial silencing. Given the
identified role of AROS in SIRT1 activation, this could be expected to result in
additive suppression on p53 acetylation. However, under basal conditions in the
HCT116 cell line this did not appear to be the case (Figure 4.7C and D). Silencing of
AROS with SIRT1 appeared to negate the stabilisation of p53 acetylation seen with
SIRT1 silencing alone. This suggests that AROS actively opposes SIRT1
suppression of p53 acetylation in this context. How this may occur is unknown, but
the theory that AROS is a mere obligate activator of SIRT1 is significantly
diminished by this observation. This adds greatly to the hypothesis that ‘the
regulation of SIRT1 by AROS is complex’.
4.7.3 AROS and SIRT1
AROS and SIRT1 form a direct interaction (Kim et al. 2007; Autiero et al.
2009). This association has been verified in Chapter 7. The interaction was
previously reported to influence SIRT1 activity (Kim et al. 2007). Importantly, no
effect on the expression of either protein was reported following modulation of the
other. Here, in a subset of cell lines and under specific conditions the AROS and
SIRT1 interaction appears to extend to influence reciprocal protein abundance.
AROS appeared to promote SIRT1 protein abundance in the HCT116 and
ARPE19 cell lines following administration of etoposide and TSA (Figure 4.11).
This was the only condition analysed where AROS influenced SIRT1 protein
abundance. This decrease in SIRT1 expression did not correlate with a greater effect
on SIRT1 activity, assayed as p53 acetylation. Indeed, under these conditions AROS
silencing did not affect p53 in either cell line, despite the reduction in SIRT1
expression. Why AROS may promote SIRT1 expression under these conditions but
not others is unclear.
SIRT1 silencing appeared to influence AROS protein expression on various
occasions throughout the Chapter. These are summarised in Table 4.1 – Column 5.
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In four separate experiments silencing of SIRT1 reduced the protein abundance of
AROS. These could be correlated into two distinct groups. Firstly, SIRT1 appeared
to promote AROS expression in two cell lines originating from the mammary gland
epithelium (MCF7 - Figure 4.8A and MCF10A - Figure 4.9C). SIRT1 also appeared
to promote AROS expression in the two colorectal adenocarcinoma cell lines
(HCT116 and HCT116 p53-/-) treated with UV irradiation stress (Figure 4.13A).
Correlation to this cell origin and stress condition is striking. However, the reason
for this specific effect is unknown. It may relate to the complexity of the AROS-
SIRT1 interaction and unknown cell line and context specific effects.
The modulation of AROS expression by SIRT1 appears to occur both
positively and negatively. In the WI38 cell line silencing of SIRT1 appeared to
significantly increase the expression of AROS, suggesting that SIRT1 suppresses
AROS expression (Figure 4.9A). This is the only cell line analysed from a non-
epithelial origin, WI38 cells being fibroblastic. In later Chapters further functions of
AROS are uncovered where the data presented here will be discussed in the context
of SIRT1 influencing these new functions.
4.7.4 AROS protein stability
Reduction in AROS protein abundance following AROS siRNA treatment
varied between cell lines. In non-cancer cells (ARPE19, MCF10A and potentially
WI38) AROS silencing at the protein level appeared to be efficient (Figure 4.6C and
Figure 4.9). This was also the case for the MCF7 mammary gland epithelium cancer
cell line (Figure 4.8A) and the p53 null colorectal adenocarcinoma cell line, the
HCT116 p53-/- (Figure 4.10).
However, in 3 further colorectal adenocarcinoma cell lines with wild-type
p53 (HCT116 – Figure 4.6A, LoVo –Figure 4.8A) and mutant p53 (DLD1 –Figure
4.8C) AROS protein did not appear to be greatly reduced compared to Mock
treatment by AROS siRNA. In each case this was despite efficient reduction in
AROS mRNA. Furthermore, the stability of AROS did not correlate with the higher
expression of AROS in these cell lines over lines where AROS was efficiently
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silenced (Figure 4.4B). This implies that the AROS resistance to depletion by siRNA
is a post-transcriptional event. This is likely a result of increased protein stability.
Thus there appears to be heightened AROS protein stability in colorectal
adenocarcinoma cells, with the exception being the HCT116 p53-/- cell lines. This
has some important possible implications. Firstly, the increased level of AROS in
these cancer cell types may indicate an important function of AROS within these
cells. Whether this is an important function in colorectal adenocarcinoma cells, or
colorectal epithelial cells in general is unclear, as the expression of AROS in non-
cancerous colorectal epithelial cells was not carried out. If the case, increased
stability of AROS in colorectal adenocarcinoma cells may be useful biomarker.
AROS protein stability also appears to rely on the expression of p53 – wild-
type or mutant. This is based on the effective silencing of AROS protein observed in
the HCT116 p53-/- cell line (Figure 4.10B), compared to the otherwise isogenic
HCT116 cell line. As such, p53 may promote AROS stability and resistance to
siRNA mediated knockdown. In the context of using AROS as a biomarker, this may
also allow the status of the p53 gene to be inferred from the protein stability of
AROS.
The stability of AROS protein can be attributed to the cytoplasmic fraction of
the protein in HCT116 cells (Figure 4.6B), with this also a possibility for the other
colorectal adenocarcinoma cell lines. This allows speculation as to how the stability
is achieved. AROS is known to interact with the ribosomal protein RPS19 (Maeda et
al. 2006). A variety of proteins bind the ribosome in the cytoplasm. Thus, with
AROS expressed and stable in the cytoplasm it is possible that AROS interacts with
ribosomes via RPS19 and that this contributes to the stability of AROS protein. This
possibility is analysed and discussed further in Chapter 8.
Cell line Condition
HCT116 Basal
Eto+TSA
UV
HCT116
p53-/-
Basal
UV
DLD1 Basal
LoVo Basal
MCF7 Basal
ARPE19 Basal
Eto+TSA
MCF10A Basal
WI38 Basal
Table 4.1: Summary of data from AROS RNAi experiments
This Table collates the data presented in the
described in the text. ‘Basal’ refers to the application of RNAi as validated in the
Methods. ‘Eto+TSA’ represents etoposide and TSA tre
ultraviolet light irradiation. Stabilisation of p53 acetylation following AROS
knockdown is indicated by a ‘tick’ in Column 3. No effect is indicated by a ‘cross’.
Comparison of the effect of AROS (listed in Column 3) and SIRT1 is i
‘tick’ or ‘cross’ in Column 4. Dashes indicate no data available. Square brackets
indicate an inferred result from total p53 levels. The effect of SIRT1 on AROS
protein stability is shown in Column 5
‘~’ indicates no effect and a downward arrow indicates a negative effect.
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4.8 Conclusions
1. AROS is conserved among animalia and widely expressed in human cell
lines and tissues.
2. AROS is present in both the cytoplasm (a previously unreported population)
and the nucleus of two human cell lines.
3. AROS does not always suppress p53. This alters according to:
a. cell line,
b. and potentially cell context – basal compared to stress.
4. SIRT1 and AROS can modulate reciprocal protein abundance in a subset of
cell lines and conditions.
Together Conclusions 3 and 4 suggest that the AROS-SIRT1 relationship is
more complex than obligate activation. Thus, perhaps a more accurate description of
the relationship is: AROS and SIRT1 form a variable relationship, which appears to
be able to suppress p53, but this is dependent on cell line and condition.
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5 The influence of AROS on cell fate
5.1 Overview
In Chapter 4 the molecular effects of silencing AROS were compared to the
silencing of SIRT1 across a range of cancer and non-cancer cell lines. This was
carried out under both basal and stress conditions. The results highlighted differences
in the role of AROS compared to SIRT1, as well as differences in the role of AROS
between cell lines and context.
SIRT1 has been extensively studied as a cancer specific survival factor
(Chapter 1). Such a role for AROS has not been as extensively studied. In this
Chapter, the role of AROS in cell viability for both cancer and non-cancer cell lines
is outlined. This continues to highlight a dichotomy of function between AROS and
SIRT1 in the regulation of p53. However, a unified role is seen in the regulation of
FOXO4, which carries importance in the regulation of cancer cell apoptosis.
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5.2 Introduction
5.2.1 p53 tumour suppression
More than half of all cancerous growth correlates with mutation in the TP53
tumour suppressor gene, with misregulation of wild-type p53 protein believed to
contribute to the remaining tumours (Vogelstein et al. 2000; Olivier et al. 2010; Goh
et al. 2011). p53 expression is responsive to DNA damage, allowing it to react to
mutagenic events by attenuating cell proliferation or viability, earning p53 the
moniker of “guardian of the genome” (Lane 1992). Perturbation of p53 protein
function following mutation or misregulation constitutively removes this suppression
of proliferation and viability. p53 function can be suppressed to result in the same
outcome. This gives great power to the factors which control p53 activity.
p53 has a short half-life under basal conditions due to rapid turnover
mediated by poly-ubiquitin ligation. p53 is targeted for degradation by a variety of
ubiquitin ligases (reviewed in Lee and Gu 2010). The first and best characterised of
these is the MDM2 protein. MDM2 acts in a comparable manner to many of the
other ubiquitin ligases in regulating p53 turnover, which ultimately leads to p53
degradation.
MDM2 poly-ubiquitinylates lysine residues of p53, then remains bound in a
p53-MDM2 complex (Haupt et al. 1997; Kubbutat et al. 1997). This complex is
labelled for degradation, during which both p53 and MDM2 are degraded, due to
auto-ubiquitinylation of MDM2 (Fang et al. 2000; Honda and Yasuda 2000). The
p53-MDM2 complex is exported to the cytoplasm, negating p53 transcription factor
activity (Roth et al. 1998; Tao and Levine 1999), and is ultimately silenced by
proteasomal degradation (Honda et al. 1997). MDM2 also represses p53 by a
degradation independent mechanism by forming a complex at target gene promoters,
inhibiting p53 transactivation (Ohkubo et al. 2006; Tang et al. 2008). p53 promotes
MDM2 transcription, initiating a negative feedback loop that limits p53 activity
under basal conditions (Momand et al. 1992; Barak et al. 1993; Wu et al. 1993); p53
increases MDM2 expression, which in turn mediates the degradation of both parties.
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Negative feedback suppresses the inhibitory effects of p53 on proliferating
cells but permits the rapid activation of p53 when required. Activation of p53 is
achieved by increasing protein abundance, which is classically achieved by
disruption of the pathways leading to p53 degradation, such as the p53-MDM2
pathway. This can occur, for example, through post-translational modification,
competitive interaction or sequestration of MDM2. For example, MDM2 can be
modified by ATM, inhibited by RPL11 and sequestered by ARF (Weber et al. 1999;
Lohrum et al. 2000; Maya et al. 2001).
p53 protein is subject to considerable post-translational modification,
including reversible lysine acetylation (Brooks and Gu 2011). This modification of
p53 protein leads to stabilisation due to decreased MDM2-mediated degradation,
which in turn increases p53 transcription factor activity. The gene targets of p53
promote cell cycle arrest and apoptosis, resulting in reduced cell viability. This is the
mode of p53 tumour suppression, blocking individual cell viability where
appropriate for overall survival.
5.2.2 FOXO tumour suppression
The forkhead box O (FOXO) family of transcription factors are capable of
targeting a range of genes involved in cell cycle arrest and apoptosis (van der Vos
and Coffer 2011). The array of genes the FOXOs transactivate has similarities to
those regulated by p53, promoting cell cycle arrest and apoptosis. This highlights the
role of the FOXOs in tumour suppression. There are four human FOXO family
members, FOXO1, FOXO3, FOXO4 and FOXO6, which bind to consensus regions
as monomers to activate gene transcription.
FOXO proteins are regulated by post-translational modification. This again
has similarity to p53. The 14-3-3 proteins are the key regulators of the FOXOs,
acting similarly to MDM2 in the p53-MDM2 relationship. 14-3-3 proteins target
FOXOs for nuclear export in response to phosphorylation by proto-oncogenic
kinases, such as Akt (Brunet et al. 2002). Disruption of the FOXO-14-3-3 interaction
and subsequent gene activation can be achieved by modification of either protein.
For example, JNK-mediated phosphorylation of 14-3-3 reduces its association with
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FOXO3 (Sunayama et al. 2005). FOXO4 is also a target for JNK phosphorylation in
response to stress, resulting in dissociation from the 14-3-3 proteins and increased
gene transcription (Essers et al. 2004). All FOXO proteins are subject to acetylation
and deacetylation, the latter process being mediated by SIRT1 (reviewed in Calnan
and Brunet 2008). Removal of acetyl groups from the FOXO proteins reduces their
transactivation potential, giving SIRT1 a similar role in regulation of FOXO tumour
suppression to its role in p53 tumour suppression.
5.2.3 Deacetylation and cell fate
Reversible acetylation is a key regulatory mechanism for both p53 and the
FOXO proteins. p53 is acetylated by TIP60/MOF, PCAF and p300/CBP (reviewed
in Brooks and Gu 2011). Deacetylation and subsequent down-regulation of p53
involves either of two identified deacetylases, one of which is a complex containing
the class I deacetylase HDAC1 (Luo et al. 2000). Over-expression of components of
this complex reduces p53 acetylation and p53-dependent apoptosis. Secondly, SIRT1
deacetylates p53, reducing the apoptotic capacity of cells and favouring proliferation
(Luo et al. 2001; Vaziri et al. 2001). Deacetylation by SIRT1 contributes to a basal
constitutive cycle, such that removal of SIRT1 results in stabilisation of acetyl-lysine
p53, due to continued acetylation (Ford et al. 2005).
According to the ‘Tang Model’, acetylation of p53 is essential for
transactivation (Tang et al. 2008). Thus removal of acetyl groups from p53 by
HDAC1 and SIRT1 will suppress p53 function. Given the role of p53 in suppressing
cell proliferation, deacetylation of p53 promotes cell survival. Further to this,
ubiquitinylation can only target non-acetylated p53, indicating a correlation between
deacetylation activity and subsequent MDM2-mediated degradation of p53 (Li et al.
2002). Together, this predicts that suppression of deacetylation would promote p53
activity and potentially lead to cell cycle arrest or apoptosis.
Acetylation is also important for regulation of the FOXO proteins, reportedly
enhancing their role as tumour suppressors. This is based on observations following
suppression of deacetylation. SIRT1 deacetylates all FOXO proteins, suppressing
transcription of pro-apoptotic genes (Brunet et al. 2004; Motta et al. 2004; Calnan
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and Brunet 2008). With striking similarity to the regulation of p53, deacetylation of
FOXOs promotes cell survival. The BIM gene has a FOXO binding element in its
promoter and can be regulated by the FOXOs. BIM protein is expressed de novo
when required and promotes mitochondrial apoptosis by sequestering anti-apoptotic
members of the Bcl-2 family of proteins (reviewed by Gillings et al. 2009). BIM is a
pro-apoptotic target of the FOXOs, potentially important for tumour suppression.
Consistent with this, FOXO promotion at the BIM promoter leads to apoptosis
(Gilley et al. 2003). Interestingly, of the FOXOs analysed, FOXO4 acetylation has
been linked to BIM transactivation; BIM gene expression is diminished by
deacetylation of FOXO4 by SIRT1 (Motta et al. 2004).
AROS was proposed as an obligate activator of SIRT1 activity (Kim et al.
2007). As indicated in Chapter 4, this may not always be true for SIRT1 suppression
of p53. The role of AROS in suppression of FOXO4 has not been analysed. Given
the strong evidence for a direct interaction between AROS and SIRT1, any
suppression of the FOXOs by AROS is likely to occur via SIRT1. In the context of
cancer, FOXO4 is known to be essential for apoptosis following suppression of
SIRT1 (Ford et al. 2005). Analyses similar to those presented by Ford and colleagues
(2005) were carried out following AROS silencing for comparison of the role of
AROS to that of SIRT1.
5.2.4 AROS and cell fate
The role of AROS has been reported for human cancer cells (Kim et al.
2007). Importantly, cells from non-cancerous origin were not analysed. Knockdown
of AROS resulted in an increase in cell death following etoposide and trichostatin A
treatment in this study. This correlates with the role of SIRT1 in promoting cancer
cell survival (Ford et al. 2005), and was attributed to AROS promoting SIRT1
activity. Importantly, SIRT1 is known to suppress cancer cell apoptosis under basal
conditions. The role of AROS under these conditions is not known. Furthermore,
SIRT1 is not required for non-cancer cell survival under these basal conditions.
AROS has not been studied in non-cancer cells, presenting the possibility that
AROS, like SIRT1, is a specific cancer cell survival factor.
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The data here represent the phenotypic characterisation following RNAi
against AROS and SIRT1 as validated in Chapter 4. Details of the silencing of each
target in the cell lines analysed are given in Chapter 4. Interestingly, the data
suggested that silencing of AROS had different molecular effects to the silencing of
SIRT1. This led to the conclusion that the AROS-SIRT1 relationship is more
complex than obligate activation. Whether this manifests as differences in the effect
on cell phenotype will be addressed in this Chapter.
5.2.5 Hypotheses
1. AROS is required for cancer cell survival under physiological and stress
conditions.
2. AROS is not required for non-cancer cell survival.
3. AROS and SIRT1 have different effects on cell phenotype, consistent with
different molecular effects.
4. AROS is required for SIRT1 suppression of FOXO4.
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5.3 Characterisation of cell phenotype following AROS silencing
5.3.1 Cancer cell lines - apoptosis
Lamin AC was targeted as a positive control gene which can be successfully
knocked down without altering cell fate. The data here are consistent with this.
Lamin AC silencing did not appear to alter the phenotypes of the HCT116, HCT116
p53-/- or MCF7 cancer cell lines compared to Mock transfection (Figure 5.1).
Consistent with these micrographs, Lamin AC siRNA did not cause a significant
induction of apoptosis in any of these three cell lines (Figure 5.2A).
In the DLD1 cell line Lamin AC silencing was carried out as described in
Chapter 3, revealing no alteration in phenotype following knockdown (Figure 3.6B).
The targeting of Lamin AC in the LoVo colorectal adenocarcinoma cell line caused
an alteration in cell phenotype compared to control (Figure 5.1). The cells were
aggregated and refringent under phase contrast microscopy. This cell line is able to
grow both adhered and free in the media (Drewinko et al. 1976), and the observed
phenotype may represent a shift from adherent growth towards growth in the media.
In support of this, the apoptotic phenotype of LoVo cells (and all cell lines used in
this study) appeared to be individual refringent cells. This is based on the increase in
the number of these cells following silencing of SIRT1 (Figure 5.1), which is known
to be anti-apoptotic in cancer cells (Ford et al. 2005).
SIRT1 siRNA also induced an increase in unadhered, refringent cells in the
HCT116, HCT116 p53-/-, MCF7 and DLD1 cell lines (Figure 5.1). This phenotype is
consistent with an induction of apoptosis. An induction of apoptosis was confirmed
in the HCT116, HCT116 p53-/- and MCF7 cell lines by Annexin V staining and
FACS analysis (Figure 5.2A). Thus, in five cancer cell lines SIRT1 silencing
resulted in a phenotype consistent with apoptosis, which was confirmed by flow
cytometry in three of those cell lines. This agrees with the published role of SIRT1
in promoting tumour cell viability (see Chapter 1).
AROS was analysed in parallel to SIRT1 under these basal conditions,
allowing comparison of silencing. Differences between the molecular roles of AROS
and SIRT1 detailed in Chapter 4 suggested that the phenotypes following silencing
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may also differ. However, this was not the case. An increase in individual refringent
cells was apparent following silencing of AROS in the HCT116, HCT116 p53-/-,
MCF7, DLD1 and LoVo lines (Figure 5.1).
In the HCT116 cancer cell line, two independent siRNAs against AROS
appeared to induce the same apoptotic phenotype (Figure 5.1). Significant induction
of apoptosis following use of AROS siRNA 1 was recorded in the HCT116,
HCT116 p53-/- and MCF7 cell lines after 48 hours (Figure 5.2A). Both AROS
siRNA 1 and 2 resulted in a significant fold increase in apoptosis compared to Mock
in the HCT116 cell line after 72 hours (Figure 5.2B). Interestingly, the fold induction
of apoptosis was almost identical when comparing SIRT1 siRNA and AROS siRNA
1 treated cells in all cases. The fold induction of apoptosis with AROS siRNA 2 was
lower, perhaps related to the less effective knockdown achieved with this siRNA
(Chapter 4).
These data suggest that AROS is required for cancer cell survival. This
appears to be independent of p53 status, as apoptosis was induced in the p53 null
HCT116 p53-/- cell line following AROS silencing. SIRT1 acts independently of p53
to suppress apoptosis, promoting viability of p53 null cancer cells (This work and
Ford et al. 2005). Interestingly, AROS and SIRT1 had different molecular effects on
p53 under basal conditions, characterised in Chapter 4. SIRT1 suppressed p53
acetylation, but this did not appear to be required for suppression of apoptosis.
AROS did not appear to suppress p53 acetylation under these conditions, which is
consistent with independence from p53 in suppression of apoptosis.
The absolute induction of apoptosis differed between p53 wild-type and p53
null cells, which were otherwise isogenic (Figure 5.2A). This may suggest that p53
is important in AROS suppressed apoptosis. However, this phenomenon may be
attributable to apoptosis occurring over a longer period in the HCT116 p53-/- cell line
than in HCT116 cells, as discussed in Chapter 3.
5.3.2 Cancer cell lines - cell cycle
Silencing of SIRT1 appeared to reduce the adhered cell density compared to
Mock in each of the cancer cell lines (Figure 5.1). In contrast, AROS silencing did
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not appear to reduce the adhered cell density to such an extent, despite an increase in
refringent unadhered cells. This suggests that SIRT1 and AROS have different
effects on cell cycle progression, which manifested here as differences in cell
density.
Cell cycle distribution analysis appeared to agree with the phenotypes. In the
HCT116 cell line, SIRT1 silencing resulted in a reduction in the population of cells
in S phase (Figure 5.3A). A reduced S phase population is likely to affect the cell
cycle progression of these cells. AROS silencing appeared to have no effect
compared to control in the HCT116 cell line, suggesting a difference between AROS
silencing and SIRT1 silencing. AROS silencing had a slight effect in the HCT116
p53-/- cell line, with an increase in the G2/M and S phase populations and
concomitant reduction in the G1 population (Figure 5.3B). These differences are
slight and not inconsistent with the maintenance of cell density in
Figure 5.1. In contrast, following SIRT1 silencing there was a decrease in
cells in G1 and a large increase in G2/M cells. This resulted in a decrease in the S
phase population, which is likely to impinge on cell cycle progression.
These differences in cell cycle distribution may correlate with differences in
the molecular effect of silencing AROS and SIRT1. SIRT1 silencing induced an
increase in p53 acetylation in the HCT116 cell line, whereas silencing of AROS did
not (Chapter 4). Here, SIRT1 silencing caused apoptosis and cell cycle arrest in the
HCT116 cell line, whereas AROS siRNA only induced apoptosis (Figure 5.2A and
Figure 5.3A).
p53 is known to promote both apoptosis and cell cycle arrest following
acetylation (Tang et al. 2008). The data here correlate with stabilised p53 acetylation
resulting in cell cycle arrest following SIRT1 silencing, and no arrest following
AROS silencing due to no stabilisation of p53 acetylation. This is an attractive
theory to correlate phenotype to molecular alterations. However, there is likely to be
multiple factors involved in correlating molecular alterations to phenotype. This is
suggested by the HCT116 p53-/- cell line, where SIRT1 silencing induces cell cycle
arrest, in the absence of p53. Despite this, the arrest phenotypes are different
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between the HCT116 and HCT116 p53-/- cell lines and the influence of other factors
cannot be ruled out. As such, the data are consistent with a potential phenotypic
manifestation of the AROS-SIRT1 relationship being more complex than obligate
activation.
The analysis of AROS in five cancer cell lines suggests that it is required for
evasion of apoptosis, but is perhaps redundant for promoting cell cycle progression.
These data agree with the hypothesis that ‘AROS is required for cancer cell survival
under physiological conditions’. Interestingly, the role of AROS on the fate of non-
cancer cell lines has not been analysed. Redundancy for viability in non-cancer cell
lines would present AROS as a potential anti-cancer therapeutic target.
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Figure 5.1: Cancer cell phenotype following siRNA transfection
Phase contrast micrographs of cancer cell lines following transfection of siRNA as
indicated. Cells were treated with siRNA and phenotype recorded at the time point
shown. AROS siRNA refers to siRNA 1, apart from transfection of siRNA 2 in the
HCT116 cell line.
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Figure 5.2: Silencing of
AROS or SIRT1 induces
cancer cell apoptosis
(A) Fold apoptosis compared
to Mock treated cells
following RNAi as indicated
in three cancer cell lines. Cells
were treated with siRNA for
48 hours (HCT116, MCF7) or
72 hours (HCT116 p53-/-) post-
transfection and analysed by
Annexin V staining and flow
cytometry (See Methods). (B)
Data as in (A) for the HCT116
cell line, treated with siRNA
72 hours prior to harvesting.
*** P<0.001, ** P<0.01.
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Figure 5.3: AROS and SIRT1 affect cell cycle differently
(A) Cell cycle distribution according to propidium iodide intercalation and
flow cytometry, presented as a percentage of cells for each condition (see
Methods). HCT116 cells were treated with siRNA as indicated and harvested
48 hours later. (B) Data presented as in (A) for the HCT116 p53-/- cell line
harvested 72 hours post-transfection. (C) Data presented as in (A) for the
ARPE19 cell line harvested 72 hours post-transfection.
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5.3.3 Non-cancer cell lines
Knockdown of AROS in three cell lines of non-cancerous origin did not
greatly alter cell phenotype compared to Mock or Lamin AC siRNA treated cells
(Figure 5.4). Silencing of AROS in the ARPE19 retinal epithelial cell line resulted in
a slight change in morphology, with cells appearing more rounded than Mock
transfected cells and resembling Lamin AC siRNA treated more than Mock treated
cells. Silencing of SIRT1 in this cell line causes a distinct morphological change,
with the cells becoming refringent and elongated. This has been attributed to
differentiation of the ARPE19 cells into neuronal cells and has been an independent
parallel project within the laboratory. AROS siRNA 2 also had little effect on the
phenotype of the ARPE19 cells (Figure 5.4). This difference is consistent with the
hypothesis that ‘AROS and SIRT1 have different effects on cell phenotype’.
These phenotypes are not indicative of apoptosis in the ARPE19 cell line.
This was confirmed in Figure 5.5B, where knockdown of Lamin AC, SIRT1 or
AROS did not result in a significant induction of apoptosis under basal conditions.
Silencing of AROS or SIRT1 also had little effect on cell cycle distribution (Figure
5.3C). Slight variation in the fraction of cells in G2/M or G1 occurred, but the
number of cells in S phase was comparable between conditions. This suggests that
non-cancer cell cycle progression was not affected by silencing of AROS or SIRT1.
The phenotype of the WI38 lung fibroblast cell line was unaltered from Mock
by Lamin AC, SIRT1 or AROS siRNA. Similarly, silencing of all three targets in the
MCF10A mammary gland epithelium cell line had little effect on phenotype. This is
consistent with Lamin AC, SIRT1 and AROS not being essential for either WI38 or
MCF10A viability. Consistent with this, silencing of SIRT1 and AROS in both cell
lines did not induce an increase of apoptosis compared to Mock (Figure 5.5).
Together the phenotypes of these three non-cancer cell lines suggest that
‘AROS is not required for non-cancer cell survival’. SIRT1 is a cancer specific
survival factor (Ford et al. 2005), and the data for AROS are highly correlative with
this function of SIRT1. The data also indicate that AROS may be an effective anti-
cancer therapeutic target under these basal conditions.
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Figure 5.4: AROS has little effect on non-cancer cell phenotype
Phase contrast micrographs of non-cancer cell lines following transfection of
siRNA as indicated. Cells were treated with siRNA and phenotype recorded at
72 hours post-transfection. AROS siRNA refers to siRNA 1, apart from
transfection of siRNA 2 in the ARPE19 cell line.
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Figure 5.5: AROS silencing does not induce non-cancer cell
apoptosis
Fold apoptosis compared to Mock treated cells following RNAi as indicated
in three non-cancer cell lines. Cells were treated with siRNA 72 hours prior to
harvesting and analysis by Annexin V staining and flow cytometry (See
Methods).
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5.4 Cell fate following applied stress
5.4.1 Etoposide and trichostatin A
As discussed in Chapter 4, application of etoposide and trichostatin A (TSA)
results in cell stress, indicated by an increase in p53 protein abundance. This drug
treatment was used during the original characterisation of AROS, where knockdown
was seen to stabilise p53 acetylation and induce cancer cell death (Kim et al. 2007).
However, as shown in Chapter 4, silencing of AROS in combination with etoposide
and TSA did not induce stabilisation of p53 acetylation. This was performed in two
separate cell lines – the HCT116 colorectal adenocarcinoma line and the ARPE19
retinal epithelium line, of non-cancerous origin. The effect of silencing and drug
treatment on cell phenotype is more consistent with the original report and a role for
AROS in specific cancer cell survival.
Etoposide and TSA stress in the HCT116 cell line appeared to increase the
number of apoptotic cells compared to non-drug treated cells (Figure 5.6A).
Consistent with this a slight increase in apoptosis was seen following application of
etoposide and TSA (Figure 5.6B). Silencing of SIRT1 or AROS combined with drug
treatment appeared to give an even greater increase in apoptosis seen by phase
contrast microscopy (Figure 5.6A). This was confirmed as increased apoptosis by
flow cytometry (Figure 5.6B). As previously seen in cancer cells under basal
conditions, the values for the fold induction of apoptosis are almost identical for
SIRT1 and AROS silencing.
Etoposide and TSA treatment of the non-cancer ARPE19 cell line did not
appear to alter the phenotype of the cells (Figure 5.6A). This is consistent with no
increase in apoptosis following the drug treatment (Figure 5.6B). Silencing of AROS
combined with etoposide and TSA treatment did not result in an altered phenotype or
induction of apoptosis compared to Mock siRNA and drug treated cells. In contrast,
SIRT1 silencing resulted in an increase in detached refringent cells and an alteration
in adhered morphology (Figure 5.6A). This alteration is similar to morphology under
basal conditions, which represents a neuronal differentiation. However, despite an
increase in apoptotic cells, this was not significant compared to Mock siRNA and
drug treated cells (Figure 5.6B).
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5.4.2 Ultraviolet irradiation
Ultraviolet (UV) irradiation was used as an alternative means to induce cell
stress, and analyse molecular effects, as described in Chapter 4. Under these
conditions, AROS appeared to suppress p53 acetylation. This was consistent with
AROS promoting the activity of SIRT1, which was seen to suppress p53 acetylation
in parallel. Silencing was efficiently carried out in the HCT116 and HCT116 p53-/-
cell lines. The phenotype of silencing both AROS and SIRT1 was predicted to be
similar, given the similarities in molecular alterations.
UV irradiation of Mock treated HCT116 cells produced an increase in
apoptotic cells with a concomitant reduction in the adhered cell population compared
to non-irradiated cells (Figure 5.8A). Apoptosis was confirmed by Annexin V
staining and FACS analysis (Figure 5.8B). Silencing of both SIRT1 and AROS
resulted in a comparable phenotype by phase contrast microscopy (Figure 5.8A);
HCT116 cells appeared at a lower density than Mock irradiated cells, with the
majority of cells apparently unadhered and refringent. This suggests an induction of
apoptosis, as well as alterations in the cell cycle following silencing of each target. A
significant induction of apoptosis was seen compared to Mock irradiated cells, with
both SIRT1 and AROS silencing achieving a greater than 7-fold induction (Figure
5.8B). Again consistent with the phenotype, silencing of AROS or SIRT1 altered cell
cycle distribution (Figure 5.8C). An increase in G1 cells and reduction in G2/M cells
was observed following silencing of AROS or SIRT1. The population of cells in S
phase appeared similar to Mock treated, UV irradiated cells. Interestingly, the
alteration in cell cycle distribution was almost identical between AROS and SIRT1
siRNA treated cells.
The data here suggest that in the HCT116 cell line following UV irradiation,
silencing of SIRT1 or AROS has highly similar effects on cell phenotype, apoptotic
induction and cell cycle distribution. This is in contrast to the seemingly different
roles of SIRT1 and AROS under basal conditions and following etoposide / TSA
treatment (see above). The previous differences in cell phenotype correlate with
differences in suppression of p53 – SIRT1 did suppress p53, whereas AROS did not.
Following UV irradiation here, both SIRT1 and AROS did appear to suppress p53
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acetylation (Chapter 4). Interestingly, this correlation in molecular function also
correlates with phenotype. Silencing of SIRT1 or AROS only appeared to alter cell
cycle distribution under conditions where p53 acetylation was stabilised. This
suggests that p53 is important for cell cycle distribution following silencing of
AROS or SIRT1.
To further analyse this, silencing was carried out in the HCT116 p53-/- cell
line following UV irradiation. Should p53 play an important role in cell cycle
distribution following AROS or SIRT1 silencing, this cell line would not be
expected to experience such alterations. Following AROS silencing and UV
irradiation in the HCT116 p53-/- cell line, cell cycle distribution appears almost
identical to the distribution for Mock siRNA and UV irradiated cells (Figure 5.9C).
There is perhaps a slight reduction in the S phase population, but this may not be
significant. In contrast, silencing of SIRT1 induces a reduction in the S phase
population, due to a large increase in cells in the G2/M phase (Figure 5.9C). These
data for SIRT1 silencing following UV stress are comparable to the effect recorded
under basal conditions (Figure 5.3B).
Together, the cell cycle analyses following AROS silencing reveal a potential
correlation between molecular effects and cellular outcome. AROS appeared to only
suppress p53 acetylation following the application of UV irradiation, and this
correlated with the only incidence of alterations in cell cycle distribution following
AROS silencing. As such, AROS appears to be required for stabilisation of p53
acetylation in response to UV stress, and associated suppression of alterations in the
cell cycle. Consistent with this, cell cycle distribution was not altered in the HCT116
p53-/- cell line, even with the application of UV irradiation. This is highly indicative
that the cell cycle arrest induced by AROS is dependent upon p53. The reliance upon
UV irradiation to allow AROS to influence p53 acetylation and cell cycle
distribution is indicative of an unknown factor altering the relationship between
AROS, SIRT1 and p53. This could be one of the factors themselves and/or an
external contributor, potentially activated by the UV irradiation process.
This section demonstrates a divergence from the heterogeneity between
SIRT1 and AROS function, with only subtle differences seen following UV
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irradiation. Interestingly, these differences seem to involve p53 regulation and
potentially subsequent function in controlling cell cycle progression. The data here
conclude the analysis of p53 regulation by SIRT1 and AROS. For the remainder of
the Chapter the regulation of the FOXO proteins is the focus.
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+ 0.5µM TSA
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Mock Mock AROSSIRT1
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Figure 5.6: The role of AROS in cell viability after stress -
etoposide and TSA (I)
Phase contrast micrographs of HCT116 and ARPE19 cells following
transfection with siRNA for the indicated time and administration of
etoposide (ETO) and trichostatin A (TSA) as shown. Non-drug treated cells
are included as a control.
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Figure 5.7: The role of AROS in cell viability after stress -
etoposide and TSA (II)
Values represent fold apoptosis following siRNA transfection compared to
Mock transfected, non-drug treated cells in the cell lines from Figure 5.6.
Cells were treated with siRNA as indicated and analysed by Annexin V
staining and flow cytometry (See Methods). ** P<0.01.
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Figure 5.8: The role of AROS in cell viability after stress - UV
irradiation
(A) Micrographs from phase contrast microscopy of HCT116 colorectal
adenocarcinoma cells following transfection and UV irradiation as indicated.
Cells were transfected with siRNA 48 hours prior to harvesting, and irradiated
with UV 24 hours prior to harvesting. (B) Apoptosis quantified by Annexin V
staining and flow cytometry, represented as fold change compared to non-
irradiated Mock in the HCT116 cells treated as in (A). ** P<0.01. (C) Cell
cycle distribution as a percentage of total cells analysed following transfection
and UV irradiation as detailed in (A). Cell cycle stages were determined by
propidium iodide intercalation and flow cytometry (see Methods).
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Figure 5.9 The role of AROS in cell viability after stress - UV
irradiation without p53
(A) Phase contrast micrographs of HCT116 p53-/- cell phenotype 72 hours
following siRNA transfection, and 24 hours following UV irradiation as
indicated. (B) Apoptotic cell death following treatment as in (A) quantified by
Annexin V staining and flow cytometry. Data represent fold change compared
to Mock siRNA treated non-irradiated cells. ** P<0.01. (C) Percentage of total
cells within each stage of the cell cycle, determined by flow cytometry of
propidium iodide intercalation (see Methods). Cells were treated with siRNA
and UV irradiation as in (A).
The influence of AROS on cell fate
179
5.5 Suppression of FOXO4 by AROS
5.5.1 FOXO4 promotes apoptosis downstream of AROS
AROS has been characterised as a p53 independent suppressor of apoptosis
(see above). This has parallels with the published role of SIRT1 and prompted
further analysis of potential continuing parallels (Ford et al. 2005). SIRT1
deacetylates and suppresses the pro-apoptotic function of the FOXO proteins (Brunet
et al. 2004; Motta et al. 2004). Importantly the basal anti-apoptotic function of
SIRT1 is specifically dependent upon FOXO4 expression; cosilencing of SIRT1 and
FOXO4 resulted in complete rescue of apoptosis induced by SIRT1 silencing alone
(Ford et al. 2005). Interestingly, cosilencing of SIRT1 and FOXO3 did not rescue the
apoptotic phenotype. With this considered, cosilencing of AROS was carried out
with both FOXO4 and FOXO3. Individual silencing of each FOXO protein was also
undertaken to analyse the basal roles of these tumour suppressors.
Silencing of AROS in the HCT116 colorectal adenocarcinoma cell line
resulted in a phenotype consistent with previous experiments and the induction of
apoptosis, confirmed by flow cytometry (Figure 5.10A and B). Cosilencing of
AROS with FOXO4 resulted in a phenotype comparable to Mock transfected cells,
more cells were adhered and fewer were refringent than with AROS silencing alone
(Figure 5.10A). This suggests that FOXO4 silencing rescues apoptosis suppressed by
AROS. In agreement with this, flow cytometric analysis of AROS and FOXO4
cosilencing resulted in a significant reduction in apoptosis compared to AROS
silencing alone. The level of apoptosis was similar to that following Mock
transfection. This correlates with the role of SIRT1 in regulation of FOXO4 and
supports the hypothesis that ‘AROS is required for SIRT1 suppression of FOXO4’.
As mentioned, SIRT1 does not suppress apoptosis via FOXO3 (Ford et al.
2005). Cosilencing of AROS and FOXO3 parallels this result, with no alteration in
the fold increase in apoptosis compared to AROS silencing alone (Figure 5.10).
Thus, AROS suppresses apoptosis via FOXO4, but independently of FOXO3.
Silencing of FOXO4 and FOXO3 individually resulted in a modest increase in
apoptotic HCT116 cells, but this did not constitute a significant induction of
apoptosis (Figure 5.10).
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Cancer associated SIRT1 suppression of FOXO4 occurs in both the presence
and absence of p53 (Ford et al. 2005). This is consistent with SIRT1 suppressing
apoptosis independently of p53 expression. FOXO4 appears to be a highly important
tumour suppressor for suppression by SIRT1. Silencing of AROS alongside
cosilencing of AROS with both FOXO4 and FOXO3 in the HCT116 p53-/- cell line
resulted in similar phenotypes and apoptotic induction compared to the HCT116 cell
line (Figure 5.11). The extent of rescue with FOXO4 cosilencing appears to be
reduced but is significant, supporting a p53 independent role for AROS in
suppression of FOXO4. , This correlation is consistent with the hypothesis that
‘AROS is required for SIRT1 suppression of FOXO4’.
Silencing of AROS and FOXO4 was verified at the mRNA level by qRT-PCR
for both HCT116 and HCT116 p53-/- cells (Figure 5.12A). Silencing was achieved
individually as well as by cosilencing of each target. Protein level silencing of
AROS was previously verified on multiple occasions (Chapter 4). Protein silencing
of FOXO4 was not verified due to the lack of a reliable antibody for this purpose.
However, the reduction in FOXO4 mRNA and the strong phenotypic effect of
cosilencing with AROS are highly suggestive of a reduction in the functional
FOXO4 protein.
5.5.2 AROS and SIRT1 suppress FOXO4 target gene transactivation
The pro-apoptotic Bcl-2 family protein BIM is a target for genetic
transactivation by the FOXO proteins (Gilley et al. 2003). Furthermore, reduced
SIRT1 activity has been linked to FOXO4 dependent induction of BIM transcription
(Motta et al. 2004). Consistent with this, silencing of SIRT1 in HCT116 cells
resulted in a significant increase in BIM-L mRNA compared to Mock treated cells
(Figure 5.12B). BIM-L is one of three specific splice variants derived from the BIM
gene, which is able to induce apoptosis upon overexpression (O'Connor et al. 1998).
Upregulation of BIM-L following SIRT1 silencing suggests increased transactivation
by FOXO4.
Given the similarities between SIRT1 and AROS in their suppression of the
pro-apoptotic activity of FOXO4, the effect of AROS silencing on BIM-L mRNA
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was also analysed. Silencing of AROS also induced a significant increase in BIM-L
mRNA expression compared to control, with levels of induction almost identical to
those for SIRT1 silencing (Figure 5.12B). This suggests that AROS is required for
SIRT1 suppression of FOXO4 mediated apoptosis, which is at least in part promoted
by BIM-L.
To test this further, the level of BIM-L mRNA following cosilencing of
FOXO4 with either SIRT1 or AROS would be required. This would indicate whether
FOXO4 is the key intermediary in the regulation of BIM-L by SIRT1 and AROS. It
would also be possible to co-silence AROS or SIRT1 with BIM-L in HCT116 cancer
cells. This would demonstrate if BIM-L is a crucial pro-apoptotic gene suppressed by
SIRT1 and AROS. Unfortunately, in this analysis only single silencing was analysed
due to time constraints, but these experiments represent possibilities for the future.
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Figure 5.10: FOXO4 expression is required for AROS silencing
induced apoptosis
(A) Micrographs from phase contrast microscopy of HCT116 cells treated
with basal siRNA transfection as indicated. Cells were exposed to siRNA for
48 hours prior to recording of images. (B) Apoptotic induction following
siRNA treatments detailed in (A). Data are shown as relative to apoptosis
following Mock transfection. Separate graphs indicate separate cell
experiments. *** P<0.001.
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Figure 5.11: FOXO4 expression is required for AROS silencing
induced apoptosis, independently of p53
(A) Phase contrast micrographs of HCT116 p53-/- cells 72 hours after basal
siRNA treatment targeted against specific mRNA. (B) Fold change in
apoptosis following basal siRNA transfections as indicated. Cells were
harvested for Annexin V staining and flow cytometry analysis 72 hours post-
transfection.
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(A) Total RNA was harvested 48
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(HCT116 p53-/-) following basal
siRNA transfection as indicated.
RNA was isolated by the RNeasy
method and analysed by qRT-PCR
using specific primers for target
mRNAs. Actin mRNA was used
as a loading control. (B) HCT116
cells were treated and total RNA
isolated as indicated in (A). BIM-
L mRNA was quantified by qRT-
PCR, standardised against Actin
mRNA expression. Separate
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experiments. ** P<0.01, * P<0.05.
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5.6 Discussion
5.6.1 AROS and apoptosis
AROS anti-apoptotic activity was reported during its original characterisation
(Kim et al. 2007); this was under cellular stress caused by etoposide and TSA in two
cancer cell lines (HCT116, H1299). This has been expanded here with the
observation that AROS is anti-apoptotic in a larger panel of cancer cell lines of both
wild-type and null p53 status. AROS appeared to be required for apoptotic evasion
in all the cancer cell lines analysed, consistent with the hypothesis that ‘AROS is
required for cancer cell survival under physiological and stress conditions’.
Independence from p53 is desirable for putative anti-cancer therapeutic
targets due to the high mutation and misregulation rate of p53 in human tumours
(Vogelstein et al. 2000; Olivier et al. 2010; Goh et al. 2011). AROS appears to be
essential for suppression of basal apoptotic pathways that do not require p53. Thus,
targeting of AROS may activate these pathways and induce cancer cell death
irrespective of p53 status.
This role of AROS is similar to the reported role of SIRT1 (Ford et al. 2005),
which has also been confirmed here. In Chapter 4 the complete knockdown of
AROS was not achieved – a population of AROS persisted in the cytoplasm of
HCT116 cells after AROS siRNA treatment. Importantly, this level of knockdown
induced apoptosis as recorded here. The molecular data in Chapter 4 also indicated
that AROS did not affect p53 in the HCT116 cell line. This is consistent with the p53
independence in apoptotic induction reported in this Chapter.
Strikingly, the fold induction of apoptosis in all cancer cell lines analysed
under all conditions is almost identical for both SIRT1 and AROS silencing (this
Chapter). The values for the fold induction of apoptosis are listed in the Appendix.
The data are suggestive of a highly similar role in the suppression of apoptosis for
both proteins. Furthermore, the similarities between SIRT1 and AROS extend to
their downstream effects. Both SIRT1 and AROS suppress FOXO4 pro-apoptotic
activity, evinced by requirement for FOXO4 for apoptosis in the absence of SIRT1
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or AROS (Ford et al. 2005 and Figures 8 and 9). This is summarised in Figure 5.13A
and B.
The correlation between silencing of AROS and SIRT1 appears to extend
further downstream of FOXO4. Both AROS and SIRT1 silencing induce expression
of BIM-L mRNA, a pro-apoptotic target of FOXO4, which is consistent with both
AROS and SIRT1 suppressing FOXO4 function, with AROS and SIRT1 likely
acting in complex as proposed by Kim and colleagues (2007). This is consistent with
the hypothesis that ‘AROS is required for SIRT1 suppression of FOXO4’. These
observations represent the first characterisation of regulation of FOXO4 by AROS,
and the first characterisation of the effect of AROS on multiple SIRT1 targets – both
p53 and FOXO4.
Dependence upon FOXO4 and BIM as pro-apoptotic effectors following
targeting prompts the analysis of gene expression in cancer cells. For effective anti-
cancer therapeutic targeting of AROS or SIRT1, the FOXO4 or BIM genes may need
to be intact. Mutation of either gene would be detrimental for the application of
therapeutics against either AROS or SIRT1. Interestingly the mutation rate of the
FOXO proteins in primary glioblastomas reported by The Cancer Genome Atlas
Research Network (2008) was 1% . Furthermore, no mutations were reported in the
BIM gene. This indicates that FOXO4 or BIM mutation may be rare in cancer, and is
promising for the targeting of AROS or SIRT1 for anti-cancer therapeutic gain.
5.6.2 AROS and the cell cycle
AROS appeared to affect the cell cycle distribution of HCT116 colorectal
adenocarcinoma cells only following UV irradiation and in the presence of p53,
which is strong evidence that AROS can suppress p53 activity under certain
conditions, and that this has a functional significance. This correlates well with the
molecular effects seen in Chapter 4, with AROS only affecting cell cycle
distribution in the single case where it suppressed p53 acetylation in the HCT116
cells.
SIRT1 appeared to regulate the cell cycle under all conditions, in the
presence or absence of p53. The observed cases of p53 independence suggest that
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SIRT1 is able to influence cell cycle distribution via mechanisms not involving p53.
This contrasts to the proposed role for AROS, which strictly requires p53 and is
consistent with the hypothesis that ‘AROS and SIRT1 have different effects on cell
phenotype, consistent with different molecular effects’. These differences are
summarised in Figure 5.13A and B. A further implication of the data is that SIRT1 is
able to suppress p53, and other targets, without the need for AROS as an activator
protein under certain conditions.
5.6.3 AROS as an anti-cancer therapeutic target
AROS is required for survival of multiple cancer cell lines under all conditions
analysed. Importantly, AROS does not appear to be required for non-cancer cell
survival, based on data presented for 3 non-cancer cell lines (Figure 5.4). These cell
lines are from multiple origins: the pigmented retinal epithelium (ARPE10), the
mammary gland epithelium (MCF10A) and lung fibroblasts (WI38). Further to this,
AROS does not appear to regulate the ARPE19 cell cycle, with only slight
alterations in cell cycle distribution seen following silencing (Figure 5.3C).
Redundancy for AROS following transient knockdown in relation to survival in
these cell lines agrees with the hypothesis that ‘AROS is not required for non-cancer
cell survival’, and presents AROS as a cancer-specific survival factor.
The data also suggest that the AROS-SIRT1 interaction is important for
regulation of cell survival, mediated via FOXO4 and BIM-L. The opportunity to
target this pathway appears feasible. Whether AROS or SIRT1 suppress this
pathway in non-cancer cells has not been assessed; however, if suppression does
occur it is clear that this is not important in the context of cell viability. Furthermore,
the indication that both AROS and SIRT1 govern this pathway suggests that
inhibition of this interaction may be sufficient to induce cancer cell death, with little
effect on non-cancer cells.
Figure 5.13: AROS and SIRT1 in HCT116 colorectal cancer cells
(A) Schematic of the role of AROS in regulation of FOXO4 and p53 in HCT116
cells. AROS suppresses FOXO
following AROS silencing. BIM
AROS. AROS also suppresses p53, but only following UV irradiation of HCT116
cells. AROS silencing induced cell cycle alteration
likely that the functions attributed to AROS here are functions of an AROS
complex. (B) Schematic as for (A) but for the function of SIRT1. SIRT1 shares the
role of AROS in suppression of FOXO4
AROS-FOXO4 relationship in (A). SIRT1 suppresses p53 under all conditions
analysed. SIRT1 suppression of cell cycle progression acts, at least i
However, it is also evident that SIRT1 suppresses cell cycle progression via p53
independent mechanisms.
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5.7 Conclusions
1. AROS is required for cancer cell survival, but not for non-cancer cell
viability. This identifies AROS as a novel anti-cancer therapeutic target.
2. AROS suppresses apoptosis via FOXO4, independent of p53 expression.
Similarity to the role of SIRT1 suggests the AROS-SIRT1 interaction as a
potential anti-cancer drug target.
3. p53 may be a crucial factor in cell cycle regulation following AROS
silencing under specific stress conditions. This differs to regulation of the cell
cycle by SIRT1.
Conclusions 2 and 3 are further evidence that the SIRT1-AROS relationship is
more complex than obligate activation. AROS appears to be able to influence both
the SIRT1 targets, FOXO4 and p53, but this is dependent upon cell context.
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6 The relationship between AROS and RPS19
6.1 Overview
This Chapter extends the analysis of AROS, which was previously analysed in
relation to modulation of SIRT1 activity (see Chapters 4 and 5). In addition to
SIRT1, AROS is also known to interact with a structural component of the small
ribosomal subunit, namely RPS19. RPS19 has been linked to cell survival, creating
the possibility that AROS promotes cancer cell survival through RPS19. Here the
relationship between AROS and RPS19 is explored using the RNAi experimental
model also used in the study of the AROS/SIRT1 relationship (Chapters 4 and 5).
This Chapter outlines an unexpected outcome of this analysis; the presence of
a novel autoregulatory loop between AROS and RPS19. Each protein promotes the
abundance of the other, but with no effect on reciprocal mRNA level. Following this
observation further analysis of the function of the AROS-RPS19 relationship forms
the remainder of this Chapter as well as Chapters 7 and 8.
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6.2 Introduction
6.2.1 Ribosomal Protein of the Small subunit 19
RPS19 is a 15kDa protein which functions primarily in the synthesis and
subsequent translational activity of ribosomes. Consistent with a role in this essential
cellular process, RPS19 mRNA and protein was widely expressed across tissue
samples and cell lines (Chapter 4 – Figure 4.2). During ribosome biogenesis RPS19
is required for the processing of pre-ribosomal RNA into 18S rRNA (Choesmel et al.
2007; Flygare et al. 2007; Idol et al. 2007). Both RPS19 and 18S rRNA are essential
for small ribosomal subunit structure and function (Ben-Shem et al. 2010; Rabl et al.
2011). The role of RPS19 in ribosome biogenesis is discussed and analysed in
greater detail in Chapter 8.
6.2.2 Ribosomal proteins, p53 and cell fate
As previously discussed in Chapters 4 and 5, the p53 tumour suppressor is a
key regulator of cell fate. Suppression of p53 is required to facilitate longevity of
cancer cells. At least 10 ribosomal proteins have been directly implicated in the
regulation of p53. These proteins stabilise p53 by reducing its proteasomal
degradation via sequestration of MDM2 (reviewed by Deisenroth and Zhang 2010).
Thus, some ribosomal proteins are able to activate p53. This is believed to constitute
a mechanism of ribosomal stress monitoring, reducing cell proliferation in response
to aberrations in ribosome production or function which could be deleterious for the
cell.
Importantly some ribosomal proteins appear to suppress p53 in a mechanism
independent of the MDM2 degradation pathway. Among this group of ribosomal
proteins is RPS19, which suppresses p53 protein accumulation in the mouse and
zebrafish (Danilova et al. 2008; McGowan et al. 2008; Dutt et al. 2011; Jaako et al.
2011). Consistent with this, loss of RPS19 resulted in cell death from the erythroid
lineage in these animal models. RPS19 was also required for cell survival following
RNAi mediated depletion in human cancer cells (Choesmel et al. 2007). Together
this suggests that RPS19 is an anti-apoptotic protein able to influence cell fate via
p53. Furthermore, RPS19 appears to be a cancer cell survival factor, with its effect in
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human non-cancer cells yet to be formally addressed. Although the negative effect
on murine and zebrafish erythroid cell viability suggests that RPS19 may have a
wider role in promoting cell survival.
6.2.3 RPS19 and AROS
AROS was identified as a direct binding partner of RPS19 in a yeast-two
hybrid screen using the mouse proteins (Maeda et al. 2006). This interaction has not
been experimentally identified in humans, although it has been predicted by in silico
analysis (Orru et al. 2007). Importantly, the function of the interaction is entirely
unknown. In Chapter 5, AROS was found to be anti-apoptotic in cancer cells. This
appeared to occur at least in part via SIRT1, but other factors cannot be ruled out.
Thus, the anti-apoptotic functions of RPS19 may overlap with the role of AROS in
cancer cell survival.
RPS19 suppression of p53 occurs via an unknown mechanism. In Chapter 4,
AROS was characterised as a context dependent suppressor of p53. This raises the
possibility that RPS19 suppresses p53 via AROS, and therefore SIRT1. This could
identify a functional network involving AROS and its two binding partners SIRT1
and RPS19. Furthermore, the network could extend beyond suppression of p53 to
include specific promotion of cancer cell survival.
6.2.4 Hypotheses
1. AROS and RPS19 affect reciprocal protein function.
2. AROS specifically promotes cancer cell survival via RPS19.
3. RPS19 affects p53 via regulation of AROS.
The relationship between AROS and RPS19
193
6.3 An autoregulatory loop between AROS and RPS19
6.3.1 AROS promotes RPS19 abundance
RNAi against AROS in the panel of 5 cancer cells reduces AROS protein
expression (Figure 6.1A). In the HCT116 p53-/- colorectal adenocarcinoma and
MCF7 mammary gland epithelial cancer cell lines AROS protein is efficiently
depleted by siRNA. However, in the HCT116, DLD1and LoVo colorectal
adenocarcinoma cell lines depletion of total AROS is less evident. This is consistent
with the stability of total AROS seen in Chapter 4. In that instance, AROS was
found to be depleted by siRNA from the nuclear fraction over the abundant
cytoplasmic fraction in HCT116 cells. This may contribute to the stability of total
AROS seen here. In all 5 cell lines targeting of AROS by siRNA resulted in a
specific loss of AROS mRNA (Figure 6.1B).
Unexpectedly, depletion of AROS by siRNA resulted in depletion of RPS19
protein in 3 of the 5 cell lines analysed (Figure 6.1A). In the HCT116, DLD1 and
MCF7 cell lines knock down of AROS correlated with a loss of RPS19 protein.
There was the possibility that this reduction in RPS19 protein was due to off-target
RNAi against RPS19 mRNA from the AROS siRNA. This would manifest as
decreased RPS19 mRNA expression following AROS siRNA treatment. This did not
occur in any of the 5 cancer cell lines, with no reduction in RPS19 mRNA
standardised against housekeeping controls (Figure 6.1B). Indeed, in the MCF7 cell
line RPS19 expression was increased by AROS silencing. This may represent a
compensatory mechanism attempting to increase RPS19 protein expression.
In the HCT116 p53-/- and LoVo cell lines RPS19 protein did not appear to be
affected by AROS siRNA. In the case of the LoVo cell line, silencing of AROS was
not efficient, suggesting that greater depletion of AROS may affect RPS19 protein.
However, this was not the case for the HCT116 p53-/- cell line, where AROS
depletion was efficient (Figure 6.1A). Given that the HCT116 p53 wild-type and p53
null cell lines are otherwise isogenic this data suggests a role for p53 in the
promotion of RPS19 protein abundance by AROS.
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6.3.2 RPS19 promotes AROS abundance
The data above indicate that AROS may promote RPS19 protein abundance
in cancer cell lines (Figure 6.1C). Given this observation, the effect of RPS19 on
AROS was analysed in the same panel of cancer cells using siRNA against RPS19.
Silencing of RPS19 was efficient at the protein level in all cancer lines in which
RPS19 was targeted (Figure 6.2A). Consistent with this, a significant reduction in
RPS19 mRNA level was seen, standardised against a housekeeping control mRNA
(Figure 6.2B).
Similar to the reciprocal analysis above, the abundance of AROS protein was
also reduced following targeting of RPS19. This appeared to be highly conserved,
occurring in all 5 cancer cell lines analysed. This was specific to AROS protein, as
standardised AROS mRNA expression was not depleted by RPS19 silencing in each
of the 5 cancer cell lines (Figure 6.2). Oppositely, the abundance of AROS mRNA
was significantly increased in each cell line following RPS19 silencing.
This suggests that RPS19 maintains AROS protein abundance, completing an
autoregulatory loop between AROS and RPS19 (Figure 6.2C). This is the first
indication that ‘AROS and RPS19 affect reciprocal protein function’. The increase in
AROS mRNA may represent a compensatory mechanism to ameliorate the reduced
AROS protein levels. However, this response is insufficient to counteract the loss of
AROS protein. Thus, loss of RPS19 resulted in loss of AROS protein and a
potentially associated increase in AROS mRNA.
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Figure 6.1: AROS silencing results in loss of RPS19 protein
(A) SDS-PAGE and Western blot analysis of protein abundance following
AROS siRNA 1 transfection. Cancer cells were transfected and harvested at
48 hours (HCT116 p53-/- at 72 hours) and total protein isolated (see Methods).
Equivalent protein analysed by mass. Actin expression was used as a loading
control. (B) Parallel isolation of total RNA by RNeasy method during the
transfection detailed in (A). RNA abundance quantified by qRT-PCR and
standardised against Actin mRNA (GAPDH mRNA for MCF7). *** P<0.001,
* P<0.05. (C) Schematic of the effect of AROS on RPS19 protein.
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Figure 6.2: RPS19 silencing results in loss of AROS protein
(A) Analysis of protein abundance following RPS19 siRNA transfection in cancer
cell lines. Cells were harvested 48 hours (except HCT116 p53-/- – 72 hours) post-
transfection and lysed in protein lysis buffer (see Methods). Equivalent protein by
mass was analysed and Actin expression used as a loading control. (B) Total RNA
was harvested 48 hours (HCT116, DLD1, MCF7, LoVo) or 72 hours (HCT116
p53-/-) after siRNA transfection against RPS19. RNA was isolated by the RNeasy
method and analysed by qRT-PCR using specific primers for each mRNA,
standardised against Actin (HCT116, HCT116 p53-/-, DLD1, LoVo) or GAPDH
(MCF7) mRNA expression. (C) Schematic of the effect of RPS19 on AROS
protein, completing an autoregulatory loop between the two proteins.
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6.4 RPS19 and cancer cell fate
6.4.1 Cancer cell phenotype
AROS appeared to be a survival factor for cancer cells in Chapter 5. RPS19
may also have a role in promoting cancer cell viability, given that knockdown of
RPS19 resulted in apoptosis in a human cancer cell line (Choesmel et al. 2007). In
order to analyse the role of RPS19 in cancer cell fate, RPS19 siRNA was applied to
the panel of cancer cell lines used throughout the Thesis. To provide a direct
comparison to RPS19 silencing, AROS siRNA1 transfection was carried out in
parallel.
RPS19 siRNA resulted in an apparent reduction in cell density in all 5 human
cancer cell lines analysed (Figure 6.3). There also appeared to be an increase in cell
refringency in each cell line, either due to increased individual cell detachment
(DLD1, MCF7), detachment of groups of cells (LoVo) or both (HCT116, HCT116
p53-/-). This was potentially indicative of cell death and impaired cell cycle
progression. AROS silencing in each cancer cell line correlated with an increase in
individual cell refringency, but with little effect on cell density, as previously stated
in Chapter 5.
6.4.2 Cancer cell apoptosis
Consistent with the alterations in cancer cell phenotype a significant increase
in apoptosis was observed in the HCT116 and HCT116 p53-/- cell lines following
silencing of RPS19 (Figure 6.4A). Thus, RPS19 appears to be anti-apoptotic in
human cancer cells. Further to this, given the apoptosis in the HCT116 p53-/- cell line
RPS19 appears to suppress apoptosis independent of p53 status. Silencing of AROS
in parallel experiments also induced significant apoptosis in the HCT116 and
HCT116 p53-/- cell lines (Figure 6.4A). Silencing of RPS19 therefore has similarities
to the roles of AROS in cancer cell apoptotic suppression (see Chapter 5), perhaps
suggestive of a unified role of the 2 proteins. These observations are consistent with
the hypothesis that ‘AROS specifically promotes cancer cell survival via RPS19’.
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6.4.3 Cancer cell cycle progression
The reduction in cell density following RPS19 silencing may be attributable
to the apparent increase in cell death (Figure 6.4A), but equally may be due to
alterations in cell cycle progression. Consistent with this possibility, in the HCT116
cell line RPS19 silencing correlated with a decrease in cells in S phase of the cell
cycle and an increased population of G1 and G2/M cells (Figure 6.4Bi). This
reduction in S phase cells may contribute to the reduction in HCT116 cell density. In
contrast to RPS19 silencing, AROS silencing in the HCT116 cells did not greatly
alter the cell cycle distribution from Mock treated cells (Figure 6.4Bi). This is the
same data presented in Chapter 5. The implication of this difference is that AROS
and RPS19 have distinct effects in determining cell cycle distribution in the HCT116
cells.
Interestingly, the cell cycle distribution of the HCT116 p53-/- cell line was not
greatly altered by RPS19 silencing, with only a moderate redistribution of cells in
G1 and G2/M seen (Figure 6.4Bii). This suggests that alterations in cell cycle status
did not contribute to the reduced cell density in this cell line. Further, it suggests that
p53 is important for suppressing cell cycle progression following loss of RPS19, and
provides further evidence that RPS19 suppresses p53 function.
AROS silencing in the HCT116 p53-/- cell line did not greatly alter the cell
cycle distribution from Mock treated cells (Figure 6.4Bii). Thus, AROS does not
appear to effect cell cycle distribution in either cell line analysed, whereas RPS19
does affect the cell cycle, but only in the presence of p53. This highlights a
difference in the roles of AROS and RPS19 in determining cell fate. This difference
is consistent with the phenotypes of the cancer cells analysed following silencing of
RPS19 and AROS, which differ in terms of resulting cell density (Figure 6.3);
RPS19 silencing reduced cell density but AROS silencing did not appear to have any
effect. This suggests that RPS19 and AROS may play distinct roles in determining
cancer cell fate. This may disagree with the hypothesis that ‘AROS specifically
promotes cancer cell survival via RPS19’.
Mock RPS19 siRNA
HCT116
Cell line AROS siRNA 1
HCT116 p53-/-
72 hours
DLD1
mutant p53
LoVo
MCF7
Figure 6.3: RPS19 knockdown causes phenotype alterations in
cancer cells
Phase contrast micrographs of HCT116, HCT116 p53-/-, DLD1, LoVo and
MCF7 cancer cell lines following transfection of siRNAs against RPS19 or
AROS. Cells were treated with siRNA and resulting phenotypes recorded 48
hours post-transfection, unless stated.
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Figure 6.4: The effect of RPS19 on cancer cell apoptosis and cell
cycle progression
(Ai) Fold apoptosis compared to Mock treated cells following siRNA transfection
in HCT116 cancer cells. Cells treated with siRNA for 48 hours and analysed by
Annexin V staining and flow cytometry (See Methods). (Aii) Data as in (Ai) for
the HCT116 p53-/- cell line, treated with siRNA 72 hours prior to harvesting. ***
P<0.001, * P<0.05. (Bi) Cell cycle distribution according to propidium iodide
intercalation and flow cytometry, presented as a percentage of cells for each
condition (see Methods). HCT116 cells were treated with siRNA as indicated, and
harvested 48 hours later. (Bii) Data presented as in (Bi) for the HCT116 p53-/- cell
line harvested 72 hours post-transfection.
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6.5 The AROS-RPS19 autoregulatory loop in non-cancer cells
In Chapter 5 AROS was found to be a cancer specific survival factor,
promoting the viability of cancer cells, but not non-cancer cells. With the hypothesis
that ‘AROS specifically promotes cancer cell survival via RPS19’ the role of RPS19
was analysed in cancer cells, where it was found to be anti-apoptotic in accordance
with the role of AROS (see above). Thus, to analyse the potential cancer specificity
of RPS19, its role in non-cancer cells was characterised. Firstly, the molecular
effects of AROS and RPS19 silencing were assessed in relation to reciprocal protein
stability, then the role of RPS19 in determining non-cancer cell fate.
6.5.1 The AROS-RPS19 auto-regulatory loop is present in non-cancer cells
siRNA-mediated targeting of AROS in ARPE19, WI38 and MCF10A non-
cancer cell lines was successful at both the protein and mRNA levels (Figure 6.5).
As previously seen in cancer cell lines, silencing of AROS reduced the abundance of
RPS19 protein in each of the non-cancer cell lines (Figure 6.5A). This was specific
to RPS19 protein as the abundance of RPS19 mRNA was not reduced compared to
Mock treatment (Figure 6.5B). Thus, the positive effect of AROS depletion on
RPS19 protein abundance occurs in both cancer and non-cancer cell lines.
In reciprocal, the silencing of RPS19 was efficient at the mRNA level, which
translated to reduced RPS19 protein expression in each of the non-cancer cell lines
analysed (Figure 6.6). As seen in the cancer cell lines, the abundance of AROS
protein was reduced following targeting of RPS19. There was no reduction in AROS
mRNA standardised against housekeeping controls, consistent with a post-
transcriptional effect of RPS19 on AROS (Figure 6.2). In the ARPE19 and WI38 cell
lines the abundance of AROS mRNA was significantly increased following RPS19
silencing. This was previously observed and discussed in cancer cell lines, with the
increase in AROS mRNA potentially representing a compensatory mechanism to
counteract the reduced AROS protein levels.
Thus, the AROS-RPS19 autoregulatory loop appears to be present in non-
cancer cells as well as cancer cells, further supporting the hypothesis that ‘AROS and
RPS19 affect reciprocal protein function’. With AROS known to specifically
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promote cancer cell survival it is possible that knockdown of RPS19 also has no
effect on non-cancer cell survival. Thus, the cellular effect of RPS19 silencing was
characterised in the ARPE19, WI38 and MCF10A non-cancer cell lines.
6.5.2 Non-cancer cell fate
Silencing of RPS19 in three non-cancer cell lines appeared to result in a
reduction in cell density compared to parallel Mock siRNA treatment (Figure 6.7).
RPS19 silencing also appeared to increase the number of refringent cells compared
to Mock treatment, indicative of an induction of apoptosis. Consistent with this,
RPS19 silencing in the non-cancer ARPE19 retinal epithelial and WI38 lung
fibroblast cell lines resulted in a significant induction of apoptosis compared to
Mock treatment (Figure 6.8A).
As such, RPS19 appears to be required for survival of not only cancer cells,
but also non-cancer cells. This contrasts the role of AROS reported in Chapter 5.
These data for AROS are shown here for side-by-side comparison to RPS19
silencing. Silencing of AROS has little effect on non-cancer cell phenotype and this
correlated with no induction of apoptosis in the ARPE19 and WI38 cell lines (Figure
6.7and Figure 6.8A). This implies that despite the conservation of the AROS-RPS19
molecular relationship between cancer and non-cancer cell lines, the effect each
protein has on cell fate is not conserved across cell types. Thus, the hypothesis that
‘AROS specifically promotes cancer cell survival via RPS19’ appears to be unlikely.
Further to this, silencing of RPS19 in the ARPE19 cell line appeared to result
in a redistribution of cells between stages of the cell cycle (Figure 6.8B). Although
the number of cells in S phase was not altered (8%), the G2/M phase population
appeared to double with a concomitant reduction in G1 phase cells. This, and the
induction of apoptosis seen in Figure 6.8Ai, may contribute to the reduction in cell
density observed following RPS19 silencing (Figure 6.7). Silencing of AROS did not
have such a significant effect on the cell cycle distribution of ARPE19 cells as
silencing of RPS19. This appears consistent with the phenotype of AROS silenced
cells shown in Figure 6.7 and indicates another difference between the roles of
AROS and RPS19 in cell fate determination.
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These phenotypic data strongly indicate that RPS19 is required for cell
survival. In contrast to the role of AROS, which was specifically required for cancer
cell survival, RPS19 appears to be required for viability of both cancer and non-
cancer cells. This requirement for RPS19 may pertain to its role as an essential
component of the small ribosomal subunit. Loss of RPS19 is likely to have negative
effects on global translation and protein production, which appears here to correlate
with a negative effect on cell fate. This suggests that the roles of RPS19 and AROS
in cell fate determination do not overlap.
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Figure 6.5: AROS silencing results in loss of RPS19 protein in
non-cancer cells
(A) SDS-PAGE and Western blot analysis for protein abundance following
AROS siRNA 1 transfection. Non-cancer cells were transfected and harvested
at 72 hours for total protein (see Methods). Equivalent protein loaded by
mass. Actin expression was used as a loading control. (B) Parallel isolation of
total RNA by RNeasy method during the transfection detailed in (A). RNA
abundance quantified by qRT-PCR and standardised against Actin mRNA
(GAPDH mRNA for MCF10A). *** P<0.001, ** P<0.01, * P<0.05.
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Figure 6.6: RPS19 silencing results in loss of AROS protein in
non-cancer cells
(A) Quantification of protein abundance following RPS19 silencing in non-
cancer cell lines (ARPE19, WI38 and MCF10A) harvested 72 hours post-
transfection. Equivalent protein mass was analysed by SDS-PAGE and
Western blotting following lysis of cells. Actin is used as a loading control
(B) qRT-PCR analysis of mRNA abundance in ARPE19, WI38 and MCF10A
non-cancer cell lines 72 hours following RPS19 siRNA transfection. Data
standardised against Actin (ARPE19, WI38) or GAPDH (MCF10A) mRNA
expression. *** P<0.001, ** P<0.01, * P<0.05.
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WI38
MCF10A
ARPE19
Figure 6.7: RPS19 silencing alters non-cancer cell
phenotype
Phase contrast micrographs of ARPE19, WI38 and MCF10A non-
cancer cell lines following transfection of siRNAs against RPS19
or AROS. Cells were treated with siRNA and phenotype recorded
72 hours post-transfection in all cases.
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indicated. Cells treated with
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Data as in (Ai) for the WI38 cell
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6.6 AROS-RPS19 autoregulatory loop function
6.6.1 Suppression of p53
RPS19 suppresses p53 accumulation in animal models, via a mechanism
distinct from MDM2-mediated proteasomal degradation (Danilova et al. 2008;
McGowan et al. 2008; Dutt et al. 2011; Jaako et al. 2011). This allows the possibility
that RPS19 suppresses p53 via AROS, which would be consistent with the
observation that RPS19 supports AROS protein abundance. AROS was characterised
as a selective activator of SIRT1 activity in Chapters 4 and 5. This was observed as
a differential effect on acetylated and total p53 levels following knock down of
AROS, variable by cell line.
To test the hypothesis that ‘RPS19 affects p53 via regulation of AROS’ the
abundance of both acetylated and total p53 was determined following basal silencing
of RPS19 in seven p53-expressing cell lines (Figure 6.9). These are summarised and
compared to the effect AROS silencing reported in Chapter 4 in Table 6.1.
6.6.1.1 HCT116
Silencing of RPS19 in the HCT116 colorectal adenocarcinoma cell line did
not appear to alter the expression of total p53, or increase the acetylation of p53 at
lysine 382 (Figure 6.9A). This is consistent with the effect of AROS silencing in this
cell line under these conditions (Chapter 4 – Figure 4.6). Thus, neither AROS nor
RPS19 appears to suppress p53 in the HCT116 cell line under these basal conditions.
6.6.1.2 DLD1
In the DLD1 colorectal adenocarcinoma cell line, silencing of RPS19 did not
affect the abundance of p53, but did induce an increase in p53 acetylation at lysine
382 compared to Mock treatment (Figure 6.9A). This is consistent with the effect of
silencing AROS in this cell line, where both total and acetylated p53 levels were
elevated (Chapter 4 – Figure 4.7). The lack of total p53 stabilisation following
RPS19 silencing compared to AROS silencing may represent a temporal difference.
Increased acetylation of p53 may lead to total p53 stabilisation. As such, the
heightened acetylation of p53 following both AROS and RPS19 silencing may only
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have stabilised total p53 following AROS silencing at the 48 hour post-transfection
time point analysed. Thus, analysis at a later time point may reveal that total p53
stabilisation was yet to occur following RPS19 silencing at 48 hours post-
transfection.
6.6.1.3 MCF7
In the MCF7 cancerous mammary gland epithelial cell line RPS19 appeared
to stabilise total p53 expression (Figure 6.9A). Unfortunately, acetylated p53 could
either not be detected in this cell line under these conditions. However, stabilisation
of total p53 correlated with p53 stabilisation seen following AROS silencing in the
MCF7 cell line (Chapter 4 – Figure 4.7).
6.6.1.4 LoVo
In the LoVo colorectal adenocarcinoma cell line silencing of RPS19 appeared
to correlate with an increase in both total and acetylated p53 (Figure 6.9A). This is
strikingly similar to the role of AROS reported in Chapter 4 – Figures 4.7, where
silencing of AROS stabilised both total and acetylated p53 levels.
6.6.1.5 ARPE19
In the ARPE19 non-cancer retinal epithelial cell line, silencing of RPS19
induced a marked stabilisation of p53 protein (Figure 6.9B). Similar to the MCF7
cell line, acetylation status of p53 could not be detected under these conditions in the
ARPE19 cell line. However, the data are similar to the stabilisation of p53 observed
following AROS silencing in Chapter 4 – Figure 4.6. Total p53 was stabilised by
AROS knockdown but the effect on acetylated p53 was difficult to interpret.
6.6.1.6 WI38
Total p53 protein levels were stabilised by RPS19 silencing in the WI38 lung
fibroblast non-cancer cell line (Figure 6.9B). The effect on acetylated p53 was
difficult to indentify due to low levels of acetylation. There appeared to be a band
appearing following RPS19 silencing, but this was faint. Nevertheless, the marked
The relationship between AROS and RPS19
210
increase in total p53 is consistent with the stabilisation of p53 seen following AROS
silencing in Chapter 4 – Figure 4.8.
6.6.1.7 MCF10A
Acetylated p53 levels were not analysed in the MCF10A non-cancer
mammary gland epithelial cell line due to lack of sample. However, total p53
appeared to be stabilised by RPS19 knockdown in this non-cancer cell line. This is
again consistent with the effect of AROS silencing observed in Chapter 4 – Figure
4.8.
Overall, the comparison of p53 levels following RPS19 silencing to p53
levels following AROS silencing in Chapter 4 reveals a striking similarity (see Table
6.1). In all cases the two conditions show some level of identity. When considered
with the loss of AROS seen following silencing of RPS19, it appears that RPS19
may promote not only AROS abundance but potentially AROS function in
suppression of p53. This is consistent with the hypothesis that ‘RPS19 affects p53
via regulation of AROS’. Thus, the AROS-RPS19 autoregulatory loop appears to be
important in the suppression of p53 (Figure 6.9C). Importantly, this could contribute
to the unknown mechanism of p53 suppression by RPS19.
6.6.2 SIRT1 abundance
Interestingly, RPS19 appears to effect the expression of the AROS binding
partner SIRT1 in 5 of the 8 cell lines analysed. In the HCT116 p53-/- and MCF7
cancer cell lines and ARPE19, WI38 and MCF10A non-cancer cell lines RPS19
silencing resulted in a decrease in the expression of SIRT1 protein (Figure 6.9).
Interestingly, the loss of SIRT1 did not correlate with increased p53 acetylation,
which would be consistent with the role of SIRT1 in deacetylation of p53 (Luo et al.
2001; Vaziri et al. 2001). However, total p53 protein levels were increased where the
p53 gene was intact, suggesting that loss of SIRT1 following silencing of RPS19
may be a factor in the subsequent stabilisation of p53.
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Figure 6.9: The effect of RPS19 silencing on p53
(A) Analysis of SIRT1 and p53 protein abundance following RPS19 siRNA
transfection in cancer cell lines. Cells were harvested 48 hours (except
HCT116 p53-/- – 72 hours) post-transfection and lysed in protein lysis buffer
(see Methods). Equivalent protein by mass was analysed and Actin expression
used as a loading control. (B) Analysis as in (A) for ARPE19, WI38 and
MCF10A non-cancer cell lines harvested at 72 hours post-transfection. (C)
Schematic representation of the AROS-RPS19 autoregulatory loop and the
similar effect of each component on p53 protein.
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Cell line RPS19
suppresses p53
HCT116
HCT116 p53-/-
DLD1
MCF7
LoVo
ARPE19
WI38
MCF10A
Table 6.1: The effect of RPS19 on p53 and SIRT1
Collation of the data from
A positive effect on the extent of acetylation and/or total levels of p53 following
RPS19 silencing is indicated in Column 2. A tick represents a positive effect,
whereas a cross represents no effect. The identity of the data in Column 2 to th
effect of AROS silencing seen in
Column 3. The effect of RPS19 on SIRT1 protein levels is also shown in Column 4.
Arrows indicate the effect of RPS19 on SIRT1 protein expression. ‘~’ indicates no
effect seen.
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6.7 Discussion
6.7.1 Auto-regulation of AROS and RPS19
The data reveal a novel effect of AROS and RPS19 silencing upon reciprocal
protein stability. Each protein promotes the abundance of the other in both cancer
cell lines (Figure 6.1 and Figure 6.2) and non-cancer cell lines (Figure 6.5 and Figure
6.6). In each case there was no negative effect on reciprocal mRNA levels, implying
that the regulation of each protein by the other occurs at the protein level. Given that
the two proteins interact in the mouse the association of the proteins seems likely to
form part of this regulatory mechanism (Maeda et al. 2006).
The loss of reciprocal protein appears likely to have an effect on the function
of that protein. As such, the data indicate that AROS may be required to maintain
RPS19 function and vice versa. No significance had previously been attributed to the
AROS-RPS19 association, making this the first indication that ‘AROS and RPS19
affect reciprocal protein function’.
The mechanism behind the autoregulatory loop may relate to the functions of
AROS and/or RPS19. RPS19 is a structural component of the ribosome (Taylor et al.
2009; Ben-Shem et al. 2010; Rabl et al. 2011), which is also essential for small
ribosomal subunit biogenesis (Choesmel et al. 2007; Flygare et al. 2007; Idol et al.
2007). Thus, loss of RPS19 is likely to impact upon ribosome abundance. Therefore,
the loss of RPS19 seen following AROS silencing may simply be an indicator of a
reduction in ribosome abundance, with a concomitant loss of RPS19. Further, the
loss of AROS following RPS19 silencing could be induced by a loss of small
ribosomal subunits, should AROS depend on small subunit abundance for stability.
The relationship between AROS and the ribosome is explored further in Chapter 8 in
an attempt to address this possibility.
Interestingly, the loop is not present in full in the HCT116 p53-/- cell line,
unlike in the wild-type HCT116 cell line. The only difference between these cell
lines is the expression of p53 in the HCT116 but not in the HCT116 p53-/-. This
gives a strong indication that the break in the loop is related to the absence of p53
expression. Silencing of RPS19 reduces AROS expression in the p53 null cell line,
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but the reciprocal effect of AROS on RPS19 is lost. The reason for this is unclear,
but implies that p53 may be required for regulation of RPS19 by AROS.
6.7.2 RPS19 and suppression of p53
AROS and SIRT1 have similar functions in determining cell fate. For
example silencing of each appears to induce a similar level of apoptosis (Chapter 5).
However, AROS and SIRT1 appeared to act differently in regulation of p53
(Chapter 4). Importantly, induction of apoptosis is independent of p53, following
AROS, SIRT1 or RPS19 silencing. Thus, the regulation of p53 appears to be
disconnected from the regulation of apoptosis in the system. Interestingly, the role of
AROS and RPS19 appears to be similar when analysed in terms of the effect each
has upon p53.
RPS19 appears to suppress p53 stabilisation in 6 of the 7 p53-expressing cell
lines analysed (Table 6.1). Furthermore, RPS19 appears to be required for
maintenance of cell cycle profile in a p53-dependent manner (Figure 6.4B). These
data are consistent with recent reports from animal models of RPS19 deficiency,
where RPS19 suppressed p53 by an unknown mechanism (Danilova et al. 2008;
McGowan et al. 2008; Dutt et al. 2011; Jaako et al. 2011). The characterisation here
suggests that RPS19 may suppress p53 via AROS and perhaps SIRT1.
The data for suppression of p53 by both AROS and RPS19 are strikingly
similar (Chapter 4, this Chapter and Table 6.1). AROS appears to be a selective
suppressor of p53, dependent upon cell line and context. Interestingly, under
conditions where AROS suppressed p53, RPS19 also appeared to suppress p53.
Crucially, under conditions where AROS did not appear to suppress p53, RPS19 too
had little effect on p53 protein. This correlation is consistent with the autoregulatory
loop between AROS and RPS19, with RPS19 knockdown reducing AROS protein
abundance and function. The data agree with the hypothesis that ‘RPS19 affects p53
via regulation of AROS’.
Interestingly there may be a more direct effect of RPS19 on SIRT1 than the
common binding of AROS. RPS19 appears to affect the expression of SIRT1 protein
in 5 of the 8 cell lines analysed. This would directly reduce the SIRT1-mediated
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suppression of p53. Consistent with this, the loss of SIRT1 following RPS19
silencing correlated with increased total p53 expression (Figure 6.9). Importantly,
AROS silencing under the same conditions does not affect SIRT1 protein abundance
(Chapter 4). Thus, the effect of RPS19 on SIRT1 abundance is likely to be
independent of AROS.
RPS19 is known to suppress p53, but via an unknown mechanism (Danilova
et al. 2008; McGowan et al. 2008; Dutt et al. 2011; Jaako et al. 2011). The data here
suggest that this may involve RPS19-mediated activation of SIRT1. This could
potentially occur via: 1) RPS19 promoting AROS abundance, and subsequent
activation of SIRT1 or, 2) RPS19 promoting SIRT1 protein abundance and function.
This provides a putative link between RPS19 and SIRT1, which could explain the
unknown mechanism of suppression of p53 by RPS19.
6.7.3 RPS19 and cell survival
RPS19 appears to be required for the viability and survival of all cell lines
analysed. This is consistent with previous analyses of RPS19 in cell viability
(Choesmel et al. 2007; Danilova et al. 2008; McGowan et al. 2008; Dutt et al. 2011;
Jaako et al. 2011). The conserved role of RPS19 in promoting cell viability is in
contrast to the specific survival functions of AROS, which appears to only promote
cancer cell survival (Chapter 5). The similarities between AROS and RPS19 in
terms of cell viability are limited. The extent of apoptosis, effect on cell cycle and
cell phenotype following silencing all appeared to be different. These differences
suggest that loss of RPS19 may not be a factor in AROS-silencing-induced cancer
cell apoptosis. Therefore, the data do not appear to support the hypothesis that
‘AROS specifically promotes cancer cell survival via RPS19’.
However, it may be possible that RPS19 is involved in this process. Cancer
cells undergo rapid proliferation, which will require heightened function of
ribosomes. In contrast, non-cancer cells grow more slowly. Targeting of the
ribosome in cancer cells may be selective for these rapidly dividing cells (Silvera et
al. 2010). It is possible that AROS only influences RPS19 function to a critical
extent in cancer cells. This could account for the cancer specificity for AROS in cell
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viability. This, and the potential modes of AROS anti-apoptotic function, is
discussed in Chapter 9.
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6.8 Conclusions
1. AROS and RPS19 form a functional autoregulatory loop.
2. RPS19 appears to be essential for survival of all cells, both cancerous and
non-cancerous .
3. RPS19 suppresses p53, via a mechanism potentially involving regulation of
AROS and SIRT1.
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7 AROS and RPS19 complexes
7.1 Overview
Chapter 6 indicated that AROS and RPS19 form an autoregulatory loop,
promoting reciprocal protein abundance and function. This presumably involves the
association of the two proteins, given the known interaction in the mouse (Maeda et
al. 2006). This Chapter aims to identify the AROS-RPS19 association between the
proteins in human cells. Exogenous expression of tagged proteins and
immunoprecipitation are used for this purpose.
Chapter 6 also revealed a potential link between RPS19 and SIRT1 function.
Given that both proteins interact with AROS, the potential for an interaction between
RPS19 and SIRT1 was also analysed. This considered a newly identified splice
variant form of SIRT1, termed SIRT1-Δ8. Again using exogenous expression and
immunoprecipitation a specific interaction between RPS19 and SIRT1-Δ8 is
identified, and analysed further for potential functional consequences.
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7.2 Introduction
7.2.1 RPS19 interactions
RPS19 is a structural component of the small ribosomal subunit, intercalating
18S ribosomal RNA (Taylor et al. 2009; Ben-Shem et al. 2010; Rabl et al. 2011).
RPS19 is also required for the synthesis of ribosomes, which occurs within the
subnuclear structure, the nucleolus (Choesmel et al. 2007; Flygare et al. 2007; Idol et
al. 2007). As such, RPS19 associates with ribosomal proteins and ribosome
biogenesis factors, likely in both the cytoplasm where ribosomes function and in the
nucleus/nucleolus during ribosome synthesis.
This role in ribosome biogenesis was evident in the published protein
interactome of RPS19, but also revealed that RPS19 forms associations with many
non-ribosomal factors (Orru et al. 2007). RPS19 associated with proteins involved in
cellular activities such as mRNA processing, transcription and signal transduction.
Thus, RPS19 is believed to have distinct extra-ribosomal functions. One such
function appears to be the suppression of p53, via an unknown mechanism (Danilova
et al. 2008; McGowan et al. 2008; Dutt et al. 2011; Jaako et al. 2011).
Human RPS19 was predicted to interact with AROS, based on the
association reported in the mouse (Maeda et al. 2006; Orru et al. 2007). Data
presented in Chapter 6 were consistent with the mechanism of p53 suppression by
RPS19 potentially occurring via AROS and SIRT1. The aim of this Chapter is to
analyse the complexes formed by AROS and RPS19 to gain insight into this
potential mechanism. The potential for interaction with SIRT1 gene products was
analysed, which encompassed association with a novel SIRT1 splice variant.
7.2.2 SIRT1 splice variation
In parallel with this study, other members of the YCR p53 Research Unit
discovered and characterised the first splice variant of the SIRT1 gene, namely
SIRT1-Δ8 (Lynch et al. 2010). SIRT1-Δ8 differs from SIRT1-FL (the ‘full length’
form of the SIRT1 gene) in its omission of exon 8. The novel SIRT1-Δ8 isoform has
reduced deacetylase activity, but is nonetheless able to suppress p53 lysine 382
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acetylation (Lynch et al. 2010). Thus it is possible that SIRT1-Δ8 plays a role in
RPS19-mediated regulation of p53.
One difference between SIRT1-Δ8 and SIRT1-FL is during the response to
applied stress. Following stress SIRT1-Δ8 is significantly upregulated, in contrast to
SIRT1-FL which is down-regulated (Lynch et al. 2010). Interestingly, this
upregulation is p53-dependent, identifying an autoregulatory loop between p53 and
SIRT1-Δ8. Furthermore, this suggests a role for SIRT1-Δ8 but not SIRT1-FL during
the cellular response to applied stress.
Importantly for the analysis carried out thus far in the Thesis, the siRNA used
to target SIRT1 is specific for SIRT1-FL. The ‘SIRT1 siRNA’ targets a region in
exon 8 of SIRT1-FL, which is absent in the SIRT1-Δ8 isoform. Thus the previous
analyses of SIRT1 function can be attributed to SIRT1-FL. Targeting of SIRT1-Δ8
by RNAi is possible using an siRNA specific to the splice junction sequence created
in this isoform from exon 7 to 9 (Lynch et al. 2010). This is used herein for analysis
of SIRT1-Δ8 function.
Initially the analysis here focuses on the complexes formed by AROS and
RPS19. Importantly, association of the two proteins has yet to be reported in human
cells. Confirmation of this association will supplement the autoregulatory loop
identified between the proteins in Chapter 6. A further focus of this Chapter is on
the potential for RPS19 to interact with SIRT1-FL and/or SIRT1-Δ8. This potential
association has not been previously reported, but may have implications for RPS19
suppression of p53. Additionally the possibility for regulation of RPS19 by the
SIRT1 isoforms is analysed.
7.2.3 Hypotheses
1. AROS and RPS19 associate in human cells.
2. RPS19 associates with SIRT1-FL and/or SIRT1-Δ8.
3. The SIRT1 gene regulates RPS19.
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7.3 Molecular interactions of AROS
Immunoprecipitation of endogenous AROS or RPS19 was attempted but
proved unsuccessful with a range of antibodies. Given the small size of AROS and
RPS19 (both less than 16kDa) the inability to co-immunoprecipitate endogenous
protein may represent occlusion of their binding domains as a result of interaction
with antibody, which have a molecular weight of ~150kDa. To address this,
exogenously expressed Flag-tagged AROS and RPS19 proteins were employed to
allow immunoprecipitation of each protein without perturbation of protein
interactions. The limitations of exogenous protein expression and
immunoprecipitation were combated by attempting reciprocal immunoprecipitations
where possible. Overexpression of exogenous constructs did not greatly alter cell
phenotypes in all cases (Appendix).
7.3.1 Flag-AROS and endogenous RPS19
Exogenous Flag-tagged AROS was successfully expressed in HCT116 cells
following the scheme in Figure 7.1A. The exogenous Flag-AROS (indicated by a *)
migrated behind endogenous AROS (indicated by a †) upon SDS-PAGE (Figure
7.1B). This is demonstrated in the ‘Input’ samples (lanes 1 and 2), which also
evidence the higher expression of the exogenous AROS, consistent with over-
expression. Flag-AROS was pulled down by Flag-immunoprecipitation when over-
expressed (lane 5) with no immunoprecipitation from the no lysate and control
transfection immunoprecipitations (lanes 3 and 4 - Figure 7.1B). In all 3 cases an
anti-Flag antibody was used for immunoprecipitation.
Endogenous RPS19 was enriched by immunoprecipitation of Flag-AROS
compared to the controls (Figure 7.1B – lane 5 compared to lanes 3 and 4). This
indicates that endogenous RPS19 associates with Flag-AROS, consistent with the
hypothesis that ‘AROS and RPS19 associate in human cells’. Negative control Actin
protein was not co-immunoprecipitated by Flag-AROS, indicating that co-
immunoprecipitation of RPS19 was not due to non-specific binding. Examples of
full Western blots from a repeat of this experiment are shown in the Appendices.
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Input and Flag-IP protein was loaded in known quantities. This allows the
quantification of the fraction of endogenous RPS19 that associated with Flag-AROS
in Figure 7.1B. The quantity of total protein that was used in immunoprecipitation
(Flag-IP protein) was loaded in excess compared to original Input protein, as
indicated in Figure 7.1B. Thus, 2-fold more Flag-IP protein was loaded compared to
Input in the lower RPS19 and Actin Western blot analyses. Quantification revealed
that over one third of total RPS19 protein appeared to associate with Flag-AROS in
the HCT116 cell line (Figure 7.1C – left graph).
7.3.2 Flag-AROS and endogenous SIRT1
Flag-AROS also appeared to associate with endogenous SIRT1 protein
(Figure 7.1B). This represents SIRT1-FL and is consistent with the published
interaction between the proteins (Kim et al. 2007). A 100-fold excess of Flag-IP
protein compared to Input protein was required to visualise the SIRT1 protein that
co-immunoprecipitated with Flag-AROS. Thus, the fraction of endogenous SIRT1
(1.72%) that co-immunoprecipitates with Flag-AROS is lower than the fraction of
endogenous RPS19 (Figure 7.1C).
7.3.3 Nuclear interactions of AROS
Flag-AROS interacts with both RPS19 and SIRT1 (see above). In Chapter 4
a novel population of AROS was observed in the cytoplasm, with lower expression
in the nucleus (Figure 4.5). Both RPS19 and SIRT1 are known to reside in both the
nucleus and the cytoplasm (Da Costa et al. 2003; Tanno et al. 2007). This raises the
question of whether Flag-AROS associates specifically with RPS19 and SIRT1 in
different compartments or across the whole cell.
To analyse this immunoprecipitation of Flag-AROS was undertaken,
following the protocol outlined in Figure 7.1A, with subcellular fractionation at the
point of harvesting according to Figure 7.2A. Flag-AROS expressed in the Input of
the cytoplasmic fraction, migrating behind endogenous AROS upon SDS-PAGE
(lane 6 –Figure 7.2B). AROS was not detected in the Input of the nuclear fraction,
presumably due to the lower expression of AROS in this fraction (Chapter 4 –
Figure 4.5). Despite this Flag-AROS was immunoprecipitated with anti-Flag
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antibody in the nuclear fraction (lane 4 –Figure 7.2B). Flag-AROS was not
immunoprecipitated in the cytoplasmic fraction which was not amenable with
immunoprecipitation. Nevertheless the cytoplasmic Input indicates even loading of
immunoprecipitations within the experiment, and lack of Lamin AC expression
compared to the nuclear fraction demonstrates efficient subcellular fractionation.
The interaction between Flag-AROS and RPS19 occurs in the nuclear
fraction of HCT116 colorectal adenocarcinoma cells (Figure 7.2B). This interaction
was quantified as representing 2.24% of nuclear RPS19 protein interacting with
nuclear Flag-AROS (Figure 7.1C – left graph). Flag-AROS appeared to associate
with one third of RPS19 protein in total cell lysate (Figure 7.1C), compared to less
than 3% of nuclear RPS19. This lower interaction in the nucleus may imply that the
total interaction seen is achieved in the cytoplasmic fraction. Perhaps consistent with
this is the relative expression of AROS between fractions reported in Chapter 4 –
Figure 4.5, where the dominant fraction of AROS was cytoplasmic. As such, these
data do not formally identify a cytoplasmic Flag-AROS-RPS19 interaction but may
allow its inference from comparison of whole cell and nuclear extract data.
SIRT1 was present in the nuclear fraction but did not appear to co-
immunoprecipitate with Flag-AROS (Figure 7.2B and C). This suggests that Flag-
AROS does not associate with SIRT1 in the nucleus, and thus that the Flag-AROS-
SIRT1 interaction may be exclusively cytoplasmic. This has implications for the
regulation of SIRT1 by AROS, which was shown to require a direct interaction
between the proteins (Kim et al. 2007). Whether AROS regulates SIRT1 in the
nucleus is questioned by this observation.
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Figure 7.1: AROS interacts with RPS19 and SIRT1
(A) Time course of Flag-immunoprecipitation protocol. Cells were plated,
then transfected with Flag-AROS pcDNA3 in liposomes 24 hours later.
Control transfection was with liposomes only. After expression for 24 hours a
known quantity of protein from cell lysate was used in Flag-
immunoprecipitation for each condition. Flag-AROS expressing lysate was
immunoprecipitated with anti-Flag conjugated beads, in parallel to lysate with
no Flag-AROS overexpression (Control transfection). ‘No lysate’ control
immunoprecipitation was run using lysis buffer only. Flag peptide was used to
elute co-immunoprecipitated proteins for subsequent analysis. (B) Co-
immunoprecipitated proteins were loaded for SDS-PAGE according to
original quantity of protein loaded for immunoprecipitation. This was
analysed in excess as indicated (2 or 100 fold) against a known quantity of
original Input protein. Actin was used as a negative control that did not co-
immunoprecipitate. Dashed line represents different exposures. (*) represents
exogenous Flag-AROS, (†) represents endogenous AROS. (C) Quantification
of co-immunoprecipitated endogenous RPS19 and SIRT1 using Quantity One
software. Values represent the percentage of total RPS19 and SIRT1 protein
found to co-immunoprecipitate with Flag-AROS.
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Figure 7.2: Nuclear AROS interacts with RPS19
(A) Subcellular fractionation protocol to analyse Flag-AROS interactions in nuclear and cytoplasmic
compartments. HCT116 cells were separated into nuclear and cytoplasmic extracts and analysed by Flag-IP (see
Methods). Immunoprecipitation protocol was not possible from cytoplasmic extract due to buffer constraints.
(B) Analysis of nuclear and cytoplasmic immunoprecipitation. Lamin AC was used as a nuclear marker protein,
present in the nuclear Input only. (*) represents exogenous Flag-AROS, (†) represents endogenous AROS. Data
represents 20-fold more protein loaded in Flag-IP than Input. (B) Quantification of the percentage of total
RPS19 and SIRT1 that co-immunoprecipitated with Flag-AROS. Data calculated using Quantity One software.
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7.4 Molecular interactions of RPS19
Given the AROS-RPS19 and AROS-SIRT1 interactions confirmed above,
there was potential for an RPS19-SIRT1 interaction in the experimental system. To
analyse this tagged RPS19 protein was overexpressed in HCT116 cancer cells
according to the protocol shown in Figure 7.3A. This allowed Flag
immunoprecipitation as carried out for Flag-AROS. The recently discovered SIRT1
splice variant form (SIRT1-Δ8) was also analysed as a potential binding partner for
RPS19, given that SIRT1-Δ8 interacts with AROS (Lynch et al. 2010). The analysis
was carried out using exogenous SIRT1-FL and SIRT1-Δ8, because the endogenous
SIRT1-Δ8 could not be detected by antibody. Given that AROS is known to interact
with both isoforms of the SIRT1 gene, Flag-AROS was used as a positive control to
immunoprecipitate SIRT1-FL and SIRT1-Δ8.
7.4.1 RPS19 auto-association
Flag-Myc-RPS19 was detected in both experimental conditions when
overexpressed (lanes 1 and 3 –Figure 7.3B). The exogenous Flag-Myc-RPS19 (*)
migrated behind endogenous RPS19 (†) by SDS-PAGE and expressed at a similar
level. Myc-SIRT1-FL was detected when overexpressed (lane 1) as was Myc-
SIRT1-Δ8 (lane 3). Thus, co-expression of exogenous RPS19 and the SIRT1 isoform
proteins was possible.
Flag-Myc-RPS19 was immunoprecipitated by Flag antibody, being detected
in the immunoprecipitation lanes 5 and 7 (Figure 7.3B). Interestingly, where
exogenous Flag-Myc-RPS19 was immunoprecipitated a fraction of endogenous
RPS19 was also immunoprecipitated (Figure 7.3B). This implies that Flag-Myc-
RPS19 interacts with endogenous RPS19, potentially in a dimer. A role for covalent
RPS19 dimers has been characterised in relation to the immune response to
apoptosis (Yamamoto 2007). This auto-association may represent a non-covalent
precursor to this dimeric form.
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7.4.2 Flag-Myc-RPS19 and endogenous AROS
The successful over-expression and immunoprecipitation of Flag-Myc-
RPS19 allows the association of exogenous RPS19 and endogenous AROS to be
analysed. This forms the reciprocal analysis to those above using exogenous Flag-
AROS (Figure 7.1B). Endogenous AROS was co-immunoprecipitated by Flag-Myc-
RPS19, indicating that the two proteins associated (Figure 7.3C). This provides
further evidence in support of the hypothesis that ‘AROS and RPS19 associate in
human cells’.
7.4.3 RPS19 specifically associates with SIRT1-Δ8
Similar to endogenous AROS, overexpressed Myc-SIRT1-Δ8 co-
immunoprecipitated with Flag-Myc-RPS19 (Figure 7.3B). Importantly, exogenous
RPS19 did not appear to co-immunoprecipitate Myc-SIRT1-FL. Together this
implies that RPS19 is able to specifically complex with SIRT1-Δ8 over SIRT1-FL
(Figure 7.3C). Importantly, this is the first instance of a protein specifically
interacting with SIRT1-Δ8 over SIRT1-FL, and indicates that ‘RPS19 associates
with SIRT1-Δ8’. Furthermore, RPS19 and SIRT1-Δ8 may influence reciprocal 
protein functions via this interaction. This is analysed later in the Chapter. First, the
specificity of the novel RPS19-SIRT1-Δ8 interaction was confirmed by analysis of
the interaction of the SIRT1 isoform with Flag-AROS.
7.4.4 Flag-AROS interactions as a positive control
AROS is known to interact with both SIRT1-FL and SIRT1-Δ8 (Lynch et al.
2010) and was used here as a positive control for interaction with both proteins.
Flag-AROS was over-expressed in parallel immunoprecipitations to those above for
Flag-Myc-RPS19 (Figure 7.4A and B). In these experiments Flag-AROS appeared to
co-immunoprecipitate both exogenous Myc-SIRT1-FL (о) and Myc-SIRT1-Δ8 (‡),
as well as endogenous SIRT1-FL (<). Endogenous SIRT1-Δ8 could not be detected
by antibody. Nevertheless, these data indicate that AROS interacts with both variants
of the SIRT1 gene (Figure 7.4C). This is consistent with the previously reported
binding capacities of AROS (Kim et al. 2007; Lynch et al. 2010). This also provides
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a repeat analysis of the Flag-AROS-RPS19 interaction, which occurs as expected
(Figure 7.4B and C).
7.4.5 RPS19 binds SIRT1-Δ8 following applied stress
SIRT1-Δ8 is upregulated following the application of stress, and may
suppress the stress response by deacetylating p53 (Lynch et al. 2010). This implies
that SIRT1-Δ8 is important during the cellular response to stress. Thus, with
exogenous RPS19 and SIRT1-Δ8 able to associate in the absence of applied stress
(Figure 7.3B) the potential for an association following applied stress was analysed.
For this a modified overexpression protocol was used, with an extra 24 hours
between cDNA transfection and harvesting to allow for UV stress treatment (Figure
7.5A). The quantity of cDNA used for over-expression was reduced by half
accordingly.
Flag-Myc-RPS19 and Myc-SIRT1-Δ8 co-immunoprecipitated following the
application of UV irradiation stress to HCT116 cells (Figure 7.4B). This indicates
that the RPS19-SIRT1-Δ8 interaction may persist under conditions where SIRT1-Δ8
may have great physiological relevance.
Interestingly the interaction between Flag-Myc-RPS19 and endogenous
AROS was not observed following the application of UV stress (Figure 7.5B). This
may be attributable to the lower relative expression of exogenous Flag-Myc-RPS19
following applied stress compared to in the absence of applied stress (Figure 7.3B
compared to Figure 7.5B) As such, the abundant endogenous RPS19 may compete
for AROS protein following UV irradiation to a greater extent than in the absence of
applied stress. This could also explain the apparent loss of RPS19 dimer associations
following applied stress.
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Figure 7.3: RPS19 interacts with SIRT1-Δ8
(A) Time course of Flag-immunoprecipitation experiments. HCT116 cells were
plated then transfected 24 hours later with cDNA encoding Flag-Myc-RPS19 and
the SIRT1 splice variant constructs. Flag-Myc-RPS19 was immunoprecipitated
from whole cell lysates 24 hours after transfection by Flag-antibody conjugated
to agarose beads. Control transfected cells were treated with liposomes only, and
then used in identical parallel immunoprecipitation. Elution was with excess Flag
peptide. (B) Samples were analysed by SDS-PAGE and Western blotting with 20-
fold excess immunoprecipitated protein loaded compared to Input protein.
Overexpressed Flag-Myc-RPS19 (*) migrated behind endogenous RPS19 (†).
Overexpressed Myc-SIRT1-FL (о) migrated behind Myc-SIRT1-Δ8 (‡).  ‘No 
lysate’ represents immunoprecipitation using lysis buffer only. p53 was used as a
protein that did not interact with Flag-Myc-RPS19. (C) Schematic of RPS19
interactions. Flag-Myc-RPS19 associated with endogenous AROS and exogenous
SIRT1-Δ8. No association was seen with exogenous SIRT1-FL.
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Figure 7.4: AROS interacts with SIRT1-FL and SIRT1-Δ8
(A) Time course of Flag-immunoprecipitation experiments. HCT116 cells were
plated then transfected with cDNA encoding Flag-AROS and the SIRT1 splice
variant constructs 24 hours later. Flag-AROS was immunoprecipitated from
whole cell lysates 24 hours after transfection using Flag-antibody conjugated to
agarose beads. Control transfected cells were treated with liposomes only then
used in parallel identical immunoprecipitation. Elution was with excess Flag
peptide. (B) Samples analysed by SDS-PAGE and Western blotting.
Overexpressed Flag-AROS (*) migrated behind endogenous AROS (†).
Overexpressed SIRT1-FL (о) migrated behind endogenous SIRT1 (<). SIRT1-Δ8 
(‡) migrated ahead of endogenous SIRT1. ‘No lysate’ lane represents
immunoprecipitation using lysis buffer only. Actin was used as a negative control
for interaction with Flag-AROS. (C) Schematic of AROS interactions. Flag-
AROS interacts with endogenous RPS19 and SIRT1-FL, as well as exogenous
SIRT1-Δ8.
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Figure 7.5: RPS19 interacts with SIRT1-Δ8 following UV stress
(A) Time course of Flag-immunoprecipitation and UV stress experiments.
HCT116 cells were plated then transfected 24 hours later with cDNA
encoding Flag-Myc-RPS19 and Myc-SIRT1-Δ8. 24 hours after transfection 
cells were stressed by the application of UV irradiation at 10J m-2. Flag-Myc-
RPS19 was immunoprecipitated from whole cell lysates 48 hours after
transfection (24 hours after UV stress) by Flag-antibody conjugated to
agarose beads. Control transfected cells were treated with liposomes only and
used in parallel identical immunoprecipitation. Elution was with excess Flag
peptide. (B) Samples analysed by SDS-PAGE and Western blotting.
Overexpressed Flag-Myc-RPS19 (*) migrated behind endogenous RPS19 (†).
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7.5 SIRT1-Δ8 regulation of RPS19
The immunoprecipitation data above indicate that RPS19 forms a specific
interaction with the SIRT1-Δ8 splice variant of the SIRT1 gene. The remainder of
this Chapter analyses the potential regulation of RPS19 by SIRT1-Δ8 via this
molecular interaction. This utilises a specific siRNA against the SIRT1-Δ8 isoform,
which targets the novel splice junction between exons 7 and 9 in SIRT1-Δ8.
7.5.1 mRNA knockdown
Use of SIRT1-Δ8 siRNA in the HCT116 cell line depleted SIRT1-Δ8 mRNA
expression compared to control, as analysed by RT-PCR (Figure 7.6A). Due to the
requirement to use a primer across the SIRT1-Δ8 exon 7 to 9 splice junction, qRT-
PCR could not be performed to amplify SIRT1-Δ8 mRNA (Lynch et al. 2010).
Commercially available antibodies are unable to detect endogenous human SIRT1-
Δ8 protein. Thus, analysis of the resulting knockdown of SIRT1-Δ8 was not
possible.
7.5.2 Cell phenotype
Targeting of SIRT1-Δ8 across 4 cell lines of cancerous (HCT116, DLD1 and
MCF7) and non-cancerous (WI38) origin did not greatly alter the phenotype
compared to Mock treatment (Figure 7.6B). In the MCF7 cell line there was an
apparent effect. SIRT1-Δ8 siRNA appeared to reduce cell density compared to Mock
treatment, with the cells appearing refringent under phase contrast microscopy. This
may be indicative of suppression of cell cycle progression in MCF7 cells, perhaps
consistent with SIRT1-Δ8 suppressing p53 (Lynch et al. 2010). In the other 3 cell
lines silencing of SIRT1-Δ8 did not greatly affect cell density or morphology
compared to Mock treatment.
7.5.3 SIRT1-Δ8 promotes RPS19 protein
SIRT1-Δ8 appeared to affect RPS19 protein abundance upon analysis by
Western blot. In each of the 4 cell lines analysed targeting of SIRT1-Δ8 reduced the
protein abundance of RPS19 compared to Mock treatment of cells (Figure 7.7A).
RPS19 mRNA was not negatively affected by loss of SIRT1-Δ8 (Figure 7.7B),
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suggesting that the effect SIRT1-Δ8 has upon RPS19 occurs at the protein level. In
the MCF7 cell line silencing of SIRT1-Δ8 actually increased RPS19 mRNA
expression compared to Mock treatment. This has parallels to the protein level
regulation of RPS19 by AROS in Chapter 6, suggesting that SIRT1-Δ8 may play a
role in the regulation of RPS19 by AROS (Figure 7.7C). This possibility is perhaps
supported by the association of AROS and SIRT1-Δ8 (Lynch et al. 2010), which
both also interact with RPS19 (this Chapter).
Knockdown of SIRT1-Δ8 had a variable effect of AROS abundance across
the 4 cell lines analysed. In the HCT116 and DLD1 cancer cell lines the protein
abundance of AROS was not affected by knockdown of SIRT1-Δ8 (Figure 7.7A).
This is despite the loss of RPS19, which was previously seen to result in loss of
AROS in Chapter 6. In the HCT116 cell line targeting of SIRT1-Δ8 reduced the
abundance of AROS mRNA compared to Mock treatment (Figure 7.7B) but this did
not translate to a reduction in total AROS protein. Stability of AROS may be
attributable to apparent higher stability of AROS in these colorectal adenocarcinoma
cell lines (see Chapter 4).
In the MCF7 mammary epithelial cancer cell line AROS protein abundance
was reduced by SIRT1-Δ8 knockdown, despite no reduction in AROS mRNA
(Figure 7.7A and B). Similarly, in the WI38 cell line AROS protein, but not mRNA,
abundance may have been reduced by knockdown of SIRT1-Δ8, although the
Western blot is open to interpretation. Together these data suggest that SIRT1-Δ8
may promote AROS protein abundance in a similar manner to its apparent
promotion of RPS19 protein above. This could give SIRT1-Δ8 an important role in
the AROS-RPS19 autoregulatory loop.
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Figure 7.6: Targeting SIRT1-Δ8 by siRNA
(A) mRNA abundance of SIRT1-Δ8 and GAPDH in HCT116 cells treated
with SIRT1-Δ8 siRNA. Total RNA was isolated by RNeasy method and 
analysed by RT-PCR. cDNA product was visualised by agarose gel
electrophoresis using ethidium bromide and UV transillumination. (B) Phase
contrast micrographs of cell lines treated with RNAi specifically against
SIRT1-Δ8 prior to harvesting at 48 hours (HCT116, DLD1 and MCF7) or 72 
hours (WI38) post-transfection.
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Figure 7.7: SIRT1-Δ8 knock down results in loss of RPS19 protein
(A) Expression of AROS and RPS19 proteins following targeting of SIRT1-
Δ8 by siRNA. Cell lines were transfected with siRNA then harvested 48 hours 
(HCT116, DLD1 and MCF7) or 72 hours (WI38) post-transfection. Whole
cell protein was isolated and loaded onto SDS-PAGE according to calculated
protein mass. Actin was used as a loading control. (B) Expression of AROS
and RPS19 mRNA following targeting of SIRT1-Δ8 by siRNA. RNA was 
isolated by RNeasy method and analysed by qRT-PCR (Methods). mRNA
abundance was standardised against Actin (HCT116, DLD1 and WI38) or
GAPDH (MCF7) mRNA abundances. ** P<0.01. (C) Schematic of potential
regulation of the AROS-RPS19 autoregulatory loop by SIRT1-Δ8.
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7.6 Discussion
7.6.1 Implications of the AROS-RPS19 association
The observation of an association between exogenous Flag-AROS and
endogenous RPS19 (Figure 7.1B), and the reciprocal association between Flag-Myc-
RPS19 and AROS (Figure 7.3B) is compelling evidence for conservation of the
AROS-RPS19 interaction originally identified in the mouse (Maeda et al. 2006).
This appears to confirm the hypothesis that ‘AROS and RPS19 associate in human
cells’. The original AROS-RPS19 association was characterised as a direct
interaction between the two proteins, suggesting that the association seen here is also
a direct interaction.
The interaction of AROS and RPS19 has implications for the autoregulatory
loop identified between the proteins (Chapter 6). It appears likely that the AROS-
RPS19 autoregulatory loop involves the direct interaction of the proteins. One
possibility is that the AROS-RPS19 complex is less liable to degradation than the
individual proteins. RPS19 was recently reported to be actively degraded by the
proteasome (Cretien et al. 2008), potentially supporting this hypothesis. The data
suggest that interaction with AROS may reduce the proteasomal degradation of
RPS19. Given the reciprocal nature of the AROS-RPS19 relationship, this also
appears to protect AROS from degradation. Future analysis into the proteasomal
degradation of RPS19 and/or AROS would be required to analyse this. Importantly
this data does not rule out a mechanism governing AROS and RPS19 protein
stability linked to ribosome stability, which remains a possibility.
Interestingly the AROS-RPS19 interaction appears to occur in the nucleus of
HCT116 cells, whereas the AROS-SIRT1 interaction was less prevalent in this
compartment (Figure 7.2B). RPS19 is required for ribosome synthesis, which occurs
within the nucleolus, a subnuclear structure (Choesmel et al. 2007; Flygare et al.
2007; Idol et al. 2007). The interaction between AROS and RPS19 within the
nucleus may be indicative of a functional role of AROS in ribosome synthesis. This
possibility is analysed in Chapter 8.
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7.6.2 Auto-association of RPS19
In Figure 7.3 exogenous Flag-Myc-RPS19 co-immunoprecipitated
endogenous RPS19 protein. This implies that RPS19 is able to form dimers. RPS19
acts as a monomeric protein during ribosome biogenesis and subsequent activity.
However, a covalently ligated dimeric form of RPS19 has been identified and
characterised (Nishiura et al. 1998). The non-covalent RPS19 dimer potentially
identified here could represent a precursor to this covalent dimeric form.
The RPS19 dimer is formed during apoptosis by the ligation of lysine 122
from one RPS19 molecule to glutamine 137 of a second RPS19 molecule (reviewed
by Yamamoto 2007). Extracellular RPS19 dimer acts as a selective chemo-attractant
for monocytes over neutrophils, which assists in the clearance of post-apoptotic cell
debris (Oda et al. 2008). The outcome of this is an acute immune response to routine
cell death promoted by monocytes, as opposed to a chronic inflammatory response
which would arise from neutrophil recruitment and activation.
During the analyses of RPS19 no covalently bound dimeric forms were
observed, which would migrate slower by SDS-PAGE. This is consistent with the
documented excretion of the covalent dimeric form from the cell, and does not rule
out the possibility that the dimer observed here contributes to the covalent dimer
described.
The presence of RPS19-RPS19 interactions may influence binding to AROS.
As such, the high abundance of the RPS19 interaction with AROS may be
attributable to dimerisation of RPS19. The dimerisation may increase the apparent
total RPS19 co-immunoprecipitated by Flag-AROS as multiple protein molecules
may have associated with a single Flag-AROS. However, the RPS19 dimerisation
appears to be a low abundance interaction and may or may not occur when AROS
associates with RPS19. Thus, although not confirmed, it seems likely that the
majority of the Flag-AROS-RPS19 association is not the result of RPS19
dimerisation, and that the AROS-RPS19 association is highly abundant.
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7.6.3 RPS19 association with SIRT1-Δ8
RPS19 appeared to specifically interact with a splice variant of SIRT1 and
not the full length protein (Figure 7.3B). The RPS19-SIRT1-Δ8 interaction appeared
to be abundant, but is of unknown significance. Interestingly, AROS interacts with
both the SIRT1-FL and SIRT1-Δ8 variants of the SIRT1 gene (This work and Lynch
et al. 2010). The effect of AROS on SIRT1-Δ8 is not known, and this data does not
indicate whether AROS and RPS19 are able to bind SIRT1-Δ8 simultaneously.
The specificity of the interaction raises the question of how does RPS19
interact with SIRT1-Δ8 but not SIRT1-FL? Other than lacking exon 8 the two
proteins are identical. However the SIRT1-Δ8 protein has a novel peptide sequence
across the splice junction, which may permit specific interactions (Figure 7.8A).
Furthermore, SIRT1-Δ8 lacks residues that bind substrates in SIRT1-FL, suggesting
that substrate specificity may be altered between the two isoforms (Lynch et al.
2010). There is no evidence of acetylation of RPS19 in the literature, suggesting that
it is not party to reversible modification in this way. However, given the role of
SIRT1-Δ8 as a deacetylase enzyme, the possibility that RPS19 is a specific substrate
for SIRT1-Δ8 cannot be ruled out (Figure 7.8A).
Conversely, specificity may be mediated by the SIRT1-FL interactome.
RPS19 binding to SIRT1-FL may be occluded by association of proteins that bind in
exon 8, meaning that loss of exon 8 in the SIRT1-Δ8 isoform promotes association
of RPS19 (Figure 7.8A). These hypothetical mechanisms of the specific interaction
between SIRT1-Δ8 and RPS19 require further analysis to validate. However, this
was not undertaken here, with the focus instead on functions of the SIRT1-Δ8-
RPS19 association.
7.6.4 RPS19 in SIRT1-Δ8 function
Both SIRT1-Δ8 and RPS19 suppress p53 acetylation (Danilova et al. 2008;
McGowan et al. 2008; Lynch et al. 2010; Dutt et al. 2011; Jaako et al. 2011). SIRT1-
Δ8 suppresses p53 via direct deacetylation, which is required for transactivation of
p53 target genes (Tang et al. 2008). The mechanism of RPS19 suppression of p53 is
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unknown. It is possible that RPS19 suppresses p53 via its association with SIRT1-
Δ8.
In Chapter 6 RPS19 promoted AROS protein stability, suggesting that
RPS19 promotes p53 suppression by AROS. RPS19 also appeared to promote
SIRT1-FL protein stability in some cell lines, suggesting that RPS19 may suppress
p53 via SIRT1-FL. The data here suggest that the RPS19 does not promote SIRT1-
FL protein abundance via association. However, the data do indicate that RPS19 may
be able to suppress p53 via a number of distinct mechanisms involving AROS and
multiple isoforms of the SIRT1 gene (Figure 7.8B).
7.6.5 SIRT1-Δ8 in RPS19 function
Knockdown of SIRT1-Δ8 resulted in a reduction in RPS19 protein
abundance in four cell lines (Figure 7.7A). This may have also resulted in loss of
AROS protein, which has been associated with RPS19 knockdown. Thus it appears
that SIRT1-Δ8 may promote RPS19 abundance and possibly function. This may
occur via the interaction between SIRT1-Δ8 and RPS19 which is also reported in
this Chapter. The potential for a role of AROS in the function of RPS19 was
identified in Chapter 6, and supplemented by the observation of AROS-RPS19
association in this Chapter. RPS19 is essential for specific steps during ribosome
biogenesis in human cells (Choesmel et al. 2007; Flygare et al. 2007; Idol et al.
2007). Thus, the next Chapter focuses on a potential role for both AROS and SIRT1-
Δ8 in ribosome biogenesis.
Figure 7.8: RPS19 and isoforms of
(A) Schematic representation of SIRT1
mechanisms for the specific interaction of RPS19 with
occlusion of RPS19 from binding SIRT1
two isoforms and RPS19 binding to the novel peptide sequence of SIRT1
Suppression of p53 by RPS19 may occur via modulation of AROS and
isoform function.
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SIRT1
-FL and SIRT1-Δ8, showing potential
SIRT1-Δ8. These are,
-FL, differences in the catalytic site of the
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7.7 Conclusions
1. AROS and RPS19 associate in human cells.
2. RPS19 specifically associates with SIRT1-Δ8 over SIRT1-FL.
3. SIRT1-Δ8 promotes RPS19 protein level abundance.
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8 Regulation of ribosome biogenesis
8.1 Overview
This final results Chapter analyses the role of AROS and SIRT1-Δ8 in the
regulation of RPS19 during ribosome biogenesis. This builds on Chapter 6 and
Chapter 7, where molecular interactions and relationships between AROS, RPS19
and SIRT1-Δ8 were characterised. Analysis utilised siRNAs against AROS and
SIRT1-Δ8 to compare the outcome against the use of RPS19 siRNA.
AROS is found to have a role in ribosome biogenesis, with parallels to the role
of RPS19. AROS specifically affects 40S ribosomal RNA and proteins.
Furthermore, sucrose density ultracentrifugation identifies an association of AROS
with 40S subunits and mature 80S ribosomes. Finally, SIRT1-Δ8 is found to have a
role in ribosome biogenesis, building on the specific interaction between SIRT1-Δ8
and RPS19 seen in Chapter 7.
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8.2 Introduction
8.2.1 The eukaryotic ribosome
Ribosomes catalyse the synthesis of protein, doing so with high fidelity at
high speed according to the sequence of mRNA. Ribosomes are essential to translate
the nucleotide encoded genetic code into the functional form that is the proteome.
All cells, from single celled bacteria to mammalian cells, including plant cells,
archaea and fungi, rely on ribosomes for production of protein. It is thought that
ribosomes represent one of the earliest developments that allowed cellular life to
exist. Over millennia of evolution the function of ribosomes in each branch of life
has remained the same, but the specific structures have diverged (Hage and
Tollervey 2004; Dinman 2009).
Translating ribosomes are in fact the association of two ribosomal subunits
upon mRNA. These are termed the small and the large subunit. In higher eukaryotes
these are referred to as 40S and 60S respectively, due to their relative density upon
sedimentation (Figure 8.1A). Together the 40S and 60S subunits form the 80S
ribosome. 40S and 60S subunits are free in the cytoplasm prior to mRNA binding to
a 40S subunit. Binding triggers association of the 60S subunit and the initiation of
translation.
Ribosomes are ribonucleoproteins as they consist of both RNA and protein
elements. There are four ribosomal RNAs (rRNAs) and 80 ribosomal proteins in the
eukaryotic ribosome. The 40S subunit contains a single rRNA (the 18S rRNA) and
33 ribosomal proteins (Figure 8.1A). The 60S subunit is larger and comprises 3
rRNAs (the 5S, 5.8S and 28S rRNAs) and 47 proteins (Figure 8.1A). Recent
structures of the eukaryotic ribosome reveal the location of the ribosomal proteins
and RNAs across each subunit (Taylor et al. 2009; Ben-Shem et al. 2010; Rabl et al.
2011). This will be used as a powerful tool for interpretation of the results presented
in this Chapter.
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8.2.2 Ribosome biogenesis
Unsurprisingly for such large and complex macromolecules the synthesis of
ribosomes is highly complex, energy consuming and regulated in the cell. Ribosome
biogenesis involves the coordinated function of transcription machinery to produce
rRNA and ribosomal protein mRNA, synthesis of the ribosomal proteins and
assembly of each subunit from its component parts. Add to this the actions of a
multitude of ribosome biogenesis factors, which are both proteins and small RNAs,
and the number of molecules that are involved in synthesis of each ribosome is in the
100s (Freed et al. 2010; Kressler et al. 2010).
Ribosome biogenesis occurs primarily in nucleoli, which are subnuclear
organelles centred on the ribosomal DNA genes (rDNA). However, the complex
process stretches beyond the nucleus, with elements such as ribosomal protein
synthesis and the final nucelolytic cleavage of pre-18S rRNA occurring in the
cytoplasm (Figure 8.1A and Rouquette et al. 2005). This adds an extra level to
ribosome biogenesis, with subcellular trafficking both into and out of the nucleus
demanding further regulation and consumption of energy.
Importantly, biogenesis of each ribosomal subunit occurs independently via
parallel pathways (Figure 8.1A and Hadjiolova et al. 1993). This is maintained at a
stoichiometric ratio of 1:1 by the co-transcription of rRNA components for both the
small and large subunits. rDNA is transcribed into a single long pre-rRNA termed
the 45S pre-rRNA. The sequences that ultimately form the 18S, 5.8S and 28S rRNAs
are present within this pre-rRNA, separated by transcribed spacers (Figure 8.1B).
Endonucleolytic cleavage within the 5’ internal transcribed spacer separates the 40S
subunit constituent (18S rRNA) from the 60S subunit components (5.8S and 28S
rRNA). 5S rRNA is transcribed independently of 45S pre-rRNA transcription to
contribute to the 60S subunit.
Further nucelolytic cleavages of pre-rRNA yield the final rRNA forms
present in each subunit (Figure 8.1B). This occurs in parallel to ribosomal protein
loading onto rRNAs in macromolecular complexes called the small and large subunit
processomes. Indeed ribosomal proteins are not passive during pre-rRNA
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processing, being required for the nucelolytic steps in synthesis of each ribosomal
subunit (Robledo et al. 2008). This indicates that ribosomal protein association is
essential for rRNA processing. As such, the biogenesis of each subunit from rRNA
and protein occurs while the rRNA is being processed (Figure 8.1A).
8.2.3 The role of RPS19 in ribosome biogenesis
As previously discussed, RPS19 is a structural component of the small
ribosomal subunit, present in the head region of the eukaryotic ribosome (Taylor et
al. 2009; Ben-Shem et al. 2010; Rabl et al. 2011). However, as well as being a
structural component, RPS19 is essential for the synthesis of 40S ribosomal subunits.
RPS19 is required for the final nuclear cleavage of the 3’ end of precursor rRNA
which ultimately yields the 18S rRNA of the 40S subunit in human cells (cleavage
step indicated by [*] in Figure 8.1B). Thus, reduction in RPS19 expression results in
reduced abundance of mature 40S subunits and a concomitant reduction in 80S
ribosomes (Choesmel et al. 2007; Flygare et al. 2007; Idol et al. 2007).
The mechanism by which RPS19 promotes this cleavage event is unknown.
It has been proposed that RPS19 is required for recruitment of factors involved in the
cleavage of the 3’ end of 18S rRNA (Taylor et al. 2009). RPS19 is surface accessible
in structures of the 40S subunit and located in proximity to the hypothesised position
of the 3’ end of pre-18S rRNA prior to cleavage (Rabl et al. 2011). The nuclease
required for this cleavage has yet to be formally recognised. RCL1 has been
proposed as this nuclease, but current data is conflicting (Horn et al. 2011; Tanaka et
al. 2011). Nevertheless the role for RPS19 has been well demonstrated and given the
positive effect of both AROS and SIRT1-Δ8 upon RPS19 protein abundance
(Chapter 6 and Chapter 7), the roles of these two proteins in RPS19 function are
analysed and discussed below.
8.2.4 AROS and SIRT1-Δ8 in ribosome function
Any role for AROS in relation to the ribosome would be a novel observation.
The possibility of a ribosomal association of AROS was first identified in Chapter 4,
where a large proportion of AROS protein was seen to reside in the cytoplasm of
both HCT116 and ARPE19 cells. The possibility of association also draws upon the
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observation that AROS directly interacts with RPS19 in the mouse (Maeda et al.
2006), with the association of the two proteins also observed in Chapter 7.
In Chapter 6 AROS was seen to promote RPS19 protein abundance. Thus it
appears possible that AROS may influence the function of RPS19 via promoting its
abundance. This could reveal a novel role for AROS in regulating the ribosome.
Similarly, SIRT1-Δ8 promotes RPS19 abundance (see Chapter 7) revealing the
possibility that SIRT1-Δ8 too has a role in regulating ribosome function. These
possibilities form the analysis in this Chapter.
8.2.5 Hypotheses
1. AROS associates with the ribosome.
2. AROS promotes ribosome biogenesis via RPS19.
3. AROS promotes cancer cell survival by promoting ribosome biogenesis.
4. SIRT1-Δ8 has a role in ribosome biogenesis.
Figure 8.1: Schematics of ribosome biogenesis
(A) Ribosomal RNA is transcribed from rDNA into a precursor termed the 45S pre
rRNA. This is cleaved into 18S (small subunit) and 5.8S and 28S (both large
subunit) rRNAs. 5S rRNA is produced independently and is requir
subunit. Ribosomal protein genes are transcribed then translated into the 80
ribosomal proteins. Assembly of 40S small subunits and 60S large subunits is
parallel and stoichiometric, due to early cleavage of 45S pre
combine upon mRNA to form translating 80S ribosomes.
processing pathways by endonucleolytic cleavage. 45S pre
annotated with internal (ITS) and external (ETS) transcribed spacers. Processing can
occur via either of two pathways
final products are identical. qRT
are indicated as white boxes.
A
B
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8.3 Association of AROS with ribosomes
8.3.1 Ribosomal subunits and mature ribosomes
Quantification of RNA abundance through a sucrose density ultracentrifuge
gradient of cytoplasmic lysate from cycling untreated HCT116 cells revealed distinct
peaks for ribosomal subunits and the 80S ribosome (Figure 8.2A). This is a
characteristic profile of ribosomal subunits and ribosomes seen in such experiments
(for example see Choesmel et al. 2007). The 80S ribosome migrates furthest into the
gradient due to its high relative density. Here 80S ribosomes penetrated into the 11th
and 12th fractions taken from the gradient. Polysomes were not detected at high
abundance in any sucrose density gradients and thus did not form part of the
analysis. The 60S large ribosomal subunit is less dense, settling above the 80S
ribosome, predominantly in fraction 9. Less dense again was the 40S small subunit,
giving a peak in fractions 6 and 7. The RNA content in the higher fractions (lanes 5
and below) represents non-ribosome associated mRNAs, tRNAs and other
miscellaneous small RNAs with lower density.
The distribution of these peaks was confirmed by analysis of ribosomal
proteins from both the small and large ribosomal subunits by Western blotting
(Figure 8.2B). Two 40S subunit proteins – RPS6 and RPS19 – were found in two
distinct populations within the fractions of the gradient: lanes 6 to 8, representing
free small ribosomal subunits; and lanes 11 to 13, representing 80S ribosomes. A
large subunit protein, RPL3, was also found in lanes 11 to 13, consistent with these
fractions representing the 80S ribosome. RPL3 protein in fractions 9 and 10 appears
to represent free large ribosomal subunits, also given the absence of small ribosomal
proteins from these fractions. RPL3 is known to form inter-subunit links in the
eukaryotic ribosome (Ben-Shem et al. 2010), suggesting that RPL3 in lanes 5 to 7
represents an association with the small ribosomal subunit.
Application of antibodies against AROS and SIRT1 across these fractions
revealed the potential for association of AROS with the ribosome, but no association
of SIRT1 (Figure 8.2B). AROS was detected in a population in lanes 6 and 7, which
represents the small ribosomal subunit (see above). This is consistent with the
association between AROS and the small ribosomal subunit protein RPS19
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identified in Chapter 7 and the hypothesis that ‘AROS associates with the ribosome’.
However, the detection of AROS in these lanes was weak, leaving this interpretation
open to debate. AROS also appeared to associate with 80S ribosomes, with protein
seen in fractions 11 to 13. AROS in fractions 14 and 15 may represent association
with polysomes. SIRT1 protein was not found in any of the fractions analysed,
suggestive of no interaction with either ribosomal subunit. This acts as a negative
control protein within this analysis. This represents SIRT1-FL protein, SIRT1-Δ8
association with ribosomes was not analysed.
8.3.2 Ribosomal proteins
Immunoprecipitation of Flag-AROS allowed the interaction between AROS
and ribosomal proteins to be assessed. This was carried out on the same samples
shown in Chapter 7 – Figure 7.5A, where SIRT1-FL and SIRT1-Δ8 were
overexpressed with Flag-AROS (Figure 8.3). The data are similar for overexpression
of each splice variant, suggesting that their expression did not alter the association of
AROS with other proteins.
Flag-AROS co-immunoprecipitated both endogenous RPS19 and RPS6 from
the small ribosomal subunit (Figure 8.3). RPS19 and RPS6 reside on opposite sides
of the 40S subunit, indicating that the interaction of AROS with both proteins may
represent an interaction with the small subunit as a whole (Taylor et al. 2009; Ben-
Shem et al. 2010; Rabl et al. 2011). This adds greatly to the hypothesis that ‘AROS
associates with the ribosome’.
Interestingly, the Flag-AROS association with RPS19 represents a larger
proportion of this ribosomal protein than the Flag-AROS interaction with RPS6.
RPS19 and RPS6 are present in the 40S subunit in equal stoichiometric quantity.
This could indicate that the AROS-RPS19 interaction is at least in part extra-
ribosomal, due to the higher proportion of RPS19 that interacts compared to RPS6.
Flag-AROS also appeared to co-immunoprecipitate RPL3 from the large
ribosomal subunit (Figure 8.3). This interaction represented a small but significant
fraction of the total RPL3. This suggests that AROS associates with large ribosomal
subunits, presumably in association with 40S subunits. This is supported by the
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sucrose density ultracentrifuge analysis where AROS was found in fractions
attributed to the 80S ribosome, but not 60S large ribosomal subunit (Figure 8.2).
However, it is possible that RPL3 associates with small ribosomal subunits via its
known location at the subunit interface, which may explain the AROS association
with RPL3.
Taken together, the sucrose density ultracentrifuge and immunoprecipitation
data suggest that ‘AROS associates with the ribosome’, specifically the small
ribosomal subunit (Figure 8.4A). This appears to be specific to small subunits, with
association not seen with the large ribosomal subunit (Figure 8.4B). Small ribosomal
subunit association is presumably mediated by the direct interaction between AROS
and RPS19 reported in the mouse (Maeda et al. 2006), and likely conserved in
human (Chapter 7 and Orru et al. 2007). The co-immunoprecipitation of 3 ribosomal
proteins with Flag-AROS, from both the small and large subunits is suggestive of an
association with the translating 80S ribosome (Figure 8.4C). An association with the
small ribosomal subunit may also indicate a role in ribosome biogenesis. This was
investigated using siRNA against AROS and analysing the effect on ribosomal
proteins, rRNAs and ribosomal subunits.
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Figure 8.2: AROS associates with small ribosomal subunits and
80S ribosomes
(A) OD260nm analysis of ribosomal subunit rRNA from HCT116 cytoplasmic
lysate. HCT116 cytoplasm was isolated and separated by sucrose density
ultracentrifugation (see Methods). RNA content of subsequent fractions were
analysed for RNA content by optical density (OD) at 260nm. Peaks
corresponding to 40S and 60S subunits as well as the 80S ribosome are
annotated. (B) SDS-PAGE separation and Western blotting analysis of fractions
generated in (A). Fractions were loaded by equivalent volume. Samples were
probed for ribosomal proteins, AROS and SIRT1 as indicated. SIRT1 protein
was detected in a positive control sample included in the Western blot.
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Figure 8.3: Flag-AROS co-immunoprecipitates ribosomal
proteins
Analysis of ribosomal proteins that co-immunoprecipitate with Flag-
AROS. HCT116 cells were transfected with pcDNA3 Flag-AROS, Myc-
SIRT1-FL or Myc-SIRT1-Δ8 constructs as indicated. Flag-AROS was
immunoprecipitated from whole cell lysates 24 hours after transfection
by Flag-antibody conjugated to agarose beads. Elution was with excess
Flag peptide. Samples were analysed by SDS-PAGE and Western
blotting for indicated protein abundance. Data represents samples as
analysed in Figure 7.5.
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Figure 8.4: Schematic of AROS association
Schematics of the interactions of AROS with ribosomal subunits and ribosomal
proteins. (A) AROS associates with free small ribosomal subunits. This potentially
explains the association with RPS19 and RPS6, which reside on opposite sides
small subunit. (B) AROS does not appear to associate with free large subunits,
indicated by grey bar.
small and large subunits. This may explain the association with RPL3 protein, which
is a component of the large subunit.
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8.4 AROS and ribosome biogenesis in cancer cells
8.4.1 AROS and ribosomal proteins
AROS promotes the abundance of RPS19 protein in an autoregulatory loop
(see Chapter 6). This effect is again observed here in the HCT116 and MCF7 cells
lines (Figure 8.5A). Loss of p53 negates the effect AROS has upon RPS19, reported
in Chapter 6 and shown again here (Figure 8.5A). To expand this analysis the effect
of AROS silencing on two further ribosomal proteins was analysed – RPS6 from the
small subunit and RPL3 from the large subunit – in parallel to RPS19 silencing.
Silencing of RPS19 resulted in depletion of RPS6 protein in all 3 human
cancer cell lines analysed – the HCT116, HCT116 p53-/- and MCF7 lines (Figure
8.5A). RPS19 had no effect on RPL3 protein expression in the HCT116 and
HCT116 p53-/- cell lines, with a slight reduction seen in the MCF7 cell line. This is
largely consistent with a small ribosomal subunit specific effect following RPS19
silencing.
Parallel silencing of AROS decreased the abundance of RPS6 protein
compared to Mock treatment in the HCT116 and MCF7 cell lines (Figure 8.5A).
This occurred to a similar extent as the reduction in RPS6 seen following RPS19
silencing in the HCT116 cell line (both giving RPS6:Actin ratio of 0.8), but to a
lesser extent in the MCF7 cell line. In the HCT116 p53-/- cell line RPS6 protein was
not greatly depleted compared to Mock treatment. This correlates with the lack of
RPS19 depletion following AROS silencing in this p53 null cell line. As such, it
appears that loss of RPS6 protein correlates with depletion of RPS19, either
following RPS19 siRNA treatment or loss of RPS19 associated with knock down of
AROS. RPL3 protein abundance did not appear to be affected following RNAi
against AROS in all cancer 3 cell lines. This is consistent with a small ribosomal
subunit specific effect role for AROS, and is the first indication that ‘AROS
promotes ribosome biogenesis via RPS19’.
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8.4.2 AROS and ribosomal RNAs
Ribosomes comprise of both protein and RNA, and it is the RNA element
that performs the key catalytic and regulatory functions to ensure rapid translation
with high fidelity. Transcription of the 18S and 28S ribosomal RNAs occurs in
tandem from ribosomal DNA genes, producing stoichiometric biogenesis pathways
yielding the 40S and 60S subunits (see Introduction and Hadjiolova et al. 1993).
Thus, factors effecting the transcription of rRNA affect the abundance of both 18S
and 28S forms, whereas factors specifically effecting one rRNA may have a role in
the synthesis of the relevant ribosomal subunit. A specific effect of RPS19 on 18S,
40S subunit, rRNA has previously been reported (Choesmel et al. 2007; Flygare et
al. 2007; Idol et al. 2007).
To analyse the role of AROS and RPS19 in regulating rRNA abundance,
amplicons specific to regions within the 18S and 28S mature rRNAs were designed,
as indicated schematically in Figure 8.1. These were used on isolated nuclear RNA,
such that the amplicons amplified regions from the nuclear precursors of each mature
rRNA, as shown in Figure 8.1. The analysis was restricted to the nuclear fraction
because this is the site of ribosome synthesis, with rRNA in this fraction likely to
alter the greatest should modulation of ribosome biogenesis occur. Analysis of
nuclear rRNAs also removes the effect of pre-existing ribosomes in the cytoplasm,
which may dilute the effects in the nucleus.
Consistent with a role in small subunit synthesis, silencing of RPS19 resulted
in a specific reduction in the 18S rRNA amplicon within nuclei of HCT116 and
HCT116 p53-/- cells (Figure 8.5B). Nuclear 40S subunit RNA content is reduced to
below 60% of control cells in both cases. In contrast no alteration in the abundance
of 28S rRNA from the large ribosomal subunit was observed. This is consistent with
a specific role for RPS19 in small ribosomal subunit synthesis (Choesmel et al.
2007; Flygare et al. 2007; Idol et al. 2007), and the data for ribosomal protein
abundance following RPS19 silencing (Figure 8.5A).
Silencing of AROS resulted in a reduction in the 18S rRNA amplicon in the
HCT116 cell line (Figure 8.5B). The reduction was comparable to that seen
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following silencing of RPS19, and is consistent with the reduction in RPS19 protein
following AROS knock down (Figure 8.5A). 28S rRNA from the large subunit did
not appear to be affected by silencing of AROS, with abundance similar to that of
Mock treated cells. As such, it appears that AROS promotion of RPS19 protein
abundance correlates with potential AROS promotion of RPS19 function in
maintaining nuclear small ribosomal subunit rRNA levels. As such, this supports the
hypothesis that ‘AROS promotes ribosome biogenesis via RPS19’. However, it is
equally possible that AROS regulates ribosome biogenesis and RPS19
simultaneously, given the crucial role of RPS19 in ribosome biogenesis.
Maintenance of RPS19 protein abundance following silencing of AROS in
the HCT116 p53-/- cell line correlated with no effect on small ribosomal subunit
rRNA (Figure 8.5A and B). Silencing of AROS in the HCT116 p53-/- cell line did
not affect nuclear 18S or 28S rRNA abundance compared to Mock treatment. This
suggests that the effect AROS has upon ribosomal proteins and rRNA are linked –
reduction in ribosomal protein correlates with reduction in rRNA. This is further
evidence that the presence of p53 is important for AROS in the regulation of RPS19,
and also suggests a role for p53 in the regulation of ribosome biogenesis.
It appears that AROS affects RPS19 abundance as well as the stability of
other small ribosomal subunit proteins (RPS6) and 18S rRNA precursors. This may
occur by a number of mechanisms; AROS may regulate extra-ribosomal RPS19,
which in turn regulates small ribosomal subunit component abundance, or AROS
may directly regulate the small ribosomal subunit, presumably via its direct
interaction with RPS19 (Maeda et al. 2006). The association of AROS with small
ribosomal subunits and 80S ribosomes is perhaps suggestive of the latter possibility
(Figure 8.2B).
8.4.3 AROS and ribosomal subunits
Given the effect of AROS and RPS19 silencing on ribosomal proteins and
RNA in the HCT116 colorectal adenocarcinoma cell line, the effect this has upon
cytoplasmic subunits and mature ribosomes was analysed by sucrose density
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ultracentrifugation. RPS19 is known to specifically affect small ribosomal subunits
in this context and was thus used as a positive control.
Analysis of isolated cytoplasm from Mock treated cells in parallel to RPS19
silencing revealed OD260nm peaks for 40S subunits, 60S subunit and 80S
ribosomes as annotated (Figure 8.6A). Following silencing of RPS19 the 40S peak
appeared to be reduced compared to Mock treatment, indicative of a reduction in the
abundance of synthesised 40S subunits. There was little effect on the abundance of
60S subunits, consistent with RPS19 specifically effecting the small ribosomal
subunit. 80S ribosomes consist of 40S and 60S subunits, with a reduction in 40S
subunits likely to result in reduced 80S ribosome abundance. Thus the reduction in
40S subunits following RPS19 silencing correlated with a reduction in 80S
ribosomes compared to Mock treatment (Figure 8.6A).
Silencing of AROS was carried out in a separate analysis in HCT116 cells.
Variation was evident in the OD260nm profile of the Mock treatment between
experiments (Figure 8.6A compared to B). 80S ribosomes gave a distinct peak, as
did the 60S ribosomal subunit. However, instead of a peak for the 40S subunits, a
shoulder from the descending smaller RNA species curve was present. This variation
could be attributable to any number of experimental factors (effectiveness of
cycloheximide treatment, total cell number for example, formation of sucrose
gradient), and stresses the point to compare within individual experiments only.
To this end, AROS silencing compared to the Mock treatment in Figure 8.6B
resulted in loss of the 40S subunit shoulder and a slight reduction in the 60S subunit
peak (Figure 8.6B). This suggests that AROS, like RPS19, is required for small
subunit abundance, consistent with the specific effects on ribosomal proteins and
rRNAs outlined in Figure 8.5. The data are consistent with the hypothesis that
‘AROS promotes ribosome biogenesis via RPS19’. There was also a reduction in the
80S ribosome peak following AROS silencing, which was almost completely lost.
This indicates that AROS promotes the production of translation competent
ribosomes, and indicates a role for AROS in translational control by provision of
ribosomes. This is summarised in Figure 8.6C, with the novel AROS-RPS19
Regulation of ribosome biogenesis
258
regulatory loop effecting 40S subunit and 80S ribosomes, but not influencing 60S
subunits.
80
100
120
140
160
P=0.028
P=0.037
HCT116Cell line
rR
N
A
co
m
pa
re
d
to
M
oc
k
(%
)
A
B
80
100
120
140
P<0.001
HCT116 p53-/-
RPS19
AROS
Cell line
WB
Actin
siRNA
HCT116
M
oc
k
A
R
O
S
1
R
P
S
19
RPS6
RPL3
HCT116 p53-/-
M
oc
k
A
R
O
S
1
R
P
S
19
40S
MCF7
M
oc
k
A
R
O
S
1
R
P
S
19
60S
RPS6 : Actin 1.00 0.85 0.84 1.00 1.06 0.62 1.00 0.67 0.15
0
20
40
60
MocksiRNA RPS19AROS 1
rR
N
A
co
m
pa
re
d
to
M
oc
k
(%
)
rRNA 18S
28S
0
20
40
60
Mock RPS19AROS 1
Figure 8.5: The effect of RPS19 and AROS on component
ribosome abundance
(A) Analysis of ribosomal protein abundance following RNAi against AROS or
RPS19. HCT116 and MCF7 cancer cells were harvested 48 hours after siRNA
transfection – HCT116 p53-/- at 72 hours. Total cell protein was separated by
SDS-PAGE, loaded by equivalent mass, and protein abundance determined by
Western blotting. The ‘RPS6:Actin’ ratio was calculated using Quantity One
densitometry as the change in RPS6 abundance compared to Mock treatment
standardised against Actin expression. (B) Expression of nuclear pre-ribosomal
RNA, quantified by qRT-PCR. HCT116 and HCT116 p53-/- cells were
transfected as in (A) then nuclear RNA was isolated and analysed for 18S and
28S rRNA qRT-PCR amplicon abundance.
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Figure 8.6: The effect of RPS19 and AROS silencing on 40S
subunit and 80S ribosome abundance
(A) Aligned OD260nm analysis of HCT116 cytoplasmic lysates from Mock
and RPS19 siRNA treatment. HCT116 cytoplasm was isolated and separated
by sucrose density ultracentrifugation. Subsequent fractions were analysed for
RNA content by reading OD at 260nm. (B) Data as for (A), following AROS
siRNA 1 transfection. (C) Schematic representation of the AROS-RPS19
relationship and its regulation of small ribosomal subunits and mature
ribosomes. The black arrows indicate promotion of 40S and 80S abundance.
The dashed grey arrow indicates no apparent effect on 60S subunits.
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8.5 AROS and ribosome biogenesis in non-cancer cells
AROS and RPS19 form an autoregulatory loop in both cancer and non-cancer
cell lines (Chapter 6). Despite this, AROS is specifically required for cancer but not
non-cancer cell survival (Chapter 5). In this Chapter AROS appears to affect RPS19
function in promoting ribosome abundance in cancer cells. Thus, the question arises
over whether AROS regulation of ribosome biogenesis is specific to cancer cells. It
is possible that AROS is not required for ribosome abundance in non-cancer cells,
which may explain its cancer specificity for cell survival. Alternatively, AROS may
regulate ribosomes in both cancer and non-cancer cells, but this may only promote
cell viability in cancer cells. It is also possible that AROS does not promote cancer
cell survival via the ribosome. This was investigated using the ARPE19 cell line as a
model non-cancer cell line.
8.5.1 AROS and ribosomal proteins
Firstly, ribosomal protein abundance was analysed in the ARPE19 retinal
epithelial cell line. Silencing of AROS did not appear to effect RPS6 protein
expression, perhaps suggestive of a cancer specific function of AROS (Figure 8.7A).
Surprisingly, RPL3 abundance may have been depleted by AROS silencing in the
ARPE19 cell line, which is in contrast to the small ribosomal subunit specific effects
seen in cancer cell lines (Figure 8.5A). However, AROS does effect RPS19 protein
abundance (Figure 8.7A), indicative of a consistent effect towards the small subunit.
8.5.2 AROS and ribosomal RNAs
ARPE19 nuclear rRNA abundance was analysed using the 18S and 28S
rRNA amplicons following AROS silencing. A significant reduction in the 18S
amplicon was observed following AROS silencing (Figure 8.7B), indicating that
AROS promotes the abundance 18S rRNA precursors. This is similar to the role of
AROS in HCT116 cancer cells (Figure 8.5B). Unlike in the HCT116 cell line, the
abundance of the 28S amplicon was significantly increased following AROS
silencing in the ARPE19 line (Figure 8.7B). This may suggest that AROS suppresses
the abundance of nuclear 28S rRNA forms, presumably at the post-transcriptional
level. The mechanism behind this is unclear. However, the data do suggest that
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AROS specifically promotes 18S rRNA precursor abundance in the ARPE19 and
HCT116 cell lines (Figure 8.7B and Figure 8.5B). These data may contradict the
hypothesis that ‘AROS promotes cancer cell survival by promoting ribosome
biogenesis’.
8.5.3 AROS and ribosomal subunits
The analysis of HCT116 cancer cells correlated a reduction in small
ribosomal subunit protein and RNA with a reduction in synthesised small subunits
following AROS silencing (Figure 8.5 and Figure 8.6). Consistent with a conserved
role of AROS across cell lines, in the ARPE19 non-cancer cell line the abundance of
small ribosomal subunits was reduced following AROS silencing (Figure 8.7C). The
40S peak in OD260nm analysis was smaller following AROS silencing compared to
parallel Mock treatment. This indicates that the role for AROS in ribosome
biogenesis is not cancer specific.
In contrast the 60S peak appeared markedly increased following AROS
silencing (Figure 8.7C). This is consistent with a role for AROS in specifically
promoting small subunit over large subunit abundance, and parallels the modulation
of nuclear rRNA levels following AROS silencing (Figure 8.7B). Furthermore, this
suggests that AROS suppresses 60S subunit biogenesis. However, the increase in
60S subunits could be attributable to release of these from 80S ribosomes following
the loss of small ribosomal subunits.
In agreement with this possibility AROS silencing resulted in a decrease in
80S ribosomes compared to Mock treatment. The 80S peak in the Mock treated
sample was almost completely lost following AROS silencing (Figure 8.7C). This is
again similar to the result seen in the HCT116 cancer cell line, which together
suggests that AROS has a conserved role in maintaining 40S subunit and 80S
ribosome abundance. The hypothesis that ‘AROS promotes cancer cell survival by
promoting ribosome biogenesis’ requires consideration as a result (see Discussion).
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Figure 8.7: The role of AROS for small subunit and 80S ribosome
abundance in non-cancer cells
(A) Expression of ribosomal proteins following silencing of AROS. ARPE19
cells were treated with AROS siRNA 1 then harvested 72 hours later. Total
protein was loaded on SDS-PAGE according to equivalent mass and analysed
by western blotting. Actin is used as a loading control. (B) Relative expression
of nuclear pre-ribosomal RNAs, quantified by qRT-PCR. ARPE19 cells were
transfected 72 hours prior to isolation of nuclear RNA (see Methods) analysed
for abundance of PCR amplicons within the 18S and 28S rRNAs. *** P<0.001,
* P<0.05. (C) Aligned OD260nm analysis of ARPE19 cytoplasmic lysates from
Mock and AROS siRNA 1 treatment. ARPE19 cytoplasm was isolated and
separated by sucrose density ultracentrifugation and subsequent fractions
analysed for RNA content by reading optical density at 260nm. (D) Schematic
of the effect of AROS on small (positive) and large (potentially negative)
ribosomal subunits and 80S ribosomes.
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8.6 SIRT1-Δ8 and ribosome biogenesis
The recently identified splice variant of the SIRT1 gene, SIRT1-Δ8 appears to
promote RPS19 abundance (Chapter 7). This potentially occurs via interaction
between RPS19 and SIRT1-Δ8, as the two proteins were also seen to specifically
associate in Chapter 7. Thus, with the role of RPS19 in ribosome biogenesis well
characterised the possibility that SIRT1-Δ8 promotes ribosome biogenesis via
RPS19 was explored in HCT116 cancer cells.
8.6.1 Ribosomal proteins and RNAs
The abundances of RPS6 and RPL3 were analysed following silencing of
SIRT1-Δ8 in the HCT116 cell line. Levels of both proteins, which represent the 40S
and 60S subunits respectively, were not reduced following SIRT1-Δ8 knockdown
(Figure 8.8A). This is in contrast to silencing of RPS19 in the same cell line, after
which levels of RPS6 were specifically reduced compared to RPL3 (Figure 8.5A).
This may suggest that the reduction in RPS19 following silencing of SIRT1-Δ8 is
distinct from reduction of RPS19 targeting by siRNA. Surprisingly the levels of
RPL3 may have increased as a result of SIRT1-Δ8 silencing, while the abundance of
RPS6 is entirely unchanged (Figure 8.8A).
This is in contrast to the effect of silencing SIRT1-Δ8 on the nuclear
abundance of the rRNA amplicons. SIRT1-Δ8 knockdown resulted in a reduction in
both 18S and 28S rRNA, to less than 50% of Mock treated samples (Figure 8.8B).
This suggests that SIRT1-Δ8 is involved in either the transcription of rRNA from
rDNA or the processing and biogenesis of both ribosomal subunits, and is an
indication that ‘SIRT1-Δ8 has a role in ribosome biogenesis’. The maintenance of
RPS6 and RPL3 proteins following SIRT1-Δ8 knockdown could suggests that
regulation of rRNA transcription is more likely. However, the effect of SIRT1-Δ8
upon RPS19 protein remains, suggesting that SIRT1-Δ8 does affect post-
transcriptional components of ribosome biogenesis.
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8.6.2 Ribosomal subunits and mature ribosomes
The effect of SIRT1-Δ8 silencing on both small and large subunit rRNA
suggests a role in ribosome biogenesis. Thus, the effect of SIRT1-Δ8 on ribosome
subunit and mature ribosome abundance was analysed by sucrose density
ultracentrifugation. As previously, Mock treatment produced distinct peaks for 40S
and 60S ribosome subunits and a peak for the 80S translating ribosome (Figure
8.8C). Silencing of SIRT1-Δ8 reduced the abundance of both 40S and 60S subunits
below the levels in Mock treatment. There was an almost complete loss of free 40S
and 60S ribosomal subunits following silencing of SIRT1-Δ8. This is in agreement
with the hypothesis that ‘SIRT1-Δ8 has a role in ribosome biogenesis’.
Interestingly silencing of SIRT1-Δ8 did not result in a large reduction in the
abundance of 80S ribosomes compared to Mock (Figure 8.8C). There appeared to be
a similar quantity of 80S ribosomes, despite the apparent reduction in abundance of
both subunits. The specific effect of SIRT1-Δ8 knockdown on ribosomal subunits
but not the translating ribosome is depicted in Figure 8.8D.
The loss of both ribosomal subunits appears to correlate with the loss of both
rRNAs following SIRT1-Δ8 silencing (Figure 8.8B). Reduced ribosomal RNA
availability may contribute to the loss of ribosomal subunits. Interestingly, this may
be independent from ribosomal protein availability, which was not negatively
affected by SIRT1-Δ8 siRNA. Together this appears to support the hypothesis that
‘SIRT1-Δ8 has a role in ribosome biogenesis’ and suggest that SIRT1-Δ8 contributes
to the transcription of rRNA at the beginning of the process.
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Figure 8.8: SIRT1-Δ8 may have a role in maintaining ribosome 
subunit abundance
(A) Ribosomal protein abundance following SIRT1-Δ8 siRNA treatment in the 
HCT116 cancer cell line. Cells were treated with siRNA then harvester 48 hours
later. Total protein was analysed by SDS-PAGE and specific antibody Western
blotting. Actin was used as a loading control. (B) Relative expression of pre-18S
and pre-28S ribosomal RNAs in isolated nuclear fractions, quantified by qRT-
PCR. HCT116 cells were transfected 48 hours prior to isolation of nuclear RNA
(see Methods) and analysed for abundance of PCR amplicons within the 18S
and 28S rRNAs. *** P<0.001. (C) Aligned OD260nm analysis of HCT116
cytoplasmic lysates from Mock and SIRT1-Δ8 treatment. HCT116 cytoplasm 
was isolated and separated by sucrose density ultracentrifugation with isolated
fractions analysed for RNA content by reading optical density at 260nm. (D)
Schematic of the regulation of small and large ribosomal subunits by SIRT1-Δ8 
in HCT116 cancer cells. Black arrows indicate promotion of 40S and 60S
abundance. Dashed grey arrow represents no apparent effect on 80S ribosomes.
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8.7 Discussion
8.7.1 AROS in ribosome biogenesis
The data here reveal that AROS promotes ribosome biogenesis in both
HCT116 cancer and ARPE19 non-cancer cells. This suggests a conserved role for
AROS during the ubiquitous process of ribosome synthesis. The role of AROS
appears similar to the role of RPS19. Taken together with the autoregulatory loop
between AROS and RPS19 reported in Chapter 6, this is highly suggestive that
AROS promotes ribosome biogenesis via RPS19. This could occur via direct
promotion of ribosome biogenesis via the association of AROS with RPS19 and
ribosomes (see discussion below) or via extra-ribosomal association of AROS and
RPS19, which in turn promotes ribosome biogenesis. The association of AROS with
the ribosome reported in this Chapter and the localisation of AROS to nucleoli, the
site of ribosome biogenesis (Maeda et al. 2006; Kim et al. 2007), support the former
option. However, as stated previously, the regulation of RPS19 and ribosome
biogenesis by AROS could be synchronous. It is difficult to interpret whether AROS
regulation of RPS19 impacts on ribosome biogenesis, or vice versa, as negative
effects on either RPS19 or ribosome biogenesis will likely result in the effects seen
on the opposite. Perhaps most likely is a co-regulation of RPS19 and ribosome
biogenesis by AROS, given the intrinsic link between the two.
Interestingly, p53 is important for the regulation of RPS19 and ribosome
biogenesis by AROS (This Chapter and Chapter 6). In the absence of p53 AROS
does not promote RPS19 protein abundance or ribosome biogenesis. Thus the role of
p53 appears to be suppression of RPS19 protein abundance following knockdown of
AROS. As such, p53 appears to support the role of AROS in promoting RPS19
abundance and ribosome biogenesis. p53 may have a defined role in the process, but
this cannot be essential as p53 null cells are able to synthesise ribosomes.
AROS is able to suppress activation of p53 via promoting its deacetylation
by SIRT1 (Chapter 4 and Kim et al. 2007). Thus with AROS able to suppress p53
and p53 appearing to suppress RPS19 following AROS knockdown, this creates a
putative mechanism whereby AROS promotes RPS19 protein abundance (Figure
8.9). In turn, maintenance of RPS19 protein abundance would allow AROS to
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promote 40S ribosomal subunit biogenesis. p53 is known to localise to the nucleoli,
which does not rule out the possibility that this regulation occurs during ribosome
biogenesis (Rubbi and Milner 2000). This putative mechanism would also require
the deacetylase activity of SIRT1 to suppress p53. SIRT1-Δ8 also appeared to have a
role in ribosome biogenesis (discussed below) and is known to deacetylate p53. Thus
the suppression of p53 supported by AROS may involve SIRT1-Δ8.
8.7.2 SIRT1-Δ8 in ribosome biogenesis
SIRT1-Δ8 silencing had a similar effect on 40S subunits as silencing of either
AROS or RPS19. This is consistent with SIRT1-Δ8 playing a part in the regulation
of RPS19 and subsequently ribosome biogenesis. Preliminary analysis of SIRT1-FL
in relation to ribosome biogenesis did not indicate a role for the protein, indicating
that the effect of SIRT1-Δ8 is specific for this isoform of the gene. SIRT1-Δ8
subcellular localisation is similar to that of SIRT1-FL, which is known to localise to
the cytoplasm, nucleus and nucleolus (Tanno et al. 2007; Murayama et al. 2008;
Lynch et al. 2010). Thus, SIRT1-Δ8 may be able to directly participate in ribosome
biogenesis in the nucleolus and across the cell.
SIRT1-FL protein regulates ribosomal RNA transcription in response to
cellular energy status (Murayama et al. 2008). SIRT1 senses energy status via its
requirement for NAD+ and is able to silence rDNA transcription via methylation in
complex with an epigenetic silencing complex. NAD+ levels are inversely
proportional to glucose availability, promoting SIRT1 to suppress rDNA
transcription during low nutrient availability. Whether SIRT1-Δ8 can also perform
this function is unknown. SIRT1-Δ8 appears to regulate synthesis of both small and
large ribosomal subunit rRNA, suggesting an early role in ribosome biogenesis, such
as during transcription (Figure 8.8). However, SIRT1-FL has a suppressive effect on
rRNA synthesis, in contrast to the positive effect seen for SIRT1-Δ8. One possibility
is that silencing of SIRT1-Δ8 removes its use of NAD+ as a co-substrate, thus
increasing NAD+ availability to promote SIRT1-FL function. This could result in the
silencing of rDNA and reduction in rRNA observed following SIRT1-Δ8
knockdown.
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The apparent maintenance of 80S ribosomes despite the loss of 40S and 60S
subunits suggests that SIRT1-Δ8 has a more direct role in translation than the
provision of ribosomal subunits. Thus, it appears that SIRT1-Δ8 suppresses the
formation of 80S ribosomes from 40S and 60S subunits. This is based on the
observation that following SIRT1-Δ8 silencing a higher proportion of the 40S and
60S subunits formed 80S ribosomes than were present as individual free subunits
(Figure 8.8C). How this may occur is entirely unknown, but would suggest an
association between SIRT1-Δ8 and ribosomal subunits.
8.7.3 Association of AROS with ribosomes
AROS appears to associate specifically with 40S ribosomal subunits over
60S subunits (Figure 8.2B), supporting the hypothesis that ‘AROS associates with
the ribosome’. This interaction is supported by immunoprecipitation data indicating
that AROS associates with both RPS19 and RPS6 from the small subunit (Figure
8.3). These two ribosomal proteins reside on opposite faces of the eukaryotic 40S
subunit, suggesting that AROS interacts with the subunit as a whole (Taylor et al.
2009; Ben-Shem et al. 2010; Rabl et al. 2011). Of course, there is the possibility that
AROS interacts with both RPS19 and RPS6 independently of the ribosome.
However, given the sucrose density gradient analysis, association with 40S subunits
seems the better explanation of these ribosomal protein associations.
This association is likely to occur via the direct interaction between AROS
and RPS19 (Maeda et al. 2006). RPS19 protein resides in the head region of the
eukaryotic ribosome, and is believed to act as a binding site for specific factors
during ribosome biogenesis (Taylor et al. 2009; Rabl et al. 2011). The location of
RPS19 is thus amenable to binding of extra-ribosomal factors, especially factors as
small as AROS, which is only 15.4kDa in size. This Chapter has identified a
putative role for AROS during the biogenesis of 40S subunits. However, AROS
associates with mature 40S subunits, potentially contradicting a role as a ribosome
biogenesis factor. These are usually recycled after use to permit further biogenesis,
and thus do not remain associated with the 40S subunit (Kressler et al. 2010).
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AROS also associated with RPL3 from the large subunit (Figure 8.3). This
may suggest an association with the 60S subunit as a whole. However, the sucrose
density gradient data do not correlate with this (Figure 8.2A). AROS does appear to
associate with 80S ribosomes, which contain both small and large subunits. Thus,
this association is likely to explain the association with RPL3 (Figure 8.4C). This
provides compelling evidence that AROS not only associates with the mature 40S
subunits, but also the translation competent 80S ribosome. This lends further support
to a role of AROS beyond ribosome biogenesis.
The association with 80S ribosomes may suggest a role in translation beyond
the provision of 40S ribosomal subunits. How and why this occurs falls beyond the
remit of this work. It is easy to speculate an association between SIRT1-Δ8 and the
ribosome, given the association observed between RPS19 and SIRT1-Δ8 in Chapter
7. SIRT1-FL was not detected in the sucrose density gradient, suggesting that any
association would be specific for SIRT1-Δ8. Should SIRT1-Δ8 associate with the
ribosome, AROS may be an important mediator in the interaction. These themes
allow scope for future work into a putative role for the SIRT1 gene during ribosome
biogenesis and possibly translation.
8.7.4 Ribosome biogenesis and cell fate
Loss of ribosomal subunits and 80S ribosomes is likely to have an impact at
the cellular level. Reduced 80S ribosome abundance seen in HCT116 cancer cells
following silencing of RPS19 or AROS likely correlates with a reduction in active
translation, and concomitant reduction in overall protein production. Consistent with
this effecting cell fate, silencing of either RPS19 or AROS resulted in apoptosis in
the HCT116 cancer cell line (Chapter 6 – Figure 6.4). However, silencing of each
factor also resulted in activation of tumour suppressors, which may contribute to this
apoptosis.
In the non-cancer ARPE19 cell line AROS is not required for cell survival
(Chapter 5), but does appear to be required for 40S subunit biogenesis (Figure 8.7).
Thus, AROS affects ribosome biogenesis in a variety of cell types. This also appears
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to contradict the theory that AROS promotes cancer cell survival via promoting
ribosome biogenesis.
However, it is possible that AROS promotion of ribosome biogenesis is only
required to promote cancer cell survival. Cancer cells proliferate rapidly, leaving
them susceptible to pharmacological targeting of processes required for such rapid
division. For example, many anti-cancer therapeutics target DNA replication, due to
its increased rate in cancer cells when compared to most non-cancer cells. However,
these treatments are not specific, resulting in death of rapidly dividing non-cancer
cells and genotoxic stress across all cells. A requirement for rapid protein translation
may also mean that the ribosome is an Achilles’ Heel for cancer cells (Silvera et al.
2010). Targeting ribosomes would also have no genotoxic side effects, unlike DNA
damaging agents. Thus, targeting of AROS could provide a means to expose a
dependence upon rapid growth.
The data following SIRT1-Δ8 silencing supports the theory that loss of 80S
ribosomes reduces translation and contributes to apoptosis. HCT116 cells depleted of
SIRT1-Δ8 exhibit neither a decrease in 80S ribosome abundance nor an apoptotic
phenotype compared to Mock treated cells (Figure 8.8C and Figure 7.7B). Thus, it
appears that maintenance of 80S correlates with cancer cell survival for the HCT116
cell line.
Figure 8.9: Regulation of RPS19 and ribosome biogenesis by AROS
Schematic of the role of p53 in the regulation of RPS19 by AROS. AROS suppresses
p53 via promoting deacetylation and p53 appears capable of suppression of RPS19
abundance. This may co
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8.8 Conclusions
1. AROS may specifically associate with 40S subunits and 80S ribosomes.
2. AROS promotes the biogenesis of 40S subunits in cancer and non-cancer cell
lines.
3. Cancer cell survival may require AROS function to support ribosome
biogenesis.
4. SIRT1-Δ8 has a role in biogenesis of 40S and 60S subunits.
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9 Conclusions
9.1 LDH-A suppresses p53 acetylation
The role of LDH-A as a decision maker during carbon metabolism has long
been known (Baumberger et al. 1933), as has the altered metabolism employed by
cancer cells, which appears to rely on LDH-A activity (Warburg 1956). However,
only recently has the possibility that LDH-A acts as a cancer specific survival factor
been analysed. LDH-A was identified as a survival factor in cancer in two recent
independent studies (Fantin et al. 2006; Le et al. 2010). In the work outlined in
Chapter 3 this has been augmented with the observation that LDH-A suppresses p53
acetylation, via a mechanism likely to involve activation of SIRT1.
9.1.1 LDH-A potentiates SIRT1 activity
In Chapter 3, suppression of LDH-A resulted in an increase in p53
acetylation, which correlated with apoptosis in cancer cell lines. This was specific
for LDH-A, with no effect seen following LDH-B suppression. Further, LDH-A was
potentially specifically required for cancer cell survival, as a non-cancer cell line was
not affected by loss of LDH-A. The mechanism of LDH-A suppression induced
cancer cell death has previously been attributed to impaired metabolism, resulting in
failure to meet energetic demands (Fantin et al. 2006; Le et al. 2010). Although this
is likely to contribute to cancer cell viability, the analysis here identifies an
intersection between cancer metabolism and apoptotic signalling pathways.
LDH-A promotes glycolysis by coupling the recycling of the reducing agent
NAD+ to the synthesis of lactate from pyruvate. It is this activity that is believed to
be upregulated in cancer to promote growth, and potentially allow targeting of LDH-
A as an anti-cancer target (Knight and Milner 2011). The analysis in Chapter 3 was
undertaken based on the assumption that provision of NAD+ by LDH-A can support
SIRT1 activity, given that SIRT1 is an NAD+-dependent deacetylase (Imai et al.
2000; Landry et al. 2000; Smith et al. 2000). The data are consistent with LDH-A
sustaining SIRT1 activity towards the tumour suppressors p53 and FOXO4, and
Conclusions
275
represent the first indication that cancer metabolism can influence SIRT1-mediated
anti-apoptotic signalling (Figure 9.3).
The data are a strong indication that LDH-A acts via SIRT1 to, at least in
part, promote cancer cell survival. The elucidation of the exact mechanism of LDH-
A was undertaken in parallel in the YCR p53 Research Unit and supports a
mechanism for LDH-A acting via provision of NAD+ for SIRT1 activity.
9.1.2 LDH-A is a p53-independent cancer cell survival factor
Further to providing the first indication that LDH-A can directly influence
apoptotic signalling, the effect of LDH-A on cancer cell survival was found to be
independent of p53 expression (Chapter 3). The analyses undertaken here are the
first observation that LDH-A is required for cancer cell survival where p53 is wild-
type, mutant or null. This is consistent with LDH-A-mediated promotion of SIRT1
activity as SIRT1 cancer cell survival function is p53-independnet. Independence
from p53 expression is important from a therapeutic point of view, as p53 is mutated
or misregulated in the majority of cancers (Vogelstein et al. 2000; Olivier et al. 2010;
Goh et al. 2011). Thus, the ability to induce cancer cell death in the absence of p53 is
an indicator of potential therapeutic success.
9.1.3 SIRT1 regulation by cancer metabolism
Upregulation of SIRT1 protein has been reported in various cancers (see
Chapter 1). However, the ability of SIRT1 protein to promote cancer cell survival is
presumably dependent on the provision of NAD+ as a co-enzyme (Imai et al. 2000;
Landry et al. 2000; Smith et al. 2000). This study identifies a putative mechanism by
which SIRT1 activity is potentially increased in cancer. Importantly, it appears likely
that LDH-A-mediated upregulation of SIRT1 does not depend upon increased SIRT1
abundance. Furthermore, the increased activity of LDH-A may be a consequence of
altered cancer metabolism (Warburg 1956). This suggests that aberrant upregulation
of SIRT1 may be a consequence of specific alterations in cancer cell energy
production. Crucially this may allow cancer specific targeting of SIRT1 via
suppression of LDH-A.
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9.2 AROS is a selective activator of SIRT1
AROS was originally characterised as an activator of SIRT1 activity (Kim et
al. 2007). In Chapter 4 and Chapter 5, analysis of well characterised targets of
SIRT1-mediated deacetylation indicated that AROS function has differences and
similarities to SIRT1. From this it was inferred that AROS acts as a selective
activator of SIRT1. For example, under basal conditions in HCT116 colorectal
adenocarcinoma cells AROS appears to suppress FOXO4 but not p53, both of which
are targets of SIRT1 suppression. Interestingly, AROS did suppress p53 following
the application of stress in the same cell line, indicating that selective activation of
SIRT1 by AROS is dynamic. The work here is the first indication of a complex
AROS-SIRT1 relationship and that SIRT1 can function in the absence of AROS.
9.2.1 How is selective activation modulated?
From the data outlined in Chapter 4 and Chapter 5, it seems unlikely that
regulation of SIRT1 by AROS occurs in an ‘on’ and ‘off’ fashion. For example,
SIRT1 appeared to be able to suppress FOXO4 but not p53 following AROS
silencing under the same conditions in HCT116 cells. Thus, AROS appears to
promote FOXO4 suppression over p53 suppression. This also implies that SIRT1
does not require AROS association for all catalytic activity, as p53 is still
deacetylated and suppressed. Therefore, as well as being dynamic in response to
stimuli it appears that AROS can modulate SIRT1 activity according to substrate.
One possible explanation for this type of relationship may be modulation of AROS
and/or SIRT1 by external factors.
Regulation of SIRT1 is an emerging field, with at least 12 protein level
activators or suppressors of SIRT1 activity identified (see Chapter 1). Regulation of
AROS is an entirely unexplored field, but future analyses are likely to reveal
multiple regulatory mechanisms. Regulation of both SIRT1 and AROS is likely to
integrate external stimuli, such as stress, into the relationship between the proteins.
Indeed, SIRT1 is subject to phosphorylation by multiple kinases known to be
modulated under stress conditions – JNK1(Nasrin et al. 2009), JNK2 (Ford et al.
2008) and mTOR (Back et al. 2011). Phosphorylation by these kinases may alter the
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ability of AROS to bind SIRT1 and affect SIRT1 function, potentially contributing
to the dynamic relationship between AROS and SIRT1 (Figure 9.1).
9.2.2 AROS as a director of SIRT1 activity
The observation that AROS selectively modulates SIRT1 activity leads to the
question of why. What is the function of AROS in the wider role of SIRT1? As
described above AROS may modulate SIRT1 function differently in response to
stress. SIRT1 is an important component of the cell stress response via its
modulation of important participants such as p53 and the FOXO proteins. It is
possible that AROS acts as an extra, but potentially subvertable, level of regulation
within this system. For example, modification of AROS (or SIRT1) following stress
may be required for AROS-mediated promotion of certain SIRT1 targets, or
conversely modification may suppress the existing regulation of SIRT1 by AROS
(Figure 9.1).
Interestingly, the modulation of SIRT1 by AROS appears to contribute to the
role of SIRT1 as a cancer cell survival factor, as AROS is also specifically required
for cancer cell survival (Chapter 5). It is possible that AROS specifically modulates
SIRT1 activity towards substrates involved in cancer cell longevity over other
substrates with alternative functions. As such, the relationship between AROS and
SIRT1 may be constitutively modified in cancer compared to non-cancer cells.
Should this be the case, there is an opportunity to exploit this for anti-cancer
therapeutic gain. The role of AROS in cancer cell survival is discussed at greater
length in Section 9.6 below.
Figure 9.1: Selective modulation of SIRT1 by AROS
(A) AROS is able to selectively promote SIRT1 activity towards certain substrates
but not others, giving AROS a role as a specific modulator of SIRT1. The
mechanism behind this modulation is unknown.
SIRT1 activity alters fol
SIRT1 activity towards different substrates, and may be attributable to reversible
alterations to AROS and/or SIRT1 proteins.
(B) AROS-mediated regulation of
lowing the application of stress. This may be able to direct
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9.3 AROS and RPS19 form an autoregulatory feedback loop
The relationship between AROS and the structural component of the 40S
ribosomal subunit, RPS19, was outlined in Chapter 6. This supplements the
observation in the mouse that the two proteins form a direct interaction (Maeda et al.
2006). Association between the human homologues of AROS and RPS19 was
observed for the first time in Chapter 7. The data in Chapter 6 provide the most
significant contribution to the knowledge of these two proteins, attributing a function
to the interaction for the first time. Each protein appears to promote the protein level
abundance of the other in a reciprocal autoregulatory loop. This raises questions
regarding the mechanism of autoregulation, and has implications in a rare disease
linked to RPS19 mutation.
9.3.1 Mechanism of autoregulation
It appears likely that the mechanism behind AROS and RPS19 autoregulation
is linked to degradation. This is based on the observation that abundance of
reciprocal mRNA is not affected by knockdown of each protein (Chapter 6),
indicating that synthesis is not likely to be a factor. Interestingly overexpression of
AROS or RPS19 did not increase reciprocal protein abundance (Chapter 7),
suggesting that each protein is required but not sufficient to promote reciprocal
protein abundance, again appearing to correlate with a mechanism linked to
degradation.
A mechanism involving degradation may relate to the association of AROS
and RPS19 in human cells (Chapter 7) likely via the direct interaction seen in mouse
cells (Maeda et al. 2006). The formation of the AROS-RPS19 complex may be
crucial to support the stability of each protein. Hypothetically, association may
negate degradation by blocking ubiquitination, which is known to regulate RPS19
stability (Cretien et al. 2008). Alternatively, association may promote modification
of either protein, which may subsequently increase stability.
In opposition to a mechanism involving degradation, there is the possibility
that translational control plays a part in the autoregulation. A recent report has
highlighted a role for RPS19 in selective translation (Horos et al. 2011). Silencing of
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RPS19 in this study resulted in reduced expression of specific proteins despite
maintenance of the respective mRNA. This was attributed to selective translation
mediated by RPS19, and is strikingly similar to the regulation of AROS by RPS19
observed in Chapter 6. Thus, AROS mRNA may be selectively translated in the
presence of RPS19, such that knockdown of RPS19 reduces translation and
subsequent protein expression. Crucially this would have no effect on AROS mRNA
levels.
The apparent association of AROS with 40S ribosomal subunits (Chapter 8)
raises the possibility that AROS and RPS19 stability is linked to the stability of
ribosomes. RPS19 stability will almost certainly be linked to that of ribosomes given
its role as a structural component of the 40S subunit. The ribosomal association
observed for AROS may link loss of ribosomes to loss of AROS protein. Similarly,
loss of RPS19 protein following AROS silencing may be a consequence of the role
of AROS in 40S subunit biogenesis observed in Chapter 8 and discussed below.
Thus, the regulation of ribosome biogenesis may be at the heart of the AROS-RPS19
relationship. Inhibition of ribosome biogenesis (for example by RNAi against other
ribosomal proteins) and the subsequent effect on AROS stability would reveal
whether AROS and RPS19 stability is dependent or independent of ribosome
stability. This analysis would also allow analysis of the putative regulation of p53 in
response to ribosome biogenesis, which may signal through AROS and SIRT1.
9.3.2 Implications in disease – Diamond-Blackfan Anaemia
RPS19 was the first ribosomal protein gene to be linked to a disease. 25% of
cases of the erythroblastopenia, Diamond-Blackfan Anaemia (DBA), present
deleterious heterozygous mutations in the RPS19 gene (Draptchinskaia et al. 1999;
Willig et al. 1999). DBA has since been linked to mutation in a further 12 ribosomal
protein genes, which in total constitute up to 54% of disease incidence (Boria et al.
2010; Ito et al. 2010). This led to the definition of DBA as the first ribosomopathy, a
disease linked to mutations in ribosomal protein genes (Luft 2010). Interestingly, the
mutated ribosomal protein genes contribute to both the small and large ribosomal
subunits and are not confined to one region of the ribosome (Ben-Shem et al. 2010;
Boria et al. 2010; Ito et al. 2010; Rabl et al. 2011). This implies that the aetiology of
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the disease may be linked to the ribosome as a whole, and not extra-ribosomal
functions of the ribosomal proteins.
AROS appears to promote RPS19 protein abundance in 6 cell lines from
multiple origins in Chapter 6, raising the possibility that AROS can influence RPS19
abundance in DBA. DBA is a disease specific to the erythroid lineage of
haematopoiesis, with cells in this lineage reduced in number resulting in an anaemic
phenotype (Diamond and Blackfan 1938). RPS19 expression is required in erythroid
progenitor cells to ensure survival (Choesmel et al. 2007; Flygare et al. 2007; Idol et
al. 2007). Thus, should AROS-mediated promotion of RPS19 abundance occur in
erythroid cells, AROS too may be required for survival of cells into mature
erythrocytes. The role of RPS19 in ribosome biogenesis has also been linked to DBA
(Choesmel et al. 2007; Flygare et al. 2007; Idol et al. 2007), perhaps consistent with
the disease being a ribosomopathy (Luft 2010). AROS promoted ribosome
biogenesis in a fashion similar to RPS19 in Chapter 8. This may be linked to the role
of RPS19 in DBA, adding further to a putative role for AROS in DBA.
The effect of AROS on other ribosomal proteins implicated in DBA has not
been assessed in this study. It is possible that AROS also promotes their expression,
potentially creating a link between these apparently disparate proteins. However,
even if this is not the case the conserved effect of AROS on RPS19 abundance,
which likely occurs via direct interaction (Maeda et al. 2006), warrants further
investigation of AROS in the context of DBA. The work here represents the first
implication of AROS as a potential factor in DBA.
Conclusions
282
9.4 RPS19 may suppress p53 via AROS/SIRT1
Silencing of RPS19 correlated with an increase in p53 levels, either
acetylated p53, total p53 or both (Chapter 6). This agrees with previous indications
that RPS19 suppresses p53 (Danilova et al. 2008; McGowan et al. 2008; Dutt et al.
2011; Jaako et al. 2011), and further, the data outlined in Chapter 6 and Chapter 7
are the first indication that RPS19 suppression of p53 may occur via AROS and/or
SIRT1. Three possible mechanisms of p53 suppression by RPS19 were identified,
which are likely to overlap.
9.4.1 Multiple mechanisms
RPS19 may act via AROS to suppress p53. This is based on the correlation
between the effect of RPS19 on p53 and selective role outlined for AROS in the
suppression of p53 activation in Chapter 4. Variation in AROS-mediated
suppression of p53 was almost exactly replicated by RPS19.
RPS19 may also suppress p53 via two SIRT1 gene products, SIRT1-FL and
SIRT1-Δ8 (Chapter 6 and Chapter 7). SIRT1-FL is capable of direct deacetylation
and suppression of p53 (Luo et al. 2001; Vaziri et al. 2001; Ford et al. 2005), as is
SIRT1-Δ8, although at a reduced rate compared to SIRT1-FL (Lynch et al. 2010).
Suppression of p53 by AROS is likely to occur via activation of SIRT1-FL by
AROS (Kim et al. 2007), and potentially activation of SIRT1-Δ8 by AROS.
However, more direct modulation of SIRT1-FL and SIRT1-Δ8 by RPS19 may also
contribute to p53 suppression.
SIRT1-FL expression was reduced by loss of RPS19 in 5 cell lines analysed
in Chapter 6. This raises the possibility that RPS19 modulates SIRT1-FL-mediated
suppression of p53 by promoting SIRT1 protein abundance. Similarly, the molecular
interactions identified in Chapter 7 indicated that RPS19 associates with SIRT1-Δ8.
The function of this interaction is unknown, but may allow RPS19 to upregulate
SIRT1-Δ8 activity, which may in turn suppress p53. Thus, RPS19 appears to be
capable of multiple mechanisms which could suppress p53, potentially acting via the
AROS-SIRT1 axis detailed in Chapter 4 and Chapter 5.
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9.4.2 Implications in disease – Diamond-Blackfan Anaemia
Stabilisation of p53 as a result of reduced RPS19 expression has been
reported in animal models of Diamond-Blackfan Anaemia (Danilova et al. 2008;
McGowan et al. 2008; Dutt et al. 2011; Jaako et al. 2011). The data reported here
prompted the proposal of various mechanisms which could lead to activation of p53
following loss of RPS19 (see above). These involve proteins that have yet to be
characterised in DBA: AROS, SIRT1-FL and SIRT1-Δ8. Almost half of the cases of
DBA have no known genetic cause. The work here suggests that reduced or altered
expression from the AROS or SIRT1 genes could contribute to DBA and that these
genes may be mutated in the disease.
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9.5 AROS has a role in ribosome biogenesis
Chapter 8 followed the observation that AROS promotes RPS19 stability
with characterisation of a known RPS19 function following silencing of AROS. The
role of RPS19 in 40S ribosomal subunit biogenesis was well established, allowing
analysis of the role of AROS and direct comparison to RPS19. Specifically RPS19 is
known to promote 40S subunit abundance by facilitating the processing of rRNA in
the nucleolus (Choesmel et al. 2007; Flygare et al. 2007; Idol et al. 2007). The role
identified for AROS is the first indication that AROS has a function in ribosome
biogenesis.
9.5.1 AROS in 40S biogenesis
AROS appeared to specifically promote 40S subunit abundance in the
cytoplasm, and the abundance of 40S subunit rRNA in the nucleus of two cell lines
of different origins – the HCT116 and ARPE19 (Chapter 8). Furthermore, the whole
cell abundance of the 40S subunit proteins RPS19 and RPS6 was decreased
following silencing of AROS in the HCT116 cells. This appeared to be specific to
the 40S subunit as the abundance of 60S subunits, rRNA and protein was not
decreased in either cell line. The data correlate well with the role of RPS19 in
ribosome biogenesis, either analysed in parallel (Chapter 8) or upon comparison to
previous publications (Choesmel et al. 2007; Flygare et al. 2007; Idol et al. 2007).
It is possible that AROS promotes 40S subunit biogenesis independently of
RPS19, potentially acting via association with alternative ribosomal proteins or
ribosomal RNA. However, analysis of a range of 40S subunit proteins identified
distinct roles for each in ribosome biogenesis (Robledo et al. 2008), suggesting that
the correlation between AROS and RPS19 function observed here is due to similar
functions. Together with the observation that AROS and RPS19 form a direct
interaction (Maeda et al. 2006), this adds further to the theory that AROS acts via, or
together with, RPS19 to promote ribosome biogenesis
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9.5.2 AROS association with ribosomes
AROS appeared to associate with 40S subunits and 80S ribosomes in the
cytoplasm of HCT116 cancer cells (Chapter 8). The association is likely to occur for
a reason, potentially allowing AROS to influence ribosome function. This is the first
observation that AROS may have a role in the function of ribosomes. The
association also suggests that AROS interacts with pre-ribosomes in the nucleus,
although this analysis was not undertaken. However, given the specific role of
AROS in 40S subunit synthesis an association would appear likely.
The association of AROS with the 40S subunits and 80S ribosomes is likely
related to the interaction between AROS and RPS19 (Maeda et al. 2006). The
structure of the 40S subunit appears amenable to association of non-ribosomal
proteins with RPS19 (Taylor et al. 2009; Ben-Shem et al. 2010; Rabl et al. 2011),
especially proteins as small as AROS. Thus, AROS seems likely to interact with
ribosomes via RPS19.
9.5.3 AROS and translational control
As well as identifying a role for AROS in the biogenesis of 40S subunits the
data in Chapter 8 also reveal a putative role for AROS in the control of translation.
Translation requires the formation of 80S ribosomes, which was impaired following
depletion of AROS. Thus, AROS appears to be able to promote translation by
providing sufficient 40S subunits for formation of translation competent ribosomes.
As well as this global function in translational control, AROS may also be
able to impart translational control via its association with 40S subunits and 80S
ribosomes. Classic ribosome biogenesis factors dissociate after carrying out their
function, to be recycled to promote further ribosome biogenesis (Freed et al. 2010;
Kressler et al. 2010). AROS does not appear to act like a classical ribosome
biogenesis factor, as it remains associated with ribosomes beyond their synthesis.
This raises the possibility that AROS fulfils a function via this prolonged
association, potentially in the control of translation.
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40S subunits bind mRNA prior to association with 60S subunits and the
initiation of translation. This gives 40S subunits the ability to select mRNAs for
translation. AROS association with 40S subunits in the cytoplasm suggests that it
may play a part in this function. This possibility is aided by the recent observation
that RPS19, with which AROS interacts and forms an autoregulatory loop (Chapter
6 and Chapter 7), imparts specific control of translation in erythroid precursors
(Horos et al. 2011). Whether AROS is involved in this process merits further
investigation.
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9.6 AROS selectively promotes cancer cell survival
Chapter 5 revealed that AROS protein is required in 3 cancer cell lines to
avoid apoptosis, with phenotypes consistent with apoptosis following knockdown of
AROS in 2 further cancer cell lines. In contrast 3 non-cancer cell lines did not
require AROS expression to maintain viability, leading to the conclusion that AROS
is a putative ‘novel anti-cancer therapeutic target’. The exact mechanism by which
AROS promotes cancer cell survival may involve two routes, acting via modulation
of SIRT1 activity and/or promotion of ribosome biogenesis. This represents the first
identification of AROS as a specific survival factor for cancer cells, and a significant
addition to potential mechanisms by which AROS suppresses cancer cell apoptosis.
9.6.1 Selective SIRT1 activation
SIRT1 is a cancer specific survival factor, promoting cancer cell viability but
being redundant for non-cancer cell survival (see Introduction and Ford et al. 2005).
Thus, the characterisation of AROS in Chapter 4 and Chapter 5 has parallels to the
functions of SIRT1. As such, it appears likely that AROS promotes cancer cell
survival, at least in part, via activation of SIRT1 (Figure 9.2).
9.6.2 Promoting ribosome biogenesis
AROS also appears to promote ribosome biogenesis (see above). Although
this appears to occur in cell lines of cancerous and non-cancerous origins, whereas
only cancer cells appear to require AROS for survival. However, the dramatic effect
on 40S subunit and 80S ribosome abundance this may have a negative effect on cell
viability. The requirement for translation is perhaps greater in rapidly dividing
cancer cells such as the HCT116 cells analysed here, than in non-cancer cells, such
as the ARPE19 cells used. Targeting translation as a means to target cancer is not a
new concept (Silvera et al. 2010), but AROS may represent a novel target (Figure
9.2).
9.6.3 AROS as an anti-cancer target
The data presented within the Thesis identify AROS as a putative anti-cancer
therapeutic target. The data indicate further that AROS is able to promote cancer cell
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survival independently of p53 expression. Thus, targeting of AROS in p53 deficient
cancers, which occurs in 50% of cancers (Vogelstein et al. 2000; Olivier et al. 2010;
Goh et al. 2011), should result in cancer cell death. The potential to promote cancer
cell growth via two distinct mechanisms (See above and Figure 9.2) adds further to
the prospects of targeting AROS in cancer. Multiple mechanisms could enhance the
effect of targeting AROS compared to targeting of each mechanism individually.
Furthermore, this may allow AROS targeting to remain effective should the
influence of one pathway in promoting cancer survival be diminished.
Figure 9.2: Potential mechanism for AROS as a cancer cell survival factor
AROS appears capable of promoting cancer cell survival via activation of SIRT1
anti-apoptotic signalling and via promotion of ribosome biogenesis.
that both mechanisms are important, which could increase the efficacy of anti
targeting of AROS.
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It is possible
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9.7 SIRT1-Δ8 has a role in ribosome biogenesis
SIRT1-Δ8 was identified as an alternatively spliced form of the SIRT1 gene,
which is translated into a protein with reduced but detectable deacetylase activity
(Lynch et al. 2010). No distinct function has previously been attributed to the
SIRT1-Δ8 form to differentiate it from the SIRT1-FL protein. SIRT1-Δ8 protein is
likely to retain the relationship SIRT1-FL has with NAD+ availability for function.
Thus, SIRT1-Δ8 may be responsive to cell metabolism. SIRT1-Δ8 but not SIRT1-FL
is responsive to stress, being upregulated after cellular insult, but this relates to
SIRT1-Δ8 regulation not function (Lynch et al. 2010).
Here, SIRT1-Δ8 appears to specifically interact with RPS19, with no
interaction detectable between RPS19 and SIRT1-FL (Chapter 7). Thus, RPS19 is
the first protein identified that preferentially associates with SIRT1-Δ8 over SIRT1-
FL. This association may also affect RPS19 abundance, as silencing of SIRT1-Δ8
appears to reduce RPS19 abundance (Chapter 7).
SIRT1-Δ8 was shown to promote the nuclear abundance of 40S and 60S
subunit rRNA and the cytoplasmic abundance of mature 40S and 60S subunits
(Chapter 8). This is the first indication that SIRT1-Δ8 regulates ribosome
biogenesis, which could have great important in linking cellular metabolism with
ribosome biogenesis (see below).
9.7.1 Subunit specific or wider effects?
How SIRT1-Δ8 affects ribosome biogenesis is not clear from the data
presented here. The data appear to suggest a role in global provision of rRNA, with
levels of nuclear 18S and 28S pre-rRNA reduced by SIRT1-Δ8 silencing (Chapter
8). In Chapter 8 this was hypothesised to relate to a known function for SIRT1-FL in
regulating rDNA loci (see below also). However, the specific association with and
promotion of RPS19 suggests that SIRT1-Δ8 may influence the function of RPS19
in ribosome biogenesis. This should be specific to the synthesis of 40S subunits,
apparently contradicting the loss of both 40S and 60S subunits following SIRT1-Δ8
knockdown.
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However, it is possible that SIRT1-Δ8 influences both subunits at the post-
transcriptional level, potentially via a similar association with a 60S subunit
protein(s) to that seen with RPS19. This could represent a post-transcriptional
method for regulation of ribosome synthesis, governed by a stress and metabolism
responsive signalling enzyme in SIRT1-Δ8.
9.7.2 Linking ribosomes and SIRT1
Ribosome biogenesis has been linked to control by SIRT1 via SIRT1-
mediated epigenetic regulation of the rDNA loci in mammalian cells (Murayama et
al. 2008). rDNA is silenced in response to reduced carbon metabolism, which is
proportional to NAD+ availability and thus SIRT1 deacetylase activity. This is
believed to suppress the energy consuming process of ribosome biogenesis in
response to low nutrient availability (Grummt and Ladurner 2008). The data
presented here suggest that SIRT1-Δ8 may be able to influence ribosome biogenesis
post transcription. This is based on the AROS-SIRT1-Δ8 and RPS19-SIRT1-Δ8
interactions, and the possibility that AROS requires SIRT1-Δ8 for its role in
ribosome biogenesis.
Furthermore, the association between AROS and ribosomes raises the
possibility that SIRT1-Δ8 also associates with 40S subunits and/or 80S ribosomes.
No association was detected between SIRT1-FL and the ribosome (Chapter 8), but
SIRT1-Δ8 was not analysed. Furthermore, the putative association may have a
functional role during ribosome function, modulating translation. A recent report has
identified a role for SIRT1 in regulating translation via modulation of eIF2 (Ghosh et
al. 2011). However, the analysis was carried out using SIRT1 null cells or RNAi
which will have depleted both SIRT1-FL and SIRT1-Δ8. Thus, it is possible that
SIRT1-Δ8 participates in translational control if the function attributed to SIRT1 is
in fact carried out by SIRT1-Δ8.
Together, the work detailed here is the first indication of a specific role for
SIRT1-Δ8 to differentiate it from SIRT1-FL. Furthermore, a putative role for SIRT1-
Δ8 is proposed during ribosome biogenesis, which could link global ribosome
abundance, translation and cellular energy and stress status.
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9.8 Cancer metabolism, ribosome biogenesis and cancer cell survival
The Thesis aimed to identify links between the metabolism of cancer cells,
ribosome biogenesis and cancer cell survival. This was based on the well
characterised role of LDH-A in metabolic regulation and a predicted role for AROS
in ribosome biogenesis. The schematic Venn diagram drawn in Chapter 1 has been
populated throughout the course of the studies to produce Figure 9.3.
9.8.1 Cancer metabolism and cancer cell survival
Cancer metabolism appears to promote cancer cell survival, in part via
regulation of p53 and FOXO4 by SIRT1, which appears to be linked to LDH-A
activity. The increase in Aerobic Glycolysis in cancer cells may drive NAD+
synthesis by LDH-A and subsequently SIRT1 activity in response to increased
NAD+ availability. In this relationship SIRT1 acts as the central node, linking cancer
metabolism to cancer cell survival. Interestingly, SIRT1 also appears to have the
capacity to alter metabolism, potentially doing so in cancer to promote metabolic
alterations that may in turn promote cancer cell survival (Knight and Milner 2011).
LDH-A represents a crucial link between cancer metabolism and cancer cell
survival, as illustrated in Figure 9.3.
9.8.2 Ribosome biogenesis and cancer cell survival
AROS appears to play an important role in promoting ribosome biogenesis
and cancer cell survival. Thus, AROS is placed at the intersection of these two areas
in Figure 9.3. As discussed above, AROS-mediated promotion of cancer cell
survival may be linked to SIRT1, or attributable to regulation of ribosome
biogenesis. Interaction between ribosome biogenesis and the SIRT1 gene is also
evident, highlighted by the characterisation of SIRT1-Δ8 as a potential regulator of
RPS19 and ribosome biogenesis. Thus, the data highlights interplay between AROS
and its roles in ribosome biogenesis and cancer cell survival, potentially involving
both SIRT1-FL and SIRT1-Δ8.
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9.8.3 Cancer metabolism and ribosome biogenesis
The potential for cancer metabolism to affect ribosome biogenesis is
highlighted by the data presented here. This did not form a large part of the analysis,
leaving room for speculation. NAD+ availability has previously been linked to
ribosome biogenesis via SIRT1 activity (Murayama et al. 2008). However, the
possibility that altered cancer metabolism promotes ribosome biogenesis has not
been formally assessed. It may be advantageous for cancer cells to upregulate
ribosome biogenesis in order to facilitate proliferation. As such, increased SIRT1
activity driven by cancer metabolism may affect ribosome biogenesis as well as
cancer cell survival via the putative model outlined here. It is also possible that
SIRT1-Δ8 participates in linking cancer metabolism to ribosome biogenesis, as it
also requires NAD+ and appears to promote both 40S and 60S subunit synthesis.
9.8.4 Concluding remarks
The broad aim of this work, identified in Chapter 1, was to analyse the
protein level regulation of SIRT1 in an attempt to discover and characterise novel
anti-cancer therapeutic targets. During the course of the analysis two factors were
found with such properties, LDH-A and AROS. LDH-A had previously been
identified as a survival factor in cancer cells (Fantin et al. 2006; Le et al. 2010), but
this work supplements this with the addition of a putative mechanism acting via
SIRT1-mediated anti-apoptotic signalling. The characterisation of AROS as a
specific survival factor is entirely novel, with AROS only previously being shown to
promote cancer cell survival (Kim et al. 2007). Furthermore, the characterisation of a
previously unknown role for AROS in ribosome biogenesis identified a possible link
between anti-apoptotic signalling and protein synthesis. Together this work has
allowed novel regulation of SIRT1 to be integrated with cancer metabolism,
ribosome biogenesis and cancer cell survival.
Figure 9.3: Cancer metabolism, ribosome biogenesis and cancer cell
The interplay between cancer metabolism and ribosome biogenesis in contributing to
cancer cell survival. The
influences and/or is influenced by each of the three factors. LDH
characterised as a link between cancer metabolism and cancer cell survival, linking
Aerobic Glycolysis with SIRT1 activity via NAD
ribosome biogenesis with cancer cell survival in the system, via
function. There is the possibility that cancer metabolism affects ribosome biogenesis
within the system, but this was not formally assessed.
SIRT1 gene occupies the centre of the relationship, as it
-A was
+ availability. AROS links
SIRT1
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survival
for the latter
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Table 10.1: Annexin V / FACS data for Chapter 3 – Figures 3.7, 3.8 and 3.10
Cell line and
siRNA
Average
(% cells)
Standard
deviation
Fold
change to
mock
Standard
deviation to
fold
Cancer cell lines
HCT116
Mock
LDH-A
LDH-B
LDH-A & B
4.33
19.59
2.77
12.78
0.15
0.48
0.10
0.77
1.00
4.53
0.64
2.95
0.03
0.02
0.04
0.06
HCT116 p53-/-
Mock
LDH-A
LDH-B
LDH-A & B
3.23
8.92
2.92
8.74
0.13
0.59
0.16
0.06
1.00
2.76
0.90
2.71
0.04
0.07
0.06
0.01
DLD1
Mock
Lamin AC
LDH-A
2.03
3.10
10.30
0.26
0.32
0.00
1.00
1.53
5.09
0.13
0.16
0.00
MCF7
Mock
LDH-B
LDH-A
1.78
3.16
9.50
0.81
0.19
1.73
1.00
1.77
5.33
0.45
0.11
0.97
Non-cancer cell line
ARPE19
Mock
LDH-A
LDH-B
LDH-A & B
0.64
0.93
0.91
1.04
0.20
0.03
0.21
0.01
1.00
1.45
1.41
1.62
0.31
0.03
0.23
0.01
FOXO4 rescue data
HCT116
Mock
LDH-A
+ FOXO4
2.56
11.52
6.28
0.12
0.06
0.41
1.00
4.51
2.46
0.05
0.02
0.16
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Table 10.2: Annexin V / FACS data for Chapter 5 - Figure 5.2
Cell line and
siRNA
Average
(% cells)
Standard
deviation
Fold
change to
mock
Standard
deviation to
fold
Cancer cell lines
HCT116
Mock
Lamin AC
SIRT1
AROS 1
4.33
7.25
21.38
19.11
0.15
0.46
1.88
0.22
1.00
1.68
4.94
4.42
0.03
0.06
0.09
0.01
HCT116 – 72h
Mock
Lamin AC
SIRT1
AROS 1
AROS 2
4.58
6.61
18.30
16.15
10.46
0.49
0.35
0.28
0.31
0.74
1.00
1.44
4.00
3.53
2.29
0.11
0.08
0.06
0.07
0.16
HCT116 p53-/-
Mock
Lamin AC
SIRT1
AROS 1
3.23
5.54
8.33
8.66
0.13
0.23
0.62
0.07
1.00
1.72
2.58
2.68
0.04
0.04
0.07
0.01
MCF7
Mock
SIRT1
AROS 1
2.00
6.22
6.52
0.20
0.47
0.47
1.00
3.22
3.11
0.10
0.08
0.07
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Table 10.3: Annexin V / FACS data for Chapter 5 - Figure 5.5
Cell line and
siRNA
Average
(% cells)
Standard
deviation
Fold
change to
mock
Standard
deviation to
fold
Non-cancer cell lines
ARPE19
Mock
Lamin AC
SIRT1
AROS 1
0.64
0.89
1.21
0.89
0.20
0.11
0.18
0.15
1.00
1.38
1.89
1.38
0.31
0.12
0.15
0.17
WI38
Mock
Lamin AC
SIRT1
AROS 1
1.68
2.22
1.67
2.12
0.25
0.03
0.01
2.12
1.00
1.32
0.99
1.26
0.15
0.01
0.01
0.17
MCF10A
Mock
SIRT1
AROS 1
1.29
1.58
2.15
0.26
0.22
0.45
1.00
1.23
1.67
0.20
0.14
0.21
Table 10.4: Annexin V / FACS data for Chapter 5 - Figure 5.7
Cell line and
siRNA
Average
(% cells)
Standard
deviation
Fold
change to
mock
Standard
deviation to
fold
HCT116
Mock
+ Etoposide / TSA
Mock
SIRT1
AROS 1
7.07
12.78
32.98
32.96
0.30
1.41
1.68
1.82
1.00
1.81
4.66
4.66
0.04
0.20
0.24
0.26
ARPE19
Mock
+ Etoposide / TSA
Mock
SIRT1
AROS 1
4.14
4.53
11.78
5.41
0.90
2.67
1.04
0.28
1.00
1.09
2.85
1.31
0.22
0.64
0.25
0.07
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Table 10.5: Annexin V / FACS data for Chapter 5 - Figures 5.8 and 5.9
Cell line and
siRNA
Average
(% cells)
Standard
deviation
Fold
change to
mock
Standard
deviation to
fold
HCT116
Mock
+ UV treatment
Mock
Lamin AC
SIRT1
AROS 1
3.75
11.76
17.34
26.00
25.22
0.33
0.11
0.09
1.30
3.12
1.00
3.13
4.62
6.93
6.72
0.09
0.03
0.02
0.35
0.83
HCT116 p53-/-
Mock
+ UV treatment
Mock
Lamin AC
SIRT1
AROS 1
3.23
5.45
11.19
15.58
18.80
0.13
0.83
1.38
1.14
0.78
1.00
1.69
3.46
4.82
5.82
0.04
0.26
0.43
0.35
0.24
Table 10.6: Annexin V / FACS data for Chapter 5 - Figures 5.10 and 5.11
Cell line and
siRNA
Average
(% cells)
Standard
deviation
Fold
change to
mock
Standard
deviation to
fold
HCT116
Mock
AROS 1
+ FOXO4
+ FOXO3
Mock
FOXO4
FOXO3
3.77
22.22
5.93
21.87
4.79
9.90
8.63
0.53
0.33
0.35
1.00
1.21
0.06
0.61
1.00
5.90
1.57
5.81
1.00
2.07
1.80
0.14
0.09
0.27
0.41
0.25
0.01
0.13
HCT116 p53-/-
Mock
AROS 1
+ FOXO4
+ FOXO3
3.61
11.78
7.46
13.38
0.39
0.17
0.93
0.98
1.00
3.27
2.07
3.71
0.11
0.05
0.26
0.27
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Table 10.7: Annexin V / FACS data for Chapter 6 – Figures 6.4 and 6.8
Cell line and
siRNA
Average
(% cells)
Standard
deviation
Fold
change to
mock
Standard
deviation to
fold
Cancer cell lines
HCT116
Mock
RPS19
AROS
4.79
10.51
17.64
1.21
0.70
4.18
1.00
2.20
3.69
0.25
0.15
0.87
HCT116 p53-/-
Mock
RPS19
AROS
4.76
8.08
10.22
0.21
0.57
0.04
1.00
1.70
2.15
0.04
0.12
0.01
Non-cancer cell lines
ARPE19
Mock
RPS19
AROS
1.08
3.09
1.24
0.16
0.14
0.06
1.00
2.87
1.15
0.15
0.13
0.06
WI38
Mock
RPS19
AROS
2.65
4.91
2.47
0.35
0.10
0.28
1.00
1.85
0.93
0.13
0.04
0.11
Mock AROS siRNA 1SIRT1 siRNALamin AC siRNA
HCT116A
Mock AROS siRNA1SIRT1 siRNALamin AC siRNA
HCT116 p53-/-B
Mock AROS siRNA 1SIRT1 siRNA
MCF7C
Figure 10.1: FACS scatter plot for Chapter 5 - Figure 5.2
(A) Scatter plots from Annexin V (x-axis) and propidium iodide (y-axis)
staining of HCT116 colorectal adenocarcinoma cells following siRNA treatment
as indicated. Analysis was carried out as described in the Methods at 48 hours
post-transfection giving values for apoptotic induction as shown in Table 10.2.
(B) Data as in (A) for the colorectal adenocarcinoma HCT116 p53-/- cell line at
72 hours post-transfection. (C) Data as in (A) for the MCF7 mammary gland
epithelial cancer cell line at 48 hours post-transfection.
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AROS siRNA 1SIRT1 siRNAMock Lamin AC siRNA
ARPE19
WI38
A
B
AROS siRNA 1
AROS siRNA 1
SIRT1 siRNA
Mock SIRT1 siRNA
MCF10A
Mock Lamin AC siRNA
C
Figure 10.2: FACS scatter plot for Chapter 5 - Figure 5.5
(A) Scatter plots from Annexin V (x-axis) and propidium iodide (y-axis)
staining of ARPE19 retinal epithelial cells following siRNA treatment as
indicated. Analysis was carried out as described in the Methods at 72 hours
post-transfection giving values for apoptotic induction as shown in Table 10.2.
(B) Data as in (A) for the WI38 lung fibroblast cell line at 72 hours post-
transfection. (C) Data as in (A) for the MCF10A mammary gland epithelial cell
line at 72 hours post-transfection.
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Mock Flag-AROS
HCT116
A Mock Flag-AROS +Myc-SIRT1-FL
Flag-AROS +
Myc-SIRT1-Δ8
HCT116
B
Mock Flag-Myc-RPS19+ Myc-SIRT1-FL
Flag-Myc-RPS19
+ Myc-SIRT1-Δ8
HCT116
C Figure 10.3: Over-expression cell
phenotypes Chapter 7
(A) Phase contrast micrographs of HCT116
colorectal adenocarcinoma cells 24 hours
following overexpression pcDNA3 Flag-AROS
HCT116
+
10 J m-2 UV
for 24 hours
vector. Cells were harvested for
immunoprecipitation at this time-point as
described in the Methods, for analysis shown in
Chapter 7 – Figure 7.1. (B) Phase contrast
micrographs of HCT116 cells following
overexpression of pcDNA3 Flag-AROS, Myc-
SIRT1-FL and Myc-SIRT1-Δ8 vectors as 
indicated. Cells were transfected and harvested
24 hours later, immediately after phenotype
was recorded, for immunoprecipitation
analysis shown in Chapter 7 – Figure 7.4. (C) Phase contrast micrographs of HCT116 cells following overexpression
of pCMV6 Flag-Myc-RPS19, pcDNA3 Myc-SIRT1-FL and pcDNA3 Myc-SIRT1-Δ8 vectors as indicated. Cells 
were transfected and harvested 24 hours later for immunoprecipitation analysis shown in Chapter 7 – Figure 7.3. For
Chapter 7 – Figure 7.5, cells were transfected then UV irradiated 24 hours later, incubated for a further 24 hours then
harvested for immunoprecipitation.
1000bps
500bps
LDH-A
426bps
<
LDH-B
489bps
<
AROS
261bps
<
RPS19 18S 28S
Primer
target
Expected
size
Primer
target
386bps
<
395bps
<
199bps
<
1000bps
500bps
Expected
size
Figure 10.4: cDNA primer products from PCR analyses
Verification of single cDNA product of the correct size following PCR
analysis of target mRNAs as indicated. The products from PCR analyses were
separated by agarose gel electrophoresis and stained with ethidium bromide
(see Methods). Two independent reactions were analysed next to a 100bp
ladder to verify cDNA size, as shown beneath each image. Arrows indicate
the product band. The smaller band in the AROS cDNA products represents a
product of primer dimerisation. This was omitted from qRT-PCR analyses by
use of a melt step prior to reading.
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1Figure 10.5: Western blotting from Flag-AROS immunoprecipitation
Sequential Western blotting analyses of a single nitrocellulose membrane containing
sample from immunoprecipitation of Flag-AROS. Flag-immunoprecipitation was
carried out as detailed in the Methods and Chapter 7. This data represents a repeat of
the Flag-AROS immunoprecipitation data presented in Chapter 7 – Figure 7.1. Also
analysed in parallel on this membrane was a Flag-SIRT1-Δ construct which lacks
residues 1-217, the region that interacts with AROS (Kim et al. 2007). Panel (A)
probed with anti-SIRT1 antibody indicates the Flag-AROS-SIRT1-FL association,
and expression and immunoprecipitation of the SIRT1-Δ construct. Panel (B) probed
with anti-RPS19 antibody reveals the association of Flag-AROS with RPS19. Panel
(C) probed with anti-SC35 antibody is used in place of Actin as a negative control
for no interaction with Flag-AROS (grey arrow). The region for Actin expression
(~43kDa) is masked in the SIRT1-Δ immunoprecipitation lane, leading to the use of 
SC35 antibody. Panel (D) probed with anti-AROS antibody indicates the
immunoprecipitation and thus expression of Flag-AROS. Endogenous or Flag-
AROS was not detected in the Input samples at this exposure. To detect AROS in the
Input, a new analysis was undertaken with an altered loading ratio between ‘Input’
and ‘Flag-IP’ samples.
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List of Abbreviations
40S Small ribosomal subunit
60S Large ribosomal subunit
80S 40S and 60S subunits associated on mRNA
ADAM10 Disintegrin and metalloproteinase domain-containing
protein 10
ADP Adenosine diphosphate
AMPK AMP-activated protein kinase
ARF Alternate reading frame protein
AROS Active regulator of SIRT1
ATM Ataxia telangiectasia mutated protein
ATP Adenosine triphosphate
BIM-L Bcl-2 interacting mediator of cell death – long isoform
BLAST Basic Local Alignment Search Tool
bps Base pairs
BRCA1 Breast cancer type 1 susceptibility protein
CaM kinase Iα Ca2+/calmodulin-dependent protein kinase Iα
cDNA Complementary DNA
ChREBP Carbohydrate response-element-binding protein
CK2 Casein Kinase II
CMV Cytomegalovirus
CO2 Carbon dioxide
CREB Cyclic-AMP responsive element binding
DBA Diamond-Blackfan Anaemia
DBC1 Deleted in breast cancer 1
DMEM Dulbecco's Modified Eagle Medium
DMSO Dimethyl sulfoxide
DNA Deoxyribonucleic acid
DTT Dithiothreitol
DYRK Dual-specificity tyrosine phosphorylation regulated kinase
E2F1 E2F transcription factor 1
EDTA Ethylenediaminetetraacetic acid
ESA Essential for SIRT1 activity
ETO Etoposide
ETS External transcribed spacer
FACS Fluorescence activated cell sorter
FCS Foetal calf serum
FL Full length
FOXO Forkhead box O
g Gravity
G1 Growth phase 1
G2 Growth phase 2
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
HDAC Histone deacetylase
HDM2 Human MDM2
hEGF Human epidermal growth factor
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HIC1 Hypermethylated in breast cancer 1
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HIF Hypoxia inducible factor
HRP Horse radish peroxidase
HuR Hu-antigen R
IgG Immunoglobulin G
IP Immunoprecipitation
ITS Internal transcribed spacer
J m-2 Joules per square metre
J/m2/s Joules per square metre per second
JNK c-Jun N-terminal kinase
K382Ac Acetylated lysine 382
kDa Kilo-Daltons
L Long exposure (on Western blots)
LDH-A Lactate dehydrogenase A
LDH-B Lactate dehydrogenase B
LDH-C Lactate dehydrogenase C
M Mitosis
MDM2 Mouse Double Minute 2
MEBM Mammary epithelial cell basal media
MEM Modified Eagle Medium
mRNA Messenger RNA
MST1 Mammalian Sterile 20-like kinase 1
mTOR Mammalian Target Of Rapamycin
NAD+ Nicotinamide adenine dinucelotide (oxidised)
NADH Nicotinamide adenine dinucelotide (reduced)
NAM Nicotinamide
NAMPT Nicotinamide phosphoribosyltransferase
NEAA Non-essential amino acids
NES Nuclear export signal
NLS Nuclear localisation sequence
NMN Nicotinamide mononucleotide
NMNAT Nicotinamide mononucleotide adenylyl transferase
OD Optical density
OXPHOS Oxidative phosphorylation
p300/CBP 300kDa protein / CREB binding protein
p53 53kDa protein
PAGE Poly-acrylamide gel electrophoresis
PARP Poly-ADP ribose polymerase
PBS Phosphate buffered saline
PCAF p300/CBP-associated factor
PCR Polymerase chain reaction
PGC-1α Peroxisome proliferator-activated receptor gamma
coactivator-1α
PI Propidium iodide
POD Peroxidase
qRT Quantitative reverse transcription
RAS Rat sarcoma protein
rDNA Ribosomal DNA
RNA Ribonucleic acid
RNAi RNA interference
RPL11 Ribosomal protein of the large subunit 11
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RPL3 Ribosomal protein of the large subunit 3
rpm Revolutions per minute
RPMI Roswell Park Memorial Institute (media)
RPS19 Ribosomal protein of the small subunit 19
RPS6 Ribosomal protein of the small subunit 6
rRNA Ribosomal RNA
RT Reverse transcription
S Short exposure (on Western blots)
S Synthesis phase
SDS Sodium dodecyl sulphate
SENP1 Sentrin-specific protease 1
SET7/9 SET domain containing 7/9
shRNA Short hairpin RNA
Sir2 Silent information regulator 2
siRNA Short interfering RNA
SIRT1 Silent information regulator type 1
SIRT3 Silent information regulator type 3
SIRT6 Silent information regulator type 6
SUMO Small ubiquitin-like modifier
TAE TRIS base, Acetic acid and EDTA
TBS(T) TRIS buffered saline (plus tween)
TP53 Tumor protein 53 (gene)
TRIS Tris(hydroxymethyl)aminomethane
tRNA Transfer RNA
TSA Trichostatin A
TSC2 Tuberous sclerosis protein 2
U Enzyme units
UV Ultra-violet
V Volts
WB Western blot
YCR Yorkshire Cancer Research
Δ8 Missing exon 8
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